

John D. Hall

10/650931

=> file registry

FILE 'REGISTRY' ENTERED AT 18:00:51 ON 07 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2007 HIGHEST RN 925228-12-2
DICTIONARY FILE UPDATES: 6 MAR 2007 HIGHEST RN 925228-12-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> file caplus

FILE 'CAPLUS' ENTERED AT 18:00:59 ON 07 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Mar 2007 VOL 146 ISS 11
FILE LAST UPDATED: 6 Mar 2007 (20070306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L65

| | | | | | | | |
|-----|------|-----|-------------|--------|--------|-----|---------|
| L63 | 1615 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | WOO | J?/AU |
| L64 | 393 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | CHI | M?/AU |
| L65 | 4 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | L63 | AND L64 |

=> d stat que L122

| | | | | | |
|------|-------|-------------------|--------|--------|---|
| L2 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | NIFEDIPINE/CN |
| L3 | 90 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 21829-25-4/CRN |
| L4 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | ISRADIPINE/CN |
| L5 | 3 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 75695-93-1/CRN |
| L6 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | LOVASTATIN/CN |
| L7 | 37 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 75330-75-5/CRN |
| L8 | 17 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | LOVASTATIN?/CN |
| L17 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | GLIPIZID?/CN |
| L18 | 18 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 29094-61-9/CRN |
| L20 | 91 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L2 OR L3) |
| L21 | 4 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L4 OR L5) |
| L22 | 53 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L6 OR L7 OR L8) |
| L23 | 19 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L17 OR L18) |
| L27 | 167 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L20 OR L21 OR L22 OR L23) |
| L67 | 57253 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | MEDLINE/LC |
| L70 | 6 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L27 AND L67 |
| L91 | 1020 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | WOO J?/AU |
| L92 | 144 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | CHI M?/AU |
| L94 | 18551 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | L70 |
| L95 | 19109 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | NIFEDIPINE |
| L96 | 1475 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | ISRADIPINE |
| L97 | 4043 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | LOVASTATIN |
| L98 | 713 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | GLIPIZIDE |
| L112 | 426 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | (ADALAT/BI OR BAY-A-1040/BI OR BAY-1040/BI OR CORDIPIN/BI OR CORDIPINE/BI OR CORINFAR/BI OR FENIGIDIN/BI OR INFEDIPIN/BI OR KORINFAR/BI OR "MONOHYDROCHLORIDE, NIFEDIPINE"/BI OR NIFANGIN/BI OR "NIFEDIPINE MONOHYDROCHLORIDE"/BI OR NIFEDIPINE-GTIS/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI) |
| L114 | 19161 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | L95 OR L112 |
| L115 | 382 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | (DYNACIRC/BI OR "ISRADIPINE, (+)-ISOMER"/BI OR "ISRADIPINE, (R)-ISOMER"/BI OR "ISRADIPINE, (S)-ISOMER"/BI OR LOMIR/BI OR "PN 200-110"/BI OR "PN 205 033"/BI OR "PN 205 034"/BI OR "PN 205-033"/BI OR "PN 205-034"/BI OR "PN 205033"/BI OR "PN 205034"/BI OR PN-200-110/BI OR PN-205-033/BI OR PN-205-034/BI OR PN205033/BI OR PN205034/BI) |
| L116 | 1595 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | L96 OR L115 |
| L117 | 404 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | ("LOVASTATIN, (1 ALPHA(S*))-ISOMER"/BI OR "LOVASTATIN, 1 ALPHA-ISOMER (WITHOUT R*/S* NOTATION)"/BI OR "MK 803"/BI OR MK-803/BI OR MK803/BI OR MEVACOR/BI OR MEVINOLIN/BI OR "MONACOLIN K"/BI) |
| L118 | 4139 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | L97 OR L117 |
| L119 | 29 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | ("ALPHAPHARM BRAND OF GLIPIZIDE"/BI OR "GLIBENESE BRAND OF GLIPIZIDE"/BI OR GLIDIAZINAMIDE/BI OR GLUCOTROL/BI OR GLUPITEL/BI OR GLYDIAZINAMIDE/BI OR GLYPIDIZINE/BI OR "K 4024"/BI OR K-4024/BI OR K4024/BI OR "KENFARMA BRAND OF GLIPIZIDE"/BI OR "LACER BRAND OF GLIPIZIDE"/BI OR "LILLY BRAND OF GLIPIZIDE"/BI OR MELIZIDE/BI OR MINDIAB/BI OR MINIDIAB/BI OR MINODIAB/BI OR OZIDIA/BI OR "PFIZER BRAND OF GLIPIZIDE"/BI OR "PHARMACIA BRAND OF GLIPIZIDE"/BI OR "PYRAZINECARBOXAMIDE, N-(2-(4-(((CYCLOHEXYLAMINO) CARBONYL) AMINO)SULFONYL) PHENYL) ETHYL)-5-METHYL-"/BI) |
| L120 | 723 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | L98 OR L119 |
| L122 | 6 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | (L94 OR L114 OR L116 OR L118 OR L120) AND (L91 OR L92) |

=> file medline

FILE 'MEDLINE' ENTERED AT 18:01:17 ON 07 MAR 2007

FILE LAST UPDATED: 7 Mar 2007 (20070307/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d stat que L122

| | | | | |
|------|-------|--------------------------|--------|---|
| L2 | 1 | SEA FILE=REGISTRY ABB=ON | PLU=ON | NIFEDIPINE/CN |
| L3 | 90 | SEA FILE=REGISTRY ABB=ON | PLU=ON | 21829-25-4/CRN |
| L4 | 1 | SEA FILE=REGISTRY ABB=ON | PLU=ON | ISRADIPINE/CN |
| L5 | 3 | SEA FILE=REGISTRY ABB=ON | PLU=ON | 75695-93-1/CRN |
| L6 | 1 | SEA FILE=REGISTRY ABB=ON | PLU=ON | LOVASTATIN/CN |
| L7 | 37 | SEA FILE=REGISTRY ABB=ON | PLU=ON | 75330-75-5/CRN |
| L8 | 17 | SEA FILE=REGISTRY ABB=ON | PLU=ON | LOVASTATIN?/CN |
| L17 | 1 | SEA FILE=REGISTRY ABB=ON | PLU=ON | GLIPIZID?/CN |
| L18 | 18 | SEA FILE=REGISTRY ABB=ON | PLU=ON | 29094-61-9/CRN |
| L20 | 91 | SEA FILE=REGISTRY ABB=ON | PLU=ON | (L2 OR L3) |
| L21 | 4 | SEA FILE=REGISTRY ABB=ON | PLU=ON | (L4 OR L5) |
| L22 | 53 | SEA FILE=REGISTRY ABB=ON | PLU=ON | (L6 OR L7 OR L8) |
| L23 | 19 | SEA FILE=REGISTRY ABB=ON | PLU=ON | (L17 OR L18) |
| L27 | 167 | SEA FILE=REGISTRY ABB=ON | PLU=ON | (L20 OR L21 OR L22 OR L23) |
| L67 | 57253 | SEA FILE=REGISTRY ABB=ON | PLU=ON | MEDLINE/LC |
| L70 | 6 | SEA FILE=REGISTRY ABB=ON | PLU=ON | L27 AND L67 |
| L91 | 1020 | SEA FILE=MEDLINE ABB=ON | PLU=ON | WOO J?/AU |
| L92 | 144 | SEA FILE=MEDLINE ABB=ON | PLU=ON | CHI M?/AU |
| L94 | 18551 | SEA FILE=MEDLINE ABB=ON | PLU=ON | L70 |
| L95 | 19109 | SEA FILE=MEDLINE ABB=ON | PLU=ON | NIFEDIPINE |
| L96 | 1475 | SEA FILE=MEDLINE ABB=ON | PLU=ON | ISRADIPINE |
| L97 | 4043 | SEA FILE=MEDLINE ABB=ON | PLU=ON | LOVASTATIN |
| L98 | 713 | SEA FILE=MEDLINE ABB=ON | PLU=ON | GLIPIZIDE |
| L112 | 426 | SEA FILE=MEDLINE ABB=ON | PLU=ON | (ADALAT/BI OR BAY-A-1040/BI OR BAY-1040/BI OR CORDIPIN/BI OR CORDIPINE/BI OR CORINFAR/BI OR FENIGIDIN/BI OR INFEDIPIN/BI OR KORINFAR/BI OR "MONOHYDROCHLORIDE, NIFEDIPINE"/BI OR NIFANGIN/BI OR "NIFEDIPINE MONOHYDROCHLORIDE"/BI OR NIFEDIPINE-GTIS/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI) |
| L114 | 19161 | SEA FILE=MEDLINE ABB=ON | PLU=ON | L95 OR L112 |
| L115 | 382 | SEA FILE=MEDLINE ABB=ON | PLU=ON | (DYNACIRC/BI OR "ISRADIPINE, (+)-ISOMER"/BI OR "ISRADIPINE, (R)-ISOMER"/BI OR "ISRADIPINE, (S)-ISOMER"/BI OR LOMIR/BI OR "PN 200-110"/BI OR "PN 205 033"/BI OR "PN 205 034"/BI OR "PN 205-033"/BI OR "PN 205-034"/BI OR "PN 205033"/BI OR "PN 205034"/BI OR PN-200-110/BI OR PN-205-033/BI OR PN-205-034/BI OR PN205033/BI OR PN205034/BI) |
| L116 | 1595 | SEA FILE=MEDLINE ABB=ON | PLU=ON | L96 OR L115 |
| L117 | 404 | SEA FILE=MEDLINE ABB=ON | PLU=ON | ("LOVASTATIN, (1 ALPHA(S*)) -ISOMER"/BI OR "LOVASTATIN, 1 ALPHA-ISOMER (WITHOUT R*/S* NOTATION)"/BI OR "MK 803"/BI OR MK-803/BI OR MK803/BI OR MEVACOR/BI OR MEVINOLIN/BI OR "MONACOLIN K"/BI) |
| L118 | 4139 | SEA FILE=MEDLINE ABB=ON | PLU=ON | L97 OR L117 |
| L119 | 29 | SEA FILE=MEDLINE ABB=ON | PLU=ON | ("ALPHAPHARM BRAND OF GLIPIZIDE"/BI OR "GLIBENESE BRAND OF GLIPIZIDE"/BI OR GLIDIAZINAMIDE/BI OR GLUCOTROL/BI OR GLUPITEL/BI OR GLYDIAZINAMIDE/BI OR GLYPIDIZINE/BI OR "K 4024"/BI OR K-4024/BI OR K4024/BI OR "KENFARMA BRAND OF GLIPIZIDE"/BI OR "LACER BRAND OF GLIPIZIDE"/BI OR "LILLY BRAND OF GLIPIZIDE"/BI OR MELIZIDE/BI OR MINDIAB/B |

I OR MINIDIAB/BI OR MINODIAB/BI OR OZIDIA/BI OR "PFIZER BRAND OF GLIPIZIDE"/BI OR "PHARMACIA BRAND OF GLIPIZIDE"/BI OR "PYRAZINECARBOXAMIDE, N-(2-(4-(((CYCLOHEXYLAMINO) CARBONYL) AMINO) SULFONYL) PHENYL) ETHYL)-5-METHYL-" /BI)

L120 723 SEA FILE=MEDLINE ABB=ON PLU=ON L98 OR L119
 L122 6 SEA FILE=MEDLINE ABB=ON PLU=ON (L94 OR L114 OR L116 OR L118 OR L120) AND (L91 OR L92)

=> file embase

FILE 'EMBASE' ENTERED AT 18:01:22 ON 07 MAR 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE COVERS 1974 TO 7 Mar 2007 (20070307/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d stat que L153

| | | | | |
|------|-------|--------------------------|--------|------------------------------------|
| L2 | 1 | SEA FILE=REGISTRY ABB=ON | PLU=ON | NIFEDIPINE/CN |
| L3 | 90 | SEA FILE=REGISTRY ABB=ON | PLU=ON | 21829-25-4/CRN |
| L4 | 1 | SEA FILE=REGISTRY ABB=ON | PLU=ON | ISRADIPINE/CN |
| L5 | 3 | SEA FILE=REGISTRY ABB=ON | PLU=ON | 75695-93-1/CRN |
| L6 | 1 | SEA FILE=REGISTRY ABB=ON | PLU=ON | LOVASTATIN/CN |
| L7 | 37 | SEA FILE=REGISTRY ABB=ON | PLU=ON | 75330-75-5/CRN |
| L8 | 17 | SEA FILE=REGISTRY ABB=ON | PLU=ON | LOVASTATIN?/CN |
| L17 | 1 | SEA FILE=REGISTRY ABB=ON | PLU=ON | GLIPIZID?/CN |
| L18 | 18 | SEA FILE=REGISTRY ABB=ON | PLU=ON | 29094-61-9/CRN |
| L20 | 91 | SEA FILE=REGISTRY ABB=ON | PLU=ON | (L2 OR L3) |
| L21 | 4 | SEA FILE=REGISTRY ABB=ON | PLU=ON | (L4 OR L5) |
| L22 | 53 | SEA FILE=REGISTRY ABB=ON | PLU=ON | (L6 OR L7 OR L8) |
| L23 | 19 | SEA FILE=REGISTRY ABB=ON | PLU=ON | (L17 OR L18) |
| L27 | 167 | SEA FILE=REGISTRY ABB=ON | PLU=ON | (L20 OR L21 OR L22 OR L23) |
| L29 | 8 | SEA FILE=REGISTRY ABB=ON | PLU=ON | SODIUM ALGINAT?/CN |
| L30 | 1 | SEA FILE=REGISTRY ABB=ON | PLU=ON | XANTHAN GUM/CN |
| L31 | 102 | SEA FILE=REGISTRY ABB=ON | PLU=ON | XANTHAN GUM?/CN |
| L33 | 28 | SEA FILE=REGISTRY ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE?/CN |
| L36 | 1 | SEA FILE=REGISTRY ABB=ON | PLU=ON | SODIUM ALGINATE/CN |
| L37 | 133 | SEA FILE=REGISTRY ABB=ON | PLU=ON | 9005-38-3/CRN |
| L38 | 137 | SEA FILE=REGISTRY ABB=ON | PLU=ON | L29 OR L36 OR L37 |
| L39 | 87 | SEA FILE=REGISTRY ABB=ON | PLU=ON | 11138-66-2/CRN |
| L40 | 111 | SEA FILE=REGISTRY ABB=ON | PLU=ON | L30 OR L31 OR L39 |
| L41 | 1 | SEA FILE=REGISTRY ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE/CN |
| L42 | 129 | SEA FILE=REGISTRY ABB=ON | PLU=ON | 9004-65-3/CRN |
| L43 | 151 | SEA FILE=REGISTRY ABB=ON | PLU=ON | L33 OR L41 OR L42 |
| L68 | 30841 | SEA FILE=REGISTRY ABB=ON | PLU=ON | EMBASE/LC |
| L71 | 6 | SEA FILE=REGISTRY ABB=ON | PLU=ON | L27 AND L68 |
| L74 | 3 | SEA FILE=REGISTRY ABB=ON | PLU=ON | L38 AND L68 |
| L77 | 1 | SEA FILE=REGISTRY ABB=ON | PLU=ON | L40 AND L68 |
| L80 | 3 | SEA FILE=REGISTRY ABB=ON | PLU=ON | L43 AND L68 |
| L95 | 19109 | SEA FILE=MEDLINE ABB=ON | PLU=ON | NIFEDIPINE |
| L96 | 1475 | SEA FILE=MEDLINE ABB=ON | PLU=ON | ISRADIPINE |
| L97 | 4043 | SEA FILE=MEDLINE ABB=ON | PLU=ON | LOVASTATIN |
| L98 | 713 | SEA FILE=MEDLINE ABB=ON | PLU=ON | GLIPIZIDE |
| L100 | 663 | SEA FILE=MEDLINE ABB=ON | PLU=ON | SODIUM ALGINATE |

L101 5653 SEA FILE=MEDLINE ABB=ON PLU=ON ALGINATE
 L105 4774 SEA FILE=MEDLINE ABB=ON PLU=ON METHYLCELLULOSE
 L106 458 SEA FILE=MEDLINE ABB=ON PLU=ON HYDROXYPROPYLMETHYLCELLULOSE
 L123 46607 SEA FILE=EMBASE ABB=ON PLU=ON (L71 OR (L95 OR L96 OR L97 OR L98))
 L124 3286 SEA FILE=EMBASE ABB=ON PLU=ON (ADALAT/BI OR "ADALAT CRONO"/BI OR "ADALAT PA"/BI OR "ADALAT RETARD"/BI OR ADALATE/BI OR ALDIPIN/BI OR ANGIBLOC/BI OR APONIFED/BI OR APRICAL/BI OR "APRICAL RETARD"/BI OR "BAY 1040"/BI OR "BAY A 1040"/BI OR "BAY A1040"/BI OR BAY1040/BI OR CALCIGARD/BI OR CHRONADALAT/BI OR CHRONADALATE/BI OR CORACTEN/BI OR CORDAFEN/BI OR CORDAFLEX/BI OR CORDICANT/BI OR CORDIPIN/BI OR CORINFAR/BI OR COROTREND/BI OR DEPIN/BI OR "DIMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2 NITROPHENYL) PYRIDINE 3,5 DICARBOXYLATE"/BI OR DURANIFIN/BI OR ECODIPIN/BI OR EMABERIN/BI OR FENIGIDIN/BI OR HERLAT/BI OR INFEDIPINE/BI OR MIFEDIPINE/BI OR MODERAT/BI OR MYOGARD/BI OR NIFANGIN/BI OR NIFEDICOR/BI OR "NIFEDICOR GOCCE"/BI OR NIFEDINE/BI OR NIFEDIPAT/BI OR NIFEHEXAL/BI OR NIFELAT/BI OR NIFENSAR/BI OR NIFEPIDINE/BI OR NIFICAL/BI OR NIFICARD/BI OR NOVONIFEDIN/BI OR PHENYLGIDINE/BI OR PIDILAT/BI OR "PIDILAT RETARD"/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI OR RONIAN/BI OR SEPAMIT/BI OR SLOFEDIPINE/BI OR "SLOFEDIPINE XL"/BI OR UNIDIPINE/BI OR ZENUSIN/BI)
 L125 1049 SEA FILE=EMBASE ABB=ON PLU=ON (ISRODIPINE/BI OR LOMIR/BI OR "PK 200110"/BI OR "PN 200 110"/BI OR "PN 200-110"/BI OR "PN 200110"/BI OR "PN 200110 N"/BI OR "PN 205033"/BI OR "PN 205034"/BI OR "PN200 110"/BI OR PN200-110/BI OR PN200110/BI OR PRESCAL/BI OR "SDZ 200 110"/BI OR VASCAL/BI)
 L126 2955 SEA FILE=EMBASE ABB=ON PLU=ON (ALTOCOR/BI OR ALTOPREV/BI OR ARTEIN/BI OR "L 654969"/BI OR LIPIVAS/BI OR LOVACOL/BI OR LOVASTATIN/BI OR MEVACOR/BI OR MEVINACOR/BI OR "MK 0803"/BI OR "MK 803"/BI OR MK0803/BI OR MK803/BI OR "MONACOLIN K"/BI OR "MONAKOLIN K"/BI OR "MSD 803"/BI OR NEOLIPID/BI)
 L127 524 SEA FILE=EMBASE ABB=ON PLU=ON ("CP 28,720"/BI OR "CP 28720"/BI OR "CP28,720"/BI OR CP28720/BI OR GLIBENESE/BI OR GLIBINESE/BI OR GLIBIZIDE/BI OR GLIDIAZINAMIDE/BI OR GLUCATROL/BI OR GLUCOTROL/BI OR "GLUCOTROL XL"/BI OR GLYDIAZENAMIDE/BI OR GLYDIAZIAMIDE/BI OR GLYDIAZINAMIDE/BI OR GLYPIZIDE/BI OR "K 4024"/BI OR MINIDIAB/BI OR MINODIAB/BI)
 L128 46760 SEA FILE=EMBASE ABB=ON PLU=ON (L123 OR L124 OR L125 OR L126 OR L127)
 L129 13985 SEA FILE=EMBASE ABB=ON PLU=ON (ALGIN/BI OR ALGINATE/BI OR "ALGINATE SODIUM"/BI OR ALGINATES/BI OR "ALGINIC GULURONIC ACID"/BI OR "BLUEPRINT RAPID"/BI OR COLOURGEL/BI OR "G-C FAST SET"/BI OR "G-C VERICOL AROMA"/BI OR KALGINATE/BI OR KELACID/BI OR "KELCOGEL LV"/BI OR KELGIN/BI OR KELTONE/BI OR "KERR ALGINATE"/BI OR "MANUGEL DJX"/BI OR "MANUGEL DMB"/BI OR MINUS/BI OR NORALGIN/BI OR NORGINE/BI OR POLYMANNURONATE/BI OR "POLYMANNURONIC ACID"/BI OR "POLYMANNURONIC GULURONIC ACID"/BI OR PROTANAL/BI OR PSOTHANOL/BI OR "SODIUM ALGINATE"/BI OR "SODIUM POLYMANNURONATE"/BI OR SORBALGON/BI OR "ZELGAN GREEN"/BI OR "ZELGAN PINK"/BI)
 L130 6223 SEA FILE=EMBASE ABB=ON PLU=ON L74 OR (L100 OR L101)
 L131 15293 SEA FILE=EMBASE ABB=ON PLU=ON (L129 OR L130)
 L132 649 SEA FILE=EMBASE ABB=ON PLU=ON L77 OR XANTHAN GUM
 L133 699 SEA FILE=EMBASE ABB=ON PLU=ON XANTHAN OR KELTROL OR RHODIGEL 23
 L134 699 SEA FILE=EMBASE ABB=ON PLU=ON (L132 OR L133)
 L135 6010 SEA FILE=EMBASE ABB=ON PLU=ON L80 OR (L105 OR L106)
 L136 1239 SEA FILE=EMBASE ABB=ON PLU=ON (ADATOCEL/BI OR CONTACTOL/BI

OR GONIOSOL/BI OR "HYDROXYPROPYL METHYL CELLULOSE"/BI OR
 "HYDROXYPROPYL METHYLCELLULOSE"/BI OR "HYDROXYPROPYLMETHYL
 CELLULOSE"/BI OR HYPROMELLOSE/BI OR "ISOPTO TEARS"/BI OR
 ISOPTONATURAL/BI OR ISOPTOPLAIN/BI OR ISOPTOTEARS/BI OR "K
 8515"/BI OR LUBAFAX/BI OR "METHOCEL E 15"/BI OR "METHOCEL
 EFK"/BI OR "METHOCEL K100M"/BI OR "METHOCEL K15M"/BI OR
 "METHOCEL K4M"/BI OR "METHOLOSE TC 5"/BI OR "METHYLHYDROXYPROPY
 L CELLULOSE"/BI OR METHYLHYDROXYPROPYLCELLULOSE/BI OR METOLOSE/
 BI OR OCCUCOAT/BI OR OCUCOAT/BI OR "PHARMACOAT 603"/BI OR
 "PHARMACOAT 606"/BI OR ULTRATEARS/BI)

L137 6060 SEA FILE=EMBASE ABB=ON PLU=ON (L135 OR L136)
 L139 23 SEA FILE=EMBASE ABB=ON PLU=ON "ALGINIC ACID PROPYLENE GLYCOL
 ESTER"+UF/CT
 L140 26 SEA FILE=EMBASE ABB=ON PLU=ON ("PROPYLENE GLYCOL ALGINATE"/BI
 OR "PROPYLENEGLYCOL ALGINATE"/BI)
 L141 34 SEA FILE=EMBASE ABB=ON PLU=ON (L139 OR L140)
 L145 1034 SEA FILE=EMBASE ABB=ON PLU=ON WOO J?/AU
 L146 165 SEA FILE=EMBASE ABB=ON PLU=ON CHI M?/AU
 L147 0 SEA FILE=EMBASE ABB=ON PLU=ON L145 AND L146
 L148 9 SEA FILE=EMBASE ABB=ON PLU=ON (L145 OR L146) AND L128
 L149 4 SEA FILE=EMBASE ABB=ON PLU=ON (L145 OR L146) AND L131
 L150 0 SEA FILE=EMBASE ABB=ON PLU=ON (L145 OR L146) AND L134
 L151 3 SEA FILE=EMBASE ABB=ON PLU=ON (L145 OR L146) AND L137
 L152 0 SEA FILE=EMBASE ABB=ON PLU=ON (L145 OR L146) AND L141
 L153 16 SEA FILE=EMBASE ABB=ON PLU=ON (L147 OR L148 OR L149 OR L150
 OR L151 OR L152)

=> file biosis

FILE 'BIOSIS' ENTERED AT 18:01:31 ON 07 MAR 2007

Copyright (c) 2007 The Thomson Corporation

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
 FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 28 February 2007 (20070228/ED)

=> d stat que L169

L2 1 SEA FILE=REGISTRY ABB=ON PLU=ON NIFEDIPINE/CN
 L3 90 SEA FILE=REGISTRY ABB=ON PLU=ON 21829-25-4/CRN
 L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON ISRADIPINE/CN
 L5 3 SEA FILE=REGISTRY ABB=ON PLU=ON 75695-93-1/CRN
 L6 1 SEA FILE=REGISTRY ABB=ON PLU=ON LOVASTATIN/CN
 L7 37 SEA FILE=REGISTRY ABB=ON PLU=ON 75330-75-5/CRN
 L8 17 SEA FILE=REGISTRY ABB=ON PLU=ON LOVASTATIN?/CN
 L17 1 SEA FILE=REGISTRY ABB=ON PLU=ON GLIPIZID?/CN
 L18 18 SEA FILE=REGISTRY ABB=ON PLU=ON 29094-61-9/CRN
 L20 91 SEA FILE=REGISTRY ABB=ON PLU=ON (L2 OR L3)
 L21 4 SEA FILE=REGISTRY ABB=ON PLU=ON (L4 OR L5)
 L22 53 SEA FILE=REGISTRY ABB=ON PLU=ON (L6 OR L7 OR L8)
 L23 19 SEA FILE=REGISTRY ABB=ON PLU=ON (L17 OR L18)
 L27 167 SEA FILE=REGISTRY ABB=ON PLU=ON (L20 OR L21 OR L22 OR L23)
 L29 8 SEA FILE=REGISTRY ABB=ON PLU=ON SODIUM ALGINAT?/CN
 L30 1 SEA FILE=REGISTRY ABB=ON PLU=ON XANTHAN GUM/CN
 L31 102 SEA FILE=REGISTRY ABB=ON PLU=ON XANTHAN GUM?/CN
 L36 1 SEA FILE=REGISTRY ABB=ON PLU=ON SODIUM ALGINATE/CN
 L37 133 SEA FILE=REGISTRY ABB=ON PLU=ON 9005-38-3/CRN
 L38 137 SEA FILE=REGISTRY ABB=ON PLU=ON L29 OR L36 OR L37

L39 87 SEA FILE=REGISTRY ABB=ON PLU=ON 11138-66-2/CRN
 L40 111 SEA FILE=REGISTRY ABB=ON PLU=ON L30 OR L31 OR L39
 L68 30841 SEA FILE=REGISTRY ABB=ON PLU=ON EMBASE/LC
 L69 196582 SEA FILE=REGISTRY ABB=ON PLU=ON BIOSIS/LC
 L72 11 SEA FILE=REGISTRY ABB=ON PLU=ON L27 AND L69
 L74 3 SEA FILE=REGISTRY ABB=ON PLU=ON L38 AND L68
 L77 1 SEA FILE=REGISTRY ABB=ON PLU=ON L40 AND L68
 L78 3 SEA FILE=REGISTRY ABB=ON PLU=ON L40 AND L69
 L95 19109 SEA FILE=MEDLINE ABB=ON PLU=ON NIFEDIPINE
 L96 1475 SEA FILE=MEDLINE ABB=ON PLU=ON ISRADIPINE
 L97 4043 SEA FILE=MEDLINE ABB=ON PLU=ON LOVASTATIN
 L98 713 SEA FILE=MEDLINE ABB=ON PLU=ON GLIPIZIDE
 L100 663 SEA FILE=MEDLINE ABB=ON PLU=ON SODIUM ALGINATE
 L101 5653 SEA FILE=MEDLINE ABB=ON PLU=ON ALGINATE
 L125 1049 SEA FILE=EMBASE ABB=ON PLU=ON (ISRODIPINE/BI OR LOMIR/BI OR
 "PK 200110"/BI OR "PN 200 110"/BI OR "PN 200-110"/BI OR "PN
 200110"/BI OR "PN 200110 N"/BI OR "PN 205033"/BI OR "PN
 205034"/BI OR "PN200 110"/BI OR PN200-110/BI OR PN200110/BI OR
 PRESCAL/BI OR "SDZ 200 110"/BI OR VASCAL/BI)
 L126 2955 SEA FILE=EMBASE ABB=ON PLU=ON (ALTOCOR/BI OR ALTOPREV/BI OR
 ARTEIN/BI OR "L 654969"/BI OR LIPIVAS/BI OR LOVACOL/BI OR
 LOVASTATIN/BI OR MEVACOR/BI OR MEVINACOR/BI OR "MK 0803"/BI OR
 "MK 803"/BI OR MK0803/BI OR MK803/BI OR "MONACOLIN K"/BI OR
 "MONAKOLIN K"/BI OR "MSD 803"/BI OR NEOLIPID/BI)
 L127 524 SEA FILE=EMBASE ABB=ON PLU=ON ("CP 28,720"/BI OR "CP
 28720"/BI OR "CP28,720"/BI OR CP28720/BI OR GLIBENESE/BI OR
 GLIBINESE/BI OR GLIBIZIDE/BI OR GLIDIAZINAMIDE/BI OR GLUCATROL/
 BI OR GLUCOTROL/BI OR "GLUCOTROL XL"/BI OR GLYDIAZENAMIDE/BI
 OR GLYDIAZIAMIDE/BI OR GLYDIAZINAMIDE/BI OR GLYPIZIDE/BI OR "K
 4024"/BI OR MINIDIAB/BI OR MINODIAB/BI)
 L129 13985 SEA FILE=EMBASE ABB=ON PLU=ON (ALGIN/BI OR ALGINATE/BI OR
 "ALGINATE SODIUM"/BI OR ALGINATES/BI OR "ALGINIC GULURONIC
 ACID"/BI OR "BLUEPRINT RAPID"/BI OR COLOURGEL/BI OR "G-C FAST
 SET"/BI OR "G-C VERICOL AROMA"/BI OR KALGINATE/BI OR KELACID/BI
 OR "KELCOGEL LV"/BI OR KELGIN/BI OR KELTONE/BI OR "KERR
 ALGINATE"/BI OR "MANUGEL DJX"/BI OR "MANUGEL DMB"/BI OR
 MINUS/BI OR NORALGIN/BI OR NORGINE/BI OR POLYMANNURONATE/BI OR
 "POLYMANNURONIC ACID"/BI OR "POLYMANNURONIC GULURONIC ACID"/BI
 OR PROTANAL/BI OR PSOTHANOL/BI OR "SODIUM ALGINATE"/BI OR
 "SODIUM POLYMANNURONATE"/BI OR SORBALGON/BI OR "ZELGAN
 GREEN"/BI OR "ZELGAN PINK"/BI)
 L130 6223 SEA FILE=EMBASE ABB=ON PLU=ON L74 OR (L100 OR L101)
 L132 649 SEA FILE=EMBASE ABB=ON PLU=ON L77 OR XANTHAN GUM
 L133 699 SEA FILE=EMBASE ABB=ON PLU=ON XANTHAN OR KELTROL OR RHODIGEL
 23
 L154 1198 SEA FILE=BIOSIS ABB=ON PLU=ON WOO J?/AU
 L155 244 SEA FILE=BIOSIS ABB=ON PLU=ON CHI M?/AU
 L157 25683 SEA FILE=BIOSIS ABB=ON PLU=ON L72 OR (L95 OR L96 OR L97 OR
 L98)
 L158 422 SEA FILE=BIOSIS ABB=ON PLU=ON (ADALAT/BI OR "ADALAT CRONO"/BI
 OR "ADALAT PA"/BI OR "ADALAT RETARD"/BI OR ADALATE/BI OR
 ALDIPIN/BI OR ANGIBLOC/BI OR APONIFED/BI OR APRICAL/BI OR
 "APRICAL RETARD"/BI OR "BAY 1040"/BI OR "BAY A 1040"/BI OR
 "BAY A1040"/BI OR BAY1040/BI OR CALCIGARD/BI OR CHRONADALAT/BI
 OR CHRONADALATE/BI OR CORACTEN/BI OR CORDAFEN/BI OR CORDAFLEX/B
 I OR CORDICANT/BI OR CORDIPIN/BI OR CORINFAR/BI OR COTREND/BI
 OR DEPIN/BI OR "DIMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2
 NITROPHENYL) PYRIDINE 3,5 DICARBOXYLATE"/BI OR DURANIFIN/BI OR
 ECODIPIN/BI OR EMABERIN/BI OR FENIGIDIN/BI OR HERLAT/BI OR
 INFEDIPINE/BI OR MIFEDIPINE/BI OR MODERAT/BI OR MYOGARD/BI OR

NIFANGIN/BI OR NIFEDICOR/BI OR "NIFEDICOR GOCCE"/BI OR
NIFEDINE/BI OR NIFEDIPAT/BI OR NIFEHEXAL/BI OR NIFELAT/BI OR
NIFENSAR/BI OR NIFEPIDINE/BI OR NIFICAL/BI OR NIFICARD/BI OR
NOVONIFEDIN/BI OR PHENYGDINE/BI OR PIDILAT/BI OR "PIDILAT
RETARD"/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI OR RONIAN/BI
OR SEPAMIT/BI OR SLOFEDIPINE/BI OR "SLOFEDIPINE XL"/BI OR
UNIDIPINE/BI OR ZENUSIN/BI)

L159 4086 SEA FILE=BIOSIS ABB=ON PLU=ON (L125 OR L126 OR L127)
L160 26142 SEA FILE=BIOSIS ABB=ON PLU=ON (L157 OR L158 OR L159)
L161 23308 SEA FILE=BIOSIS ABB=ON PLU=ON (L129 OR L130)
L162 1552 SEA FILE=BIOSIS ABB=ON PLU=ON (L132 OR L133)
L163 1071 SEA FILE=BIOSIS ABB=ON PLU=ON L78
L164 1552 SEA FILE=BIOSIS ABB=ON PLU=ON (L162 OR L163)
L169 8 SEA FILE=BIOSIS ABB=ON PLU=ON (L154 OR L155) AND (L157 OR
L158 OR L159 OR L160 OR L161 OR L162 OR L163 OR L164)

=> file uspatfull

FILE 'USPATFULL' ENTERED AT 18:01:42 ON 07 MAR 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Mar 2007 (20070306/PD)

FILE LAST UPDATED: 6 Mar 2007 (20070306/ED)

HIGHEST GRANTED PATENT NUMBER: US7188369

HIGHEST APPLICATION PUBLICATION NUMBER: US2007050874

CA INDEXING IS CURRENT THROUGH 6 Mar 2007 (20070306/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Mar 2007 (20070306/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006

=> d stat que L170

L154 1198 SEA FILE=BIOSIS ABB=ON PLU=ON WOO J?/AU

L155 244 SEA FILE=BIOSIS ABB=ON PLU=ON CHI M?/AU

L170 1 SEA FILE=USPATFULL ABB=ON PLU=ON L154 AND L155

=> dup rem L65 L122 L153 L169 L170

FILE 'CAPLUS' ENTERED AT 18:02:04 ON 07 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 18:02:04 ON 07 MAR 2007

FILE 'EMBASE' ENTERED AT 18:02:04 ON 07 MAR 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 18:02:04 ON 07 MAR 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 18:02:04 ON 07 MAR 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

PROCESSING COMPLETED FOR L65

PROCESSING COMPLETED FOR L122

PROCESSING COMPLETED FOR L153

PROCESSING COMPLETED FOR L169

PROCESSING COMPLETED FOR L170

L185 23 DUP REM L65 L122 L153 L169 L170 (12 DUPLICATES REMOVED)

ANSWERS '1-4' FROM FILE CAPLUS

ANSWERS '5-10' FROM FILE MEDLINE
ANSWERS '11-22' FROM FILE EMBASE
ANSWER '23' FROM FILE USPATFULL

=> d ibib abs hitind hitstr L185 1-4; d iall L185 5-22; d ibib abs L185 23

L185 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:655680 CAPLUS Full-text
DOCUMENT NUMBER: 145:110382
TITLE: Controlled release formulation for oral administration
of pharmaceuticals for diabetes treatment
INVENTOR(S): Woo, Jong Soo; Yi, Hong Gi; Chi, Moon
Hyuk; Kim, Young Hun
PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|---|--|-----------------|------------|
| WO 2006071078 | A1 | 20060706 | WO 2005-KR4609 | 20051228 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| KR 2006077812 | A | 20060705 | KR 2004-117781 | 20041231 |
| PRIORITY APPLN. INFO.: | | | KR 2004-117781 | A 20041231 |
| AB | A controlled release combination formulation for oral administration comprises a controlled release portion containing metformin or a salt thereof as an active ingredient, and a combination of a polyethylene oxide and a natural gum as a carrier for controlled release; and a rapid-release portion containing a sulfonylurea-based drug for treating diabetes as an active ingredient coated on the controlled release portion and it is capable of maintaining an effective concentration of the drugs in blood at a constant level. Thus, a combination formulation contained metformin-HCl 46.11, and glimepiride 0.18%. | | | |
| CC | 63-6 (Pharmaceuticals) | | | |
| | Section cross-reference(s): 1 | | | |
| REFERENCE COUNT: | 3 | THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT | | |

L185 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:653417 CAPLUS Full-text
DOCUMENT NUMBER: 145:110367
TITLE: Pharmaceutical combination formulations comprising a
3-hydroxy-3-methylglutaryl CoA reductase inhibitor and
an antihypertensive agent
INVENTOR(S): Woo, Jong Soo; Chi, Moon Hyuk;
Kim, Yong Il
PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea

SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2006071077 | A1 | 20060706 | WO 2005-KR4607 | 20051228 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

PRIORITY APPLN. INFO.: KR 2004-116328 A 20041230

AB A complex formulation for oral administration comprises a sustained release formulation of an HMG-CoA reductase inhibitor (e.g., mevastatin, lovastatin, or pravastatin) and a film layer for rapid release of an anti-hypertensive, the film layer being coated on the sustained release formulation, can achieve improved therapeutic effects of the anti-hypertensive agent by promptly releasing it, while maintaining a constant drug level of the HMG-CoA reductase inhibitor in blood through a slow release. Accordingly, the complex formulation is useful for preventing and treating diseases such as hyperlipidemia, atherosclerosis, hypertension and cardiovascular disease. Combination formulations of amlodipine camsylate-simvastatin mixture exhibit dissoln. rates similar to those of the sustained release formulations of simvastatin.

CC 63-6 (Pharmaceuticals)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L185 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1123805 CAPLUS Full-text

DOCUMENT NUMBER: 143:411049

TITLE: Sustained-release formulation for oral administration of HMG-Co A reductase inhibitor and method for the preparation thereof

INVENTOR(S): Woo, Jong-Soo; Yi, Hong-Gi; Chi, Moon-Hyuk; Ryu, Jae-Kuk; Jung, Si-Young; Kim, Yong-Il

PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|---|----------|-----------------|----------|
| WO 2005097194 | A1 | 20051020 | WO 2005-KR1021 | 20050408 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, | | | |

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

KR 2005099583 A 20051013 KR 2004-24734 20040410
AU 2005230362 A1 20051020 AU 2005-230362 20050408
CA 2562418 A1 20051020 CA 2005-2562418 20050408
EP 1744782 A1 20070124 EP 2005-733408 20050408

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.:

KR 2004-24734 A 20040410
WO 2005-KR1021 W 20050408

AB The sustained release formulation for oral administration of an HMG-CoA reductase inhibitor of the present invention can be easily and economically prepared and is capable of maintaining a constant drug level in blood by slowly releasing the HMG-CoA reductase inhibitor at a uniform rate for 24 h. Accordingly, the sustained release formulation of the present invention can be effectively used for lowering blood cholesterol and triglyceride levels. A sustained-release tablet contained lovastatin 60, vitamin E TPGS 20, BHT 2, HPMC-2910 50, sodium alginate 36, xanthan gum 150, locust bean gum 50, propylene glycol ester alginate 30, HPMC-2208 110, kofovidone 35, light anhydrous silicic acid 10, and magnesium stearate 2 mg. Effects of tablets on lowering cholesterol and triglyceride levels in hyperlipidemic rats is shown.

IC ICM A61K047-00

ICS A61P009-10

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L185 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:347981 CAPLUS Full-text

DOCUMENT NUMBER: 140:344933

TITLE: Sustained-release composition for oral administration of drugs

INVENTOR(S): Woo, Jong-Soo; Chi, Moon-Hyuk

PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea

SOURCE: Eur. Pat. Appl., 22 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| EP 1413295 | A1 | 20040428 | EP 2003-14596 | 20030708 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| KR 2004036130 | A | 20040430 | KR 2002-64940 | 20021023 |
| US 2004081693 | A1 | 20040429 | US 2003-650931 | 20030827 |
| CA 2502731 | A1 | 20040506 | CA 2003-2502731 | 20031023 |
| WO 2004037290 | A1 | 20040506 | WO 2003-KR2241 | 20031023 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, | | | | |

instant
innovative

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
 GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KZ, LC, LK, LR, LS,
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
 TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 ML, MR, NE, SN, TD, TG

| | | | | |
|---------------|----|----------|------------------|----------|
| AU 2003272118 | A1 | 20040513 | AU 2003-272118 | 20031023 |
| JP 2004143175 | A | 20040520 | JP 2003-362832 | 20031023 |
| BR 2003015604 | A | 20050823 | BR 2003-15604 | 20031023 |
| CN 1741819 | A | 20060301 | CN 2003-80101734 | 20031023 |
| NZ 539192 | A | 20061130 | NZ 2003-539192 | 20031023 |

PRIORITY APPLN. INFO.:

| | | |
|----------------|---|----------|
| KR 2002-64940 | A | 20021023 |
| WO 2003-KR2241 | W | 20031023 |

AB A sustained-release composition for oral administration of a drug, comprises the drug, a mixture of sodium alginate and xanthan gum as a carrier for sustained release and a mixture of hydroxypropyl Me cellulose and propylene glycol alginate as a gel hydration accelerator, which is capable of maintaining a constant drug level in blood for 24 h or more owing to the fact that the drug release rate follows zero order kinetics and does not significantly vary with the degree of gastrointestinal motility due to rapid gel hydration without forming a non-gelated core. For example, sustained-release tablets were formulated containing nifedipine 33, Na alginate 500, xanthan gum 125, propylene glycol alginate 10, hydroxypropyl Me cellulose 45, Kollidon VA64 25, light anhydrous silicic acid 7, and Mg stearate 2 parts.

IC ICM A61K009-20

CC 63-6 (Pharmaceuticals)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L185 ANSWER 5 OF 23 MEDLINE on STN DUPLICATE 2

ACCESSION NUMBER: 2005041403 MEDLINE Full-text

DOCUMENT NUMBER: PubMed ID: 15588717

TITLE: Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha).

AUTHOR: Woo Je-Tae; Nakagawa Hiroshi; Krecic Annette M; Nagai Kazuo; Hamilton Andrew D; Sebti Said M; Stern Paula H

CORPORATE SOURCE: Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Feinberg School of Medicine, 303 E. Chicago Avenue, Chicago, IL 60611, USA.

CONTRACT NUMBER: P60 AR30692 (NIAMS)

SOURCE: Biochemical pharmacology, (2005 Jan 1) Vol. 69, No. 1, pp. 87-95.

Journal code: 0101032. ISSN: 0006-2952.

PUB. COUNTRY: England: United Kingdom

DOCUMENT TYPE: (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200502

ENTRY DATE: Entered STN: 27 Jan 2005

Last Updated on STN: 16 Feb 2005

Entered Medline: 15 Feb 2005

ABSTRACT:

We have previously reported that the statin mevastatin (compactin) reversibly inhibits the fusion of TRAP-positive mononuclear preosteoclasts (pOCs) into multinucleated osteoclasts and disrupts the actin ring in mature osteoclasts through the inhibition of protein prenylation. Protein geranylgeranylation, specifically, is known to be required for pOC fusion and for the function and survival of mature osteoclasts. However, it has not been determined whether protein geranylgeranylation is involved in early differentiation of osteoclasts (pOC formation). The current study shows that statins and the geranylgeranyl transferase I inhibitor GGTI-2166 inhibit the pOC formation induced by RANKL or TNF-alpha in cultures of both mouse marrow-derived macrophage-colony-stimulating factor (M-CSF) dependent monocytes (MD cells) and the mouse monocyte cell line RAW 264.7 (RAW cells). Mevastatin, 0.1-0.6 microM, inhibited the formation of pOCs induced by receptor activator of nuclear factor-kappaB ligand (RANKL) or tumor necrosis factor (TNF-alpha) in both cell cultures. The inhibitory effects of mevastatin were overcome by the addition of mevalonate, farnesyl pyrophosphate or geranylgeranyl pyrophosphate. GGTI-2166 inhibited TRAP activity induced by RANKL or TNF-alpha in both cell cultures and prevented the incorporation of [3H]all-trans geranylgeraniol into prenylated proteins in RAW cells. However, the farnesyl transferase inhibitor FTI-2153 did not inhibit TRAP activity although FTI prevented the incorporation of [14C]mevalonate into farnesylated proteins in RAW cells. Clostridium difficile cytotoxin B (toxin B) inhibited pOC formation induced by RANKL or TNF-alpha in both cell cultures. The inhibitory effects of statins and GGTI-2166 on pOC formation may result from the inhibition of the geranylgeranylation of G-proteins, such as Rho or Rac, suggesting that the geranylgeranylation of these proteins is involved in the early differentiation of progenitor cells into pOCs.

CONTROLLED TERM: *Alkyl and Aryl Transferases: AI, antagonists & inhibitors

Alkyl and Aryl Transferases: ME, metabolism
Animals

*Carrier Proteins: BI, biosynthesis
Cell Line

Enzyme Inhibitors: PD, pharmacology

*Leukocytes, Mononuclear: DE, drug effects

Leukocytes, Mononuclear: ME, metabolism

*Lovastatin: AA, analogs & derivatives

*Lovastatin: PD, pharmacology

*Membrane Glycoproteins: BI, biosynthesis
Mice

*Osteoclasts: DE, drug effects

Osteoclasts: ME, metabolism

RANK Ligand

Receptor Activator of Nuclear Factor-kappa B

*Tumor Necrosis Factor-alpha: BI, biosynthesis

CAS REGISTRY NO.: 73573-88-3 (compactin); 75330-75-5 (Lovastatin)

CHEMICAL NAME: 0 (Carrier Proteins); 0 (Enzyme Inhibitors); 0 (Membrane Glycoproteins); 0 (RANK Ligand); 0 (Receptor Activator of Nuclear Factor-kappa B); 0 (Tnfrsf11a protein, mouse); 0 (Tnfrsf11 protein, mouse); 0 (Tumor Necrosis Factor-alpha); EC 2.5.- (Alkyl and Aryl Transferases); EC 2.5.1.- (geranylgeranyltransferase type-I)

L185 ANSWER 6 OF 23

MEDLINE on STN

DUPLICATE 3

ACCESSION NUMBER: 2004255070 MEDLINE Full-text

DOCUMENT NUMBER: PubMed ID: 15153522

TITLE: Role of calcium in pancreatic islet cell death by IFN-gamma/TNF-alpha.

AUTHOR: Chang Inik; Cho Namjoo; Kim Sunshin; Kim Ja Young; Kim

Eunshil; Woo Ji-Eun; Nam Joo Hyun; Kim Sung Joon;
 Lee Myung-Shik
CORPORATE SOURCE: Department of Medicine, Samsung Medical Center,
 Sungkyunkwan University School of Medicine, Seoul, Korea.
SOURCE: Journal of immunology (Baltimore, Md. : 1950), (2004 Jun 1)
 Vol. 172, No. 11, pp. 7008-14.
 Journal code: 2985117R. ISSN: 0022-1767.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200408
ENTRY DATE: Entered STN: 22 May 2004
 Last Updated on STN: 7 Aug 2004
 Entered Medline: 6 Aug 2004

ABSTRACT:

We studied the intracellular events associated with pancreatic beta cell apoptosis by IFN-gamma/TNF-alpha synergism. IFN-gamma/TNF-alpha treatment of MIN6N8 insulinoma cells increased the amplitude of high voltage-activated Ca(2+) currents, while treatment with IFN-gamma or TNF-alpha alone did not. Cytosolic Ca(2+) concentration ([Ca(2+)](c)) was also increased by IFN-gamma/TNF-alpha treatment. Blockade of L-type Ca(2+) channel by ***nifedipine*** abrogated death of insulinoma cells by IFN-gamma/TNF-alpha. Diazoxide that attenuates voltage-activated Ca(2+) currents inhibited MIN6N8 cell death by IFN-gamma/TNF-alpha, while glibenclamide that accentuates voltage-activated Ca(2+) currents augmented insulinoma cell death. A protein kinase C inhibitor attenuated MIN6N8 cell death and the increase in [Ca(2+)](c) by IFN-gamma/TNF-alpha. Following the increase in [Ca(2+)](c), calpain was activated, and calpain inhibitors decreased insulinoma cell death by IFN-gamma/TNF-alpha. As a downstream of calpain, calcineurin was activated and the inhibition of calcineurin activation by FK506 diminished insulinoma cell death by IFN-gamma/TNF-alpha. BAD phosphorylation was decreased by IFN-gamma/TNF-alpha because of the increased calcineurin activity, which was reversed by FK506. IFN-gamma/TNF-alpha induced cytochrome c translocation from mitochondria to cytoplasm and activation of caspase-9. Effector caspases such as caspase-3 or -7 were also activated by IFN-gamma/TNF-alpha treatment. These results indicate that IFN-gamma/TNF-alpha synergism induces pancreatic beta cell apoptosis by Ca(2+) channel activation followed by downstream intracellular events such as mitochondrial events and caspase activation and also suggest the therapeutic potential of Ca(2+) modulation in type 1 diabetes.

CONTROLLED TERM: Animals
 *Apoptosis
 Calcineurin: PH, physiology
 *Calcium: PH, physiology
 Carrier Proteins: ME, metabolism
 Caspases: ME, metabolism
 Cytochromes c: ME, metabolism
 *Interferon Type II: PD, pharmacology
 *Islets of Langerhans: PA, pathology
 Mice
 Mice, Inbred NOD
 Phosphorylation
 Protein Transport
 *Tumor Necrosis Factor-alpha: PD, pharmacology
 bcl-Associated Death Protein

CAS REGISTRY NO.: 7440-70-2 (Calcium); 82115-62-6 (Interferon Type II);
 9007-43-6 (Cytochromes c)
CHEMICAL NAME: 0 (Bad protein, mouse); 0 (Carrier Proteins); 0 (Tumor
 Necrosis Factor-alpha); 0 (bcl-Associated Death Protein);

EC 3.1.3.- (Calcineurin); EC 3.4.22.- (Caspases)

L185 ANSWER 7 OF 23 MEDLINE on STN DUPLICATE 6
ACCESSION NUMBER: 95032999 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 7946177
TITLE: Sustained-release *isradipine* compared with
spirapril in the treatment of elderly patients with
isolated systolic hypertension.
AUTHOR: Tomlinson B; Woo J; Critchley J A; Or K K; Chan T
Y; Sanderson J E
CORPORATE SOURCE: Department of Clinical Pharmacology, Chinese University of
Hong Kong, Shatin, New Territories.
SOURCE: American journal of hypertension : journal of the American
Society of Hypertension, (1994 Jul) Vol. 7, No. 7 Pt 2, pp.
35S-39S.
Journal code: 8803676. ISSN: 0895-7061.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
(COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199412
ENTRY DATE: Entered STN: 10 Jan 1995
Last Updated on STN: 3 Feb 1997
Entered Medline: 12 Dec 1994
ABSTRACT:
The benefits of treating isolated systolic hypertension (ISH) have been
established, but the most appropriate choice of drug is still uncertain. For
this reason, a sustained-release formulation of *isradipine* was
compared with spirapril in a double-blind randomized study in elderly Chinese
patients with ISH. The dosage was titrated if necessary after 4 weeks of
treatment. The reduction in systolic/diastolic blood pressure after 8 weeks
was similar for both treatments--20/10 mm Hg with *isradipine* versus
24/6 mm Hg with spirapril--measured in the supine position. There were no
orthostatic symptoms and both treatments were well tolerated.
CONTROLLED TERM: Check Tags: Female; Male
Aged
Angiotensin-Converting Enzyme Inhibitors: TU, therapeutic
use
Blood Pressure: DE, drug effects
Delayed-Action Preparations
Double-Blind Method
Enalapril: AE, adverse effects
*Enalapril: AA, analogs & derivatives
Enalapril: TU, therapeutic use
Heart Rate: DE, drug effects
Humans
*Hypertension: DT, drug therapy
Hypertension: PP, physiopathology
Isradipine: AE, adverse effects
**Isradipine*: TU, therapeutic use
Peak Expiratory Flow Rate: DE, drug effects
Systole
CAS REGISTRY NO.: 75695-93-1 (*Isradipine*); 75847-73-3 (Enalapril);
83647-97-6 (spirapril)
CHEMICAL NAME: 0 (Angiotensin-Converting Enzyme Inhibitors); 0
(Delayed-Action Preparations)

L185 ANSWER 8 OF 23 MEDLINE on STN DUPLICATE 8
 ACCESSION NUMBER: 93083264 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 1451544
 TITLE: *Isradipine* treatment for hypertension in general practice in Hong Kong.
 AUTHOR: Tomlinson B; Woo J; Critchley J A; Teoh R
 CORPORATE SOURCE: Department of Clinical Pharmacology, Prince of Wales Hospital, Shatin, Hong Kong.
 SOURCE: Chinese medical journal, (1992 Jun) Vol. 105, No. 6, pp. 446-50.
 Journal code: 7513795. ISSN: 0366-6999.
 PUB. COUNTRY: China
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199301
 ENTRY DATE: Entered STN: 29 Jan 1993
 Last Updated on STN: 29 Jan 1993
 Entered Medline: 6 Jan 1993

ABSTRACT:

A 6-week open study of the introduction of *isradipine* treatment was conducted in general practice in Hong Kong. 303 Chinese patients with mild to moderate hypertension entered the study. Side effects were reported in 21% of patients and caused withdrawal from the study in 3 patients. The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with *isradipine* or with placebo. Supine blood pressure was reduced (P less than 0.01) from 170 +/- 20/102 +/- 6 mmHg to 153 +/- 19/92 +/- 8, 147 +/- 18/88 +/- 7 and 144 +/- 14/87 +/- 6 mmHg at 2, 4 and 6 weeks respectively in evaluable patients. Similar reductions occurred in standing blood pressure and there was no evidence of postural hypotension. Normalization and responder rates at 6 weeks were 86% and 69% respectively. Dosage was increased from 2.5 mg b.d. to 5 mg b.d. at 4 weeks in patients with diastolic blood pressure greater than 90 mmHg and their further response was greater than those remaining on 2.5 mg b.d.

CONTROLLED TERM: Antihypertensive Agents: AE, adverse effects
 *Antihypertensive Agents: TU, therapeutic use
 Dizziness: CI, chemically induced
 Family Practice
 Headache: CI, chemically induced
 Hong Kong
 Humans
 *Hypertension: DT, drug therapy
Isradipine: AE, adverse effects
 **Isradipine*: TU, therapeutic use

CAS REGISTRY NO.: 75695-93-1 (*Isradipine*)
 CHEMICAL NAME: 0 (Antihypertensive Agents)

L185 ANSWER 9 OF 23 MEDLINE on STN DUPLICATE 9
 ACCESSION NUMBER: 92215632 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 1666837
 TITLE: A high incidence of cough associated with combination therapy of hypertension with *isradipine* and lisinopril in Chinese subjects.
 AUTHOR: Woo J; Chan T Y
 CORPORATE SOURCE: Department of Medicine, Chinese University of Hong Kong.
 SOURCE: The British journal of clinical practice, (1991 Autumn) Vol. 45, No. 3, pp. 178-80.
 Journal code: 0372546. ISSN: 0007-0947.

PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199205
ENTRY DATE: Entered STN: 29 May 1992
Last Updated on STN: 29 May 1992
Entered Medline: 13 May 1992

ABSTRACT:

The efficacy and tolerability of combination therapy using Lisinopril (5-20 mg om) and *Isradipine* (1.25 mg-2.50 mg bd) was assessed in 29/50 Chinese subjects, whose blood pressures were not controlled on *Isradipine* alone. The addition of Lisinopril produced approximately two-fold reductions in blood pressure compared to *Isradipine* alone, increasing the responder rate of the original cohort of 50 subjects by 18% and normalization rate, by 32%. No significant changes in haematological or biochemical parameters, CXR or ECG, were observed. However, use of Lisinopril in our subjects was associated with a high incidence of cough (48%), possibly limiting its use in this population.

CONTROLLED TERM: Check Tags: Female; Male
Adult
Aged
Antihypertensive Agents: AE, adverse effects
Antihypertensive Agents: TU, therapeutic use
Cough: CI, chemically induced
*Dihydropyridines: TU, therapeutic use
Drug Therapy, Combination
Enalapril: AE, adverse effects
*Enalapril: AA, analogs & derivatives
Enalapril: TU, therapeutic use
Humans
*Hypertension: DT, drug therapy
Isradipine
Lisinopril
Middle Aged
CAS REGISTRY NO.: 75695-93-1 (*Isradipine*); 75847-73-3 (Enalapril);
83915-83-7 (Lisinopril)
CHEMICAL NAME: 0 (Antihypertensive Agents); 0 (Dihydropyridines)

L185 ANSWER 10 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2000241769 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 10780857
TITLE: Compactin suppresses bone resorption by inhibiting the fusion of pre-fusion osteoclasts and disrupting the actin ring in osteoclasts.
AUTHOR: Woo J T; Kasai S; Stern P H; Nagai K
CORPORATE SOURCE: Department of Bioengineering, Tokyo Institute of Technology, Yokohama, Japan.
SOURCE: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, (2000 Apr) Vol. 15, No. 4, pp. 650-62.
Journal code: 8610640. ISSN: 0884-0431.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200007
ENTRY DATE: Entered STN: 10 Aug 2000

Last Updated on STN: 10 Aug 2000
Entered Medline: 25 Jul 2000

ABSTRACT:

Compactin (mevastatin), which inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and thus biosynthesis of cholesterol and the prenylation of proteins, inhibits osteoclastic bone resorption. Although it has been suggested that compactin inhibits bone resorption by inducing apoptosis of osteoclasts, the pathway by which compactin inhibits resorption has not been established. We investigated the effect of compactin on the differentiation of osteoclasts and the relationship between the morphological changes elicited by compactin and its inhibitory effect on bone resorption. Compactin inhibited the differentiation of osteoclasts, interfering with the fusion process by which prefusion osteoclasts (pOCs) develop into multinucleated osteoclast-like cells (OCLs), and also disrupted the actin ring of OCLs. The potency of compactin to inhibit fusion of pOCs and to disrupt the actin ring of OCLs corresponded to that of compactin to inhibit bone resorption. The effects of compactin were prevented by the addition of MVA lactone or its downstream products farnesylpyrophosphate (FPP) and geranylgeranyl-pyrophosphate (GGPP) but not by squalene. Apoptosis of OCLs was not induced by the concentration of compactin that inhibited fusion of pOCs and disrupted the actin ring. The normal process of pOC fusion and the integrity of the actin ring were restored by the withdrawal of compactin from the cultures after they had been treated with compactin for 24 h, but they were not restored by the addition of zVAD-fmk, a caspase inhibitor. Compactin also reversibly inhibited interleukin-1beta (IL-1beta)-, 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3)-, and parathyroid hormone (PTH)-stimulated 45Ca release in bone organ cultures. Our results indicate that the inhibitory effects of compactin on bone resorption result from the inhibition of fusion of pOCs into OCLs and disruption of actin ring in OCLs and that apoptosis of OCLs is not necessary for these inhibitory effects of compactin. These effects of compactin are likely to be a consequence of the inhibition of prenylation of proteins that play an important role in the fusion of pOCs and in maintaining actin ring integrity in OCLs.

CONTROLLED TERM:

Check Tags: Male
*Actins: DE, drug effects
Actins: ME, metabolism
Animals
Apoptosis
*Bone Resorption: PP, physiopathology
Calcitriol: PD, pharmacology
Calcium: ME, metabolism
Coculture Techniques
Hydroxymethylglutaryl-CoA Reductase Inhibitors: ME, metabolism
*Hydroxymethylglutaryl-CoA Reductase Inhibitors: PD, pharmacology
Interleukin-1: PD, pharmacology
*Lovastatin: AA, analogs & derivatives
Lovastatin: ME, metabolism
Lovastatin: PD, pharmacology
*Membrane Fusion: DE, drug effects
Mevalonic Acid: ME, metabolism
Mice
*Osteoclasts: DE, drug effects
Osteoclasts: ME, metabolism
Parathyroid Hormone: PD, pharmacology
Polyisoprenyl Phosphates: ME, metabolism

CAS REGISTRY NO.:

13058-04-3 (farnesyl pyrophosphate); 150-97-0 (Mevalonic Acid); 32222-06-3 (Calcitriol); 6699-20-3 (geranylgeranyl pyrophosphate); 73573-88-3 (compactin); 7440-70-2

(Calcium); 75330-75-5 (Lovastatin)
CHEMICAL NAME: 0 (Actins); 0 (Hydroxymethylglutaryl-CoA Reductase
Inhibitors); 0 (Interleukin-1); 0 (Parathyroid Hormone); 0
(Polyisoprenyl Phosphates)

L185 ANSWER 11 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN DUPLICATE 1

ACCESSION NUMBER: 2006613981 EMBASE Full-text

TITLE: Low-intensity ultrasound stimulates the viability and matrix gene expression of human articular chondrocytes in **alginate** bead culture.

AUTHOR: Choi B.H.; Woo J.-I.; Min B.-H.; Park S.R.

CORPORATE SOURCE: S.R. Park, Department of Physiology, Inha University College of Medicine, Incheon, Korea, Republic of.
srpark@inha.ac.kr

SOURCE: Journal of Biomedical Materials Research - Part A, (15 Dec 2006) Vol. 79, No. 4, pp. 858-864.

Refs: 25

ISSN: 0021-9304 E-ISSN: 1552-4965 CODEN: JBMRCH

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 027 Biophysics, Bioengineering and Medical Instrumentation

029 Clinical Biochemistry

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 3 Jan 2007

Last Updated on STN: 3 Jan 2007

ABSTRACT: We investigated the effects of low-intensity ultrasound (LIUS) on the activity of human articular chondrocytes isolated from osteoarthritis patients and cultured in the three-dimensional **alginate** beads. LIUS was treated at 0, 100, 200, and 300 mW/cm(2) for 10 min everyday for 2, 7, or 15 days. LIUS induced the viability of cells only at day 15 but not until day 7 after treatment, when examined by trypan blue exclusion and LIVE/DEAD® assay kit. When examined at day 7, the proliferation of cells was not changed by LIUS in the (3)H-thymine incorporation. The expression of matrix producing proteins (type II collagen and proteoglycan) was clearly induced by 200-300 mW/cm(2) LIUS in the incorporation of radioactivity and Northern blot analysis. Although the expression of MMP-1, a matrix degrading protein, was decreased, that of TIMP-1, an inhibitor of MMPs, was not affected by LIUS. Histological analysis revealed an increase in the number and size of glycosaminoglycan-positive lacunae and cellular organelles, appearing as rough endoplasmic reticulum and mitochondria by LIUS. These results showed that the viability and metabolism of human articular chondrocytes in **alginate** culture was induced by LIUS treatment, suggesting that they could be a promising autologous source for cartilage tissue engineering. .COPYRGT. 2006 Wiley Periodicals, Inc.

CONTROLLED TERM: Medical Descriptors:

*ultrasound
*gene expression
*cartilage cell
*cell culture
*cell viability
cell stimulation
cell activity
cell proliferation
protein expression
Northern blotting
cell organelle

rough endoplasmic reticulum
cell size
cell metabolism
cell assay
collagen synthesis
human
controlled study
human tissue
human cell
aged
adult
article

CONTROLLED TERM: Drug Descriptors:
*alginic acid
trypan blue
thymine
collagen type 2: EC, endogenous compound
proteoglycan: EC, endogenous compound
interstitial collagenase: EC, endogenous compound
tissue inhibitor of metalloproteinase 1: EC, endogenous compound
glycosaminoglycan: EC, endogenous compound
matrix protein: EC, endogenous compound

CAS REGISTRY NO.: (alginic acid) 28961-37-7, 29894-36-8, 9005-32-7,
9005-38-3; (trypan blue) 72-57-1; (thymine)
65-71-4; (tissue inhibitor of metalloproteinase 1)
140208-24-8

NAME OF PRODUCT: (1) Noblelife; (2) LIVE/DEAD

COMPANY NAME: (1) Duplogen (Korea, Republic of) ; (2) Molecular Probes
(United States)

L185 ANSWER 12 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN DUPLICATE 4

ACCESSION NUMBER: 1998276743 EMBASE Full-text

TITLE: Glucosamine-induced insulin resistance in 3T3-L1 adipocytes is caused by depletion of intracellular ATP.

AUTHOR: Hresko R.C.; Heimberg H.; *Chi M.M.-Y.*; Mueckler M.

CORPORATE SOURCE: M. Mueckler, Dept. of Cell Biology and Physiology, Washington Univ. School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110, United States. mike@cellbio.wustl.edu

SOURCE: Journal of Biological Chemistry, (7 Aug 1998) Vol. 273, No. 32, pp. 20658-20668. .
Refs: 42
ISSN: 0021-9258 CODEN: JBCHA3

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 003 Endocrinology
029 Clinical Biochemistry

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 17 Sep 1998
Last Updated on STN: 17 Sep 1998

ABSTRACT: Glucosamine, which enters the hexosamine pathway downstream of the rate-limiting step, has been routinely used to mimic the insulin resistance caused by high glucose and insulin. We investigated the effect of glucosamine on insulin-stimulated glucose transport in 3T3-L1 adipocytes. The Δ -insulin (insulin-stimulated minus basal) value for 2-deoxyglucose uptake was dramatically inhibited with increasing concentrations of glucosamine with an ED50 of 1.95 mM. Subcellular fractionation experiments

demonstrated that reduction in insulin-stimulated 2-deoxyglucose uptake by glucosamine was due to an inhibition of translocation of both Glut 1 and Glut 4 from the low density microsomes (LDM) to the plasma membrane. Analysis of the insulin signaling cascade revealed that glucosamine impaired insulin receptor autophosphorylation, insulin receptor substrate (IRS-1) phosphorylation, IRS-1-associated PI 3-kinase activity in the LDM, and AKT-1 activation by insulin. Measurement of intracellular ATP demonstrated that the effects of glucosamine were highly correlated with its ability to reduce ATP levels. Reduction of intracellular ATP using azide inhibited Glut 1 and Glut 4 translocation from the LDM to the plasma membrane, insulin receptor autophosphorylation, and IRS-1 tyrosine phosphorylation. Additionally, both the reduction in intracellular ATP and the effects on insulin action caused by glucosamine could be prevented by the addition of inosine, which served as an alternative energy source in the medium. We conclude that direct administration of glucosamine can rapidly lower cellular ATP levels and affect insulin action in fat cells by mechanisms independent of increased intracellular UDP-N-acetylhexosamines and that increased metabolism of glucose via the hexosamine pathway may not represent the mechanism of glucose toxicity in fat cells.

CONTROLLED TERM: Medical Descriptors:
 *insulin resistance
 glucose metabolism
 protein phosphorylation
 signal transduction
 enzyme activity
 enzyme activation
 enzyme substrate complex
 adipocyte
 nonhuman
 mouse
 controlled study
 animal cell
 article
 priority journal
 Drug Descriptors:
 *adenosine triphosphate: EC, endogenous compound
 *insulin: EC, endogenous compound
 CAS REGISTRY NO.: (adenosine triphosphate) 15237-44-2, 56-65-5, 987-65-5;
 (insulin) 9004-10-8

L185 ANSWER 13 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN DUPLICATE 5
 ACCESSION NUMBER: 97329019 EMBASE Full-text
 DOCUMENT NUMBER: 1997329019
 TITLE: An estimate of chronic disease burden and some economic consequences among the elderly Hong Kong population.
 AUTHOR: Woo J.; Ho S.C.; Chan S.G.; Yu A.L.M.; Yuen Y.K.; Lau J.
 CORPORATE SOURCE: Prof. J. Woo, Department of Medicine, Prince of Wales Hospital, Shatin NT, Hong Kong
 SOURCE: Journal of Epidemiology and Community Health, (1997) Vol. 51, No. 5, pp. 486-489. .
 Refs: 16
 ISSN: 0143-005X CODEN: JECHDR
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
 020 Gerontology and Geriatrics
 036 Health Policy, Economics and Management
 LANGUAGE: English

SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 13 Nov 1997
Last Updated on STN: 13 Nov 1997

ABSTRACT: Objectives - To estimate the burden of chronic disease for an elderly Chinese population aged 70 years and over, and to illustrate the use of this information in estimating the economic consequences of disease burden using stroke as an example. Participants - A total of 1902 subjects recruited by random sampling of the old age and disability allowance schemes, which cover over 90% of the Hong Kong elderly population, stratified by sex and five year age groups from age 70 years onwards. Method - Information was collected on 10 medical conditions at baseline: arthritis, hypertension, cardiac disease, stroke, chronic obstructive airways disease, peptic ulcer, diabetes mellitus, osteoporotic fracture, malignancy, and dementia. A follow up survey was carried out after 18 months to determine the occurrence of new disease and the number with disease who had died. Disease burden is calculated as the number with disease at baseline plus the number developing new disease *minus* the number who had died. Results - Disease burden figures were highest for arthritis, hypertension, cardiac disease, and peptic ulcer, and were higher in the 70-79 age group than the 80+ age group for some diseases. For stroke, the economic cost based on a population projection for 2001 was estimated to be around HK\$1,900,000,000, or US\$250 million. Conclusion - Information on the burden of chronic disease is important. It enables the economic consequences to be estimated so that strategies can be developed to prevent diseases with high costs and known effective preventive methods.

CONTROLLED TERM: Medical Descriptors:
*chronic disease
*economic evaluation
*population research
aged
arthritis: EP, epidemiology
article
cost
dementia: EP, epidemiology
diabetes mellitus: EP, epidemiology
disease association
disease control
female
heart disease: EP, epidemiology
hong kong
human
hypertension: EP, epidemiology
major clinical study
male
malignant neoplastic disease: EP, epidemiology
obstructive airway disease: EP, epidemiology
osteoporosis: EP, epidemiology
peptic ulcer: EP, epidemiology
stroke: EP, epidemiology

L185 ANSWER 14 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN DUPLICATE 7

ACCESSION NUMBER: 92110257 EMBASE Full-text

DOCUMENT NUMBER: 1992110257

TITLE: Tolerability and efficacy of *isradipine* in Chinese hypertensives in general practice.

AUTHOR: Tomlinson B.; Critchley J.A.J.H.; Woo J.; Teoh R.

CORPORATE SOURCE: Dept. of Clinical Pharmacology, Prince of Wales Hospital, Shatin, N.T., Hong Kong, Hong Kong

SOURCE: Current Therapeutic Research - Clinical and Experimental,

(1992) Vol. 51, No. 3, pp. 448-455. .

ISSN: 0011-393X CODEN: CTCEA

COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 006 Internal Medicine
018 Cardiovascular Diseases and Cardiovascular Surgery
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 8 May 1992
Last Updated on STN: 8 May 1992

ABSTRACT: A multicenter open study of *isradipine* in 449 Asian patients, mainly of Chinese extraction, with mild to moderate hypertension was conducted in general practice in Hong Kong and Singapore. The initial dosage was 2.5 mg BID and this was doubled or halved after four weeks, if necessary. Side effects were reported in 18.7% of patients and caused withdrawal from the study in 2.4%. Another 15% of patients were lost to follow-up. The incidence and pattern of side effects were similar to those reported in other studies with *isradipine* or with placebo. The overall reductions in blood pressure over six weeks in evaluable patients were 23/14 mmHg supine and 21/14 mmHg standing with normalization and responder rates of 82% and 74%, respectively. Patients responding less well showed further improvement with dosage increase from 2.5 mg BID to 5 mg BID, whereas those showing the greatest response maintained most of the effect when dosage was reduced to 1.25 mg BID.

CONTROLLED TERM: Medical Descriptors:
*drug efficacy
*drug tolerance
*hypertension: DT, drug therapy
article
chinese
dyspepsia: SI, side effect
flushing
headache
priority journal
vertigo: SI, side effect

L185 ANSWER 15 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN DUPLICATE 10

ACCESSION NUMBER: 91044770 EMBASE Full-text
DOCUMENT NUMBER: 1991044770
TITLE: A clinical evaluation of the efficacy and tolerability of *isradipine* in the treatment of hypertension in a Chinese population.
AUTHOR: Woo J.; Chan T.Y.K.; Critchley J.A.J.H.
CORPORATE SOURCE: Department of Medicine, The Prince of Wales Hospital, Shatin, N.T., Hong Kong
SOURCE: Advances in Therapy, (1990) Vol. 7, No. 6, pp. 362-368. .
ISSN: 0741-238X CODEN: ADTHE7
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 006 Internal Medicine
017 Public Health, Social Medicine and Epidemiology
018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 16 Dec 1991

Last Updated on STN: 16 Dec 1991

ABSTRACT: The efficacy and tolerability of *isradipine* (1.25 and 2.5 mg BID) were assessed in a placebo-controlled open trial in 50 Chinese subjects of varying ages (mean \pm SD age 64 \pm 11 years, range 40 - 79 years). Significant reductions in blood pressure were achieved with both dosages of ***isradipine***, and the overall responder and normalization rates were 68% and 40%, respectively. No age-related changes in efficacy were demonstrated. There were no changes in hematological or biochemical parameters, chest x-ray, or electrocardiographic findings. The incidence of side effects was not different from that on placebo. These findings are similar to those reported in Caucasian subjects.

CONTROLLED TERM: Medical Descriptors:

*blood pressure
*hypertension: DT, drug therapy
adult
aged
article
china
controlled study
female
flushing
headache: SI, side effect
heart palpitation: SI, side effect
human
major clinical study
male
side effect

Drug Descriptors:

*isradipine: AE, adverse drug reaction
*isradipine: DT, drug therapy
*isradipine: DO, drug dose
*isradipine: CT, clinical trial

placebo

CAS REGISTRY NO.: (*isradipine*) 75695-93-1,
88977-22-4

COMPANY NAME: Sandoz (United Kingdom)

L185 ANSWER 16 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2007018332 EMBASE Full-text

TITLE: Optimization of tamsulosin hydrochloride controlled release pellets coated with Surelease and neutralized HPMCP.

AUTHOR: Kim M.-S.; Kim J.-S.; Lee S.; Jun S.W.; Park J.-S.; Woo J.-S.; Hwang S.-J.

CORPORATE SOURCE: S.-J. Hwang, National Research Laboratory of Pharmaceutical Technology, College of Pharmacy, Chungnam National University, 220 Gung-dong, Yuseong-gu, Daejeon 305-764, Korea, Republic of. sjhwang@cnu.ac.kr

SOURCE: Journal of Pharmacy and Pharmacology, (2006) Vol. 58, No. 12, pp. 1611-1616.

Refs: 19

ISSN: 0022-3573 CODEN: JPPMAB

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 037 Drug Literature Index
039 Pharmacy

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 14 Feb 2007
Last Updated on STN: 14 Feb 2007

ABSTRACT: This study was to optimize the coating level in the development of controlled release pellets coated with Surelease and neutralized ***hydroxypropyl*** methylcellulose phthalate (HPMCP) by a computer optimization technique based on a response surface methodology utilizing polynomial equation. A full factorial 3(2) design was used for the optimization procedure with coating level (X(1)) and HPMCP content (X(2)) as the independent variables. The drug release percent at 2, 3 and 5 h were the target responses, which were restricted to 12-39% (Y(1)), 44-70% (Y(2)) and 70-100% (Y(3)), respectively. The quadratic model was well fitted to the data, and the resulting equation was used to predict the responses in the optimal region. It was shown that the optimized coating formulation was achieved at the ratio of 3:1 (Surelease: neutralized HPMCP) with 20% coating level. The optimized formulation showed release profiles and responses, which were close to predicted responses. Therefore, a full factorial 3(2) design and optimization technique can be successfully used in the development of optimized coating formulations based on Surelease and neutralized HPMCP to achieve a controlled release drug delivery system containing tamsulosin hydrochloride. .COPYRG. 2006 The Authors.

CONTROLLED TERM: Medical Descriptors:
article
computer system
controlled release formulation
drug coating
drug delivery system
drug formulation
drug release
drug solubility

CONTROLLED TERM: Drug Descriptors:
*ethyl cellulose: PR, pharmaceuticals
*hydroxypropylmethylcellulose phthalate: PR, pharmaceuticals
*tamsulosin: PR, pharmaceuticals

CAS REGISTRY NO.: (ethyl cellulose) 9004-57-3; (
hydroxypropylmethylcellulose phthalate)
9050-31-1; (tamsulosin) 106133-20-4, 106138-88-9,
106463-17-6, 80223-99-0, 94666-07-6

CHEMICAL NAME: (1) Surelease

COMPANY NAME: (1) Colorcon (United States); Shinetsu (Japan); Youn sung
fine chemicals (Kenya)

L185 ANSWER 17 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights
reserved on STN

ACCESSION NUMBER: 2005559180 EMBASE Full-text

TITLE: Cefuroxime axetil solid dispersions prepared using solution
enhanced dispersion by supercritical fluids.

AUTHOR: Jun S.W.; Kim M.-S.; Jo G.H.; Lee S.; Woo J.S.;
Park J.-S.; Hwang S.-J.

CORPORATE SOURCE: S.-J. Hwang, National Research Laboratory Pharmaceutical
Technology, College of Pharmacy, Chungnam National
University, 220 Gung-dong, Yuseong-gu, Daejeon 305-764,
Korea, Republic of. sjhwang@cnu.ac.kr

SOURCE: Journal of Pharmacy and Pharmacology, (2005) Vol. 57, No.
12, pp. 1529-1537.

Refs: 38

ISSN: 0022-3573 CODEN: JPPMAB

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 037 Drug Literature Index
039 Pharmacy

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 12 Jan 2006

Last Updated on STN: 12 Jan 2006

ABSTRACT: Cefuroxime axetil (CA) solid dispersions with HPMC 2910/PVP K-30 were prepared using solution enhanced dispersion by supercritical fluids (SEDS) in an effort to increase the dissolution rate of poorly water-soluble drugs. Their physicochemical properties in solid state were characterized by differential scanning calorimeter (DSC), powder X-ray diffraction (PXRD), Fourier transform infrared spectrometry (FT-IR) and scanning electron microscopy. No endothermic and characteristic diffraction peaks corresponding to CA were observed for the solid dispersions in DSC and PXRD. FTIR analysis demonstrated the presence of intermolecular hydrogen bonds between CA and HPMC 2910/PVP K-30 in solid dispersions, resulting in the formation of amorphous or non-crystalline CA. Dissolution studies indicated that the dissolution rates were remarkably increased in solid dispersions compared with those in the physical mixture and drug alone. In conclusion, an amorphous or non-crystalline CA solid dispersion prepared using SEDS could be very useful for the formulation of solid dosage forms. .COPYRGHT. 2005 The Authors.

CONTROLLED TERM: Medical Descriptors:
*dispersion
*supercritical fluid
drug solubility
differential scanning calorimetry
X ray diffraction
infrared spectroscopy
scanning electron microscopy
diffraction
hydrogen bond
solid
drug formulation
article
Drug Descriptors:
*cefuroxime axetil: PR, pharmaceuticals
hydroxypropylmethylcellulose: PR, pharmaceuticals
povidone derivative: PR, pharmaceuticals
hpmc 2910
CAS REGISTRY NO.: (cefuroxime axetil) 64544-07-6; (
hydroxypropylmethylcellulose) 9004-65-3
CHEMICAL NAME: (1) Hpmc 2910; (2) Pvp k 30
COMPANY NAME: (2) BASF (Germany); Hanni (Korea, Republic of)

L185 ANSWER 18 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003098727 EMBASE Full-text
TITLE: Contribution of Na(+)-Ca(2+) exchanger to pinacidil-induced relaxation in the rat mesenteric artery.
AUTHOR: Suk Y.T.; Yao X.; *Chi M.W.*; Chak L.A.; Zhen Y.C.; Huang Y.
CORPORATE SOURCE: Y. Huang, Department of Physiology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, Hong Kong.
yu-huang@cuhk.edu.hk
SOURCE: British Journal of Pharmacology, (2003) Vol. 138, No. 3, pp. 453-460. .
Refs: 28
ISSN: 0007-1188 CODEN: BJPCBM
COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 030 Pharmacology
037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 25 Mar 2003

Last Updated on STN: 25 Mar 2003

ABSTRACT: 1. Pinacidil relaxes blood vessels through opening the K(ATP) channels with a resultant membrane hyperpolarization and inhibition of Ca(2+) influx. The aim of this study was to examine the mechanisms thereby pinacidil induces K(+) channel-independent relaxation in isolated endothelium-denuded rat mesenteric artery. 2. Pinacidil-induced relaxation was inhibited by glibenclamide (1-10 μ M) in phenylephrine-precontracted rings, but was unaffected by glibenclamide after inhibition of K(+) channels and VGCCs. Pinacidil-induced K(+) channel-independent relaxation remained unchanged after treatment with cyclopiazonic acid (10 μ M), thapsigargin (1 μ M), ouabain (100 μ M), propranolol (10 μ M), Rp-cAMPS triethylamine (30 μ M), L-NNA (100 μ M), or ODQ (10 μ M). 3. Pinacidil induced more relaxant effect in the presence of *nifedipine* than in the presence of 60 mM K(+) plus ***nifedipine.*** Pretreatment with Na(+)-Ca(2+) exchanger inhibitors, nickel (30-300 μ M) or benzamil (20 μ M) attenuated pinacidil-induced relaxation in normal or in *nifedipine*-containing solution. Pinacidil (1 μ M) produced less relaxant effect with decreasing extracellular Na(+) concentration. Na(+)-free condition abolished the inhibitory effect of benzamil. Both nickel and benzamil inhibited pinacidil-induced relaxation in the presence of glibenclamide (10 μ M). Nickel (300 μ M) did not affect the relaxant response to sodium nitroprusside. 4. Pinacidil relaxed the rings precontracted by active phorbol and U46619 with similar potency. 5. The present results indicate that stimulation of the forward mode Na(+)-Ca(2+) exchange pathway is in part responsible for pinacidil-induced K(+) channel-independent vasorelaxation. Pinacidil also induces K(+) channel-dependent but VGCCs-independent relaxation. The PKC-mediated cellular pathway may be a target site for pinacidil only in higher concentrations.

CONTROLLED TERM: Medical Descriptors:
*artery dilatation
mesenteric artery
potassium channel
isolated artery
drug mechanism
concentration response
calcium channel
extracellular space
drug effect
drug potency
nonhuman
male
rat

controlled study
animal tissue
article
priority journal

Drug Descriptors:

*sodium calcium exchange protein: EC, endogenous compound
*pinacidil: PD, pharmacology
glibenclamide: PD, pharmacology
phenylephrine: PD, pharmacology
cyclopiazonic acid: PD, pharmacology
thapsigargin: PD, pharmacology

ouabain: PD, pharmacology
 propranolol: PD, pharmacology
 n(g) nitroarginine: PD, pharmacology
 1h 1,2,4 oxadiazolo[4,3 a]quinoxalin 1 one: PD,
 pharmacology
nifedipine: CB, drug combination
nifedipine: PD, pharmacology
 potassium ion: CB, drug combination
 potassium ion: PD, pharmacology
 protein inhibitor: PD, pharmacology
 sodium calcium exchange protein inhibitor: PD, pharmacology
 nickel: PD, pharmacology
 benzamil: PD, pharmacology
 sodium
 nitroprusside sodium: PD, pharmacology
 phorbol: PD, pharmacology
 15 hydroxy 11alpha,9alpha epoxymethanoprostanoic acid: PD, pharmacology
 cyclic AMP derivative: PD, pharmacology
 unclassified drug
 (pinacidil) 60560-33-0; (glibenclamide) 10238-21-8;
 (phenylephrine) 532-38-7, 59-42-7, 61-76-7; (cyclopiazonic
 acid) 18172-33-3, 83136-88-3; (thapsigargin) 67526-95-8;
 (ouabain) 11018-89-6, 630-60-4; (propranolol) 13013-17-7,
 318-98-9, 3506-09-0, 4199-09-1, 525-66-6; (n(g)
 nitroarginine) 2149-70-4; (1h 1,2,4 oxadiazolo[4,3
 a]quinoxalin 1 one) 41443-28-1; (*nifedipine*)
 21829-25-4; (potassium ion) 24203-36-9; (nickel)
 7440-02-0; (benzamil) 2898-76-2; (sodium) 7440-23-5;
 (nitroprusside sodium) 14402-89-2, 15078-28-1; (15 hydroxy
 11alpha,9alpha epoxymethanoprostanoic acid)
 56985-40-1

CAS REGISTRY NO.:

CHEMICAL NAME:

COMPANY NAME:

(1) U 46619
 (1) Sigma (United States); Merck (Germany)

L185 ANSWER 19 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1998200312 EMBASE Full-text
 TITLE: Effect of nimodipine on memory after cerebral infarction.
 AUTHOR: Sze K.H.; Sim T.C.; Wong E.; Cheng S.; Woo J.
 CORPORATE SOURCE: Dr. K.H. Sze, Medical and Geriatric Unit, Shatin Hospital,
 33A Kung Kok Street, Ma On Shah, N.T., Hong Kong
 SOURCE: Acta Neurologica Scandinavica, (1998) Vol. 97, No. 6, pp.
 386-392. .
 Refs: 25
 ISSN: 0001-6314 CODEN: ANRSAS
 COUNTRY: Denmark
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 008 Neurology and Neurosurgery
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 14 Aug 1998
 Last Updated on STN: 14 Aug 1998

ABSTRACT: Objectives - Epidemiological studies indicate widespread memory impairment in patients with stroke in the early post-ictal stage. Nimodipine may have psychopharmacological properties and may improve memory. We conducted a single-blind randomized controlled trial to determine whether nimodipine given 7-14 days after cerebral infarction improved memory. Material and methods - One hundred patients with acute cerebral infarction were

consecutively enrolled between D7 to D14. After stratification, patients were randomized to receive oral nimodipine 90 mg daily for 12 weeks, or no drug. Independent assessors administered Mini-Mental State Examination (MMSE) and Fuld Object-Memory Evaluation (FOME) at baseline, 6 weeks, and 12 weeks. Results - Patients receiving nimodipine showed greater improvement in FOME mean scores at 12 weeks ($P=0.0334$), and also in FOME score change across time ($P=0.0283$). Patients with severe disability who received nimodipine also showed greater MMSE score change across time ($P=0.0495$). Conclusion - Nimodipine given 7-14 days after cerebral infarction for 3 months results in memory improvement.

CONTROLLED TERM: Medical Descriptors:
 *memory
 *brain infarction: DT, drug therapy
 *stroke: DT, drug therapy
 *stroke: PC, prevention
 drug effect
 psychopharmacology
 neuropsychological test
 disability
 secondary prevention
 human
 male
 female
 major clinical study
 clinical trial
 randomized controlled trial
 single blind procedure
 controlled study
 aged
 adult
 oral drug administration
 article

Drug Descriptors:
 *nimodipine: CT, clinical trial
 *nimodipine: DT, drug therapy
nifedipine: DT, drug therapy
 acetylsalicylic acid: DT, drug therapy
 warfarin: DT, drug therapy

CAS REGISTRY NO.: (nimodipine) 66085-59-4; (*nifedipine*)
 21829-25-4; (acetylsalicylic acid) 493-53-8,
 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; (warfarin)
 129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2

L185 ANSWER 20 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 94229976 EMBASE Full-text
 DOCUMENT NUMBER: 1994229976
 TITLE: A model of nitrogen removal in waste-waters using
 alginate-entrapped cyanobacteria Anabaena CH3.
 AUTHOR: Lu C.; Chi Mei Lee; Wei Ming Lu; Chen P.-C.
 CORPORATE SOURCE: Dept. of Environmental Engineering, National Chung-Hsing
 University, Taichung 40227, Taiwan, Province of China
 SOURCE: Environment International, (1994) Vol. 20, No. 4, pp.
 529-540. .
 ISSN: 0160-4120 CODEN: ENVIDV
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 046 Environmental Health and Pollution Control
 LANGUAGE: English

SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 17 Aug 1994
Last Updated on STN: 17 Aug 1994

ABSTRACT: A mathematical model accounting for the mass transfer process and the growth kinetics of *alginate*-entrapped cyanobacteria *Anabaena* CH3 in a batch reactor is presented to predict the removal of nitrogenous compounds in wastewaters. The governing equations were cast in dimensionless form and solved by the method of explicit finite difference. The mass transfer behaviour around a spherical bead and diffusion process within the cell-containing gel were drawn from the literature. The biological kinetic parameters of *Anabaena* CH3 in the nitrogenous medium were determined by a series of batch experiments. Good agreement between model predictions and experimental data was obtained by comparing dimensionless concentration profiles of ammonia and nitrate in the bulk liquid phase. The effects of dimensionless groups on the model performance were carried out in the sensitivity analysis. The Thiele modulus (ϕ_2) and the total volume of the cell-containing gel beads available for liquid-phase mass transfer (α) were identified to strongly influence the ammonia removal rate in wastewaters.

CONTROLLED TERM: Medical Descriptors:
*waste water
anabaena
article
mathematical model
nitrogen fixation
priority journal
Drug Descriptors:
*ammonia

CAS REGISTRY NO.: (ammonia) 14798-03-9, 51847-23-5, 7664-41-7

L185 ANSWER 21 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 93117313 EMBASE Full-text
DOCUMENT NUMBER: 1993117313
TITLE: Phototherapeutic keratectomy in nine eyes with superficial corneal diseases.
AUTHOR: Tae Won Hahn; *Woo Jin Sah*; Jae Ho Kim
CORPORATE SOURCE: Department of Ophthalmology, Kangnam St Mary's Hospital, Catholic University Medical College, 505, Banpo-dong, Seocho-ku, Seoul 137-040, Korea, Republic of
SOURCE: Refractive and Corneal Surgery, (1993) Vol. 9, No. 2 SUPPL., pp. S115-S118. .
ISSN: 0883-0444 CODEN: RCSUEH
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 012 Ophthalmology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 30 May 1993
Last Updated on STN: 30 May 1993
CONTROLLED TERM: Medical Descriptors:
*cornea dystrophy: SU, surgery
*cornea dystrophy: DI, diagnosis
*keratectomy
*keratopathy: SU, surgery
*keratopathy: DI, diagnosis
*scar: SU, surgery
*scar: DI, diagnosis
adult

article
 astigmatism: CO, complication
 clinical article
 collagen synthesis
 cornea disease: DI, diagnosis
 cornea disease: SU, surgery
 cornea epithelium
 cornea opacity: DI, diagnosis
 cornea opacity: ET, etiology
 cornea opacity: CO, complication
 cornea transplantation
 excimer laser
 eye photography
 female
 human
 hypermetropia: DI, diagnosis
 hypermetropia: CO, complication
 laser surgery
 male
 pterygium: SU, surgery
 slit lamp
 surgical technique
 topical drug administration
 topography
 visual acuity
 Drug Descriptors:
 ***methylcellulose**
 collagen: EC, endogenous compound
 prednisolone acetate: AD, drug administration
 prednisolone acetate: DO, drug dose

CAS REGISTRY NO.: (methylcellulose) 79484-92-7, 9004-67-5;
 (collagen) 9007-34-5; (prednisolone acetate) 52-21-1,
 52628-64-5

L185 ANSWER 22 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights
 reserved on STN

ACCESSION NUMBER: 85125564 EMBASE Full-text
 DOCUMENT NUMBER: 1985125564
 TITLE: Intrauterine death from ergotamine overdose.
 AUTHOR: Au K.L.; Woo J.S.K.; Wong V.C.W.
 CORPORATE SOURCE: Department of Obstetrics and Gynaecology, University of
 Hong Kong, Hong Kong, Hong Kong
 SOURCE: European Journal of Obstetrics Gynecology and Reproductive
 Biology, (1985) Vol. 19, No. 5, pp. 313-315. .
 CODEN: EOGRAL
 COUNTRY: Netherlands
 DOCUMENT TYPE: Journal
 FILE SEGMENT: 038 Adverse Reactions Titles
 037 Drug Literature Index
 010 Obstetrics and Gynecology
 052 Toxicology
 021 Developmental Biology and Teratology
 030 Pharmacology
 LANGUAGE: English
 ENTRY DATE: Entered STN: 10 Dec 1991
 Last Updated on STN: 10 Dec 1991

ABSTRACT: Fetal death in a primigravid patient who had taken an overdose of
 ergotamine tartrate is presented. Non-stress cardiotocography performed
 shortly after admission was technically unsatisfactory for interpretation but
 revealed the presence of very frequent uterine contractions. The cause of

fetal death in this patient is discussed. Overdosage of ergotamine must be considered a serious threat to the well-being of the fetus in utero.

CONTROLLED TERM: Medical Descriptors:
*adverse drug reaction
*drug overdose
*fetus death
case report
intoxication
suicide attempt
priority journal
fetus
pregnancy
fatality
oral drug administration
human
Drug Descriptors:
*caffeine
*cyclizine
*ergotamine
*ergotamine tartrate
*migril
*nifedipine

CAS REGISTRY NO.: (caffeine) 30388-07-9, 58-08-2; (cyclizine) 303-25-3;
5897-18-7, 82-92-8; (ergotamine) 113-15-5, 52949-35-6;
(ergotamine tartrate) 379-79-3; (*nifedipine*)
21829-25-4

CHEMICAL NAME: Migril

L185 ANSWER 23 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2004:107294 USPATFULL Full-text

TITLE: Sustained release composition for oral administration
of drugs

INVENTOR(S): Woo, Jong-Soo, Suwon-si, KOREA, REPUBLIC OF
Chi, Moon-Hyuk, Suwon-Si, KOREA, REPUBLIC OF

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2004081693 | A1 | 20040429 |
| APPLICATION INFO.: | US 2003-650931 | A1 | 20030827 (10) |

| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | KR 2002-64940 | 20021023 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | David A. Einhom, Esq., Anderson Kill & Olick, P.C., 1251 Avenue of the Americas, New York, NY, 10020 | |
| NUMBER OF CLAIMS: | 9 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 9 Drawing Page(s) | |
| LINE COUNT: | 432 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A sustained-release composition for oral administration of a drug,
comprising the drug, a mixture of sodium alginate and xanthan gum as a
carrier for sustained release and a mixture of hydroxypropyl methylcellulose
and propylene glycol alginate as a gel hydration accelerator, which is

capable of maintaining a constant drug level in blood for 24 hours or more owing to the fact that the drug release rate follows zero order kinetics and does not significantly vary with the degree of gastrointestinal motility due to rapid gel hydration without forming a non-gelated core.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file registry

FILE 'REGISTRY' ENTERED AT 18:03:14 ON 07 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2007 HIGHEST RN 925228-12-2
DICTIONARY FILE UPDATES: 6 MAR 2007 HIGHEST RN 925228-12-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> file caplus

FILE 'CAPLUS' ENTERED AT 18:03:17 ON 07 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Mar 2007 VOL 146 ISS 11
FILE LAST UPDATED: 6 Mar 2007 (20070306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L55

| | | | | | | |
|----|----|-----|---------------|--------|--------|---------------|
| L2 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | NIFEDIPINE/CN |
| L3 | 90 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 21829-25-4/CN |
| L4 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | ISRADIPINE/CN |
| L5 | 3 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 75695-93-1/CN |
| L6 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | LOVASTATIN/CN |

| | | | | | | |
|-----|-------|-----|---------------|--------|--------|---|
| L7 | 37 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 75330-75-5/CRN |
| L8 | 17 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | LOVASTATIN?/CN |
| L17 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | GLIPIZID?/CN |
| L18 | 18 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 29094-61-9/CRN |
| L20 | 91 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L2 OR L3) |
| L21 | 4 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L4 OR L5) |
| L22 | 53 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L6 OR L7 OR L8) |
| L23 | 19 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L17 OR L18) |
| L27 | 167 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L20 OR L21 OR L22 OR L23) |
| L28 | 12370 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | L27 |
| L29 | 8 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINAT?/CN |
| L30 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM/CN |
| L31 | 102 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM?/CN |
| L33 | 28 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE?/CN |
| L34 | 2 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | PROPYLENE GLYCOL ALGINATE?/CN |
| L36 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINATE/CN |
| L37 | 133 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 9005-38-3/CRN |
| L38 | 137 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L29 OR L36 OR L37 |
| L39 | 87 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 11138-66-2/CRN |
| L40 | 111 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L30 OR L31 OR L39 |
| L41 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE/CN |
| L42 | 129 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 9004-65-3/CRN |
| L43 | 151 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L33 OR L41 OR L42 |
| L44 | 6 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (130392-34-6/CRN OR 9005-37-2 /CRN) |
| L45 | 8 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L34 OR L44 |
| L46 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L38 AND (L40 OR L43 OR L45) |
| L47 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L40 AND (L43 OR L45) |
| L49 | 62 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | L38 AND L40 AND L43 AND L45 |
| L50 | 1 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | L46 AND L43 AND L45 |
| L51 | 0 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | L38 AND L47 AND L45 |
| L52 | 0 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | L46 AND L47 AND L45 |
| L53 | 1 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | L46 AND L45 |
| L54 | 0 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | L47 AND L45 |
| L55 | 4 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | (L49 OR L50 OR L51 OR L52 OR L53 OR L54) AND L28 |

=> d stat que L60

| | | | | | | |
|-----|-----|-----|---------------|--------|--------|--|
| L29 | 8 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINAT?/CN |
| L30 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM/CN |
| L31 | 102 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM?/CN |
| L33 | 28 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE?/CN |
| L34 | 2 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | PROPYLENE GLYCOL ALGINATE?/CN |
| L36 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINATE/CN |
| L37 | 133 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 9005-38-3/CRN |
| L38 | 137 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L29 OR L36 OR L37 |
| L39 | 87 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 11138-66-2/CRN |
| L40 | 111 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L30 OR L31 OR L39 |
| L41 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE/CN |
| L42 | 129 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 9004-65-3/CRN |
| L43 | 151 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L33 OR L41 OR L42 |
| L44 | 6 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (130392-34-6/CRN OR 9005-37-2 /CRN) |

```

L45      8 SEA FILE=REGISTRY ABB=ON  PLU=ON  L34 OR L44
L46      1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND (L40 OR L43 OR L45)
L47      1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND (L43 OR L45)
L49      62 SEA FILE=CAPLUS ABB=ON  PLU=ON  L38 AND L40 AND L43 AND L45
L50      1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L43 AND L45
L51      0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L38 AND L47 AND L45
L52      0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L47 AND L45
L53      1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L45
L54      0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L47 AND L45
L56      14331 SEA FILE=CAPLUS ABB=ON  PLU=ON  NIFEDIPINE/BI
L57      908 SEA FILE=CAPLUS ABB=ON  PLU=ON  ISRADIPINE/BI
L58      3338 SEA FILE=CAPLUS ABB=ON  PLU=ON  LOVASTATIN/BI
L59      1072 SEA FILE=CAPLUS ABB=ON  PLU=ON  GLIPIZIDE/BI
L60      4 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L56 OR L57 OR L58 OR L59) AND
      (L49 OR L50 OR L51 OR L52 OR L53 OR L54)

```

=> file medline

FILE 'MEDLINE' ENTERED AT 18:03:32 ON 07 MAR 2007

FILE LAST UPDATED: 7 Mar 2007 (20070307/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d stat que L109

```

L2      1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NIFEDIPINE/CN
L3      90 SEA FILE=REGISTRY ABB=ON  PLU=ON  21829-25-4/CRN
L4      1 SEA FILE=REGISTRY ABB=ON  PLU=ON  ISRADIPINE/CN
L5      3 SEA FILE=REGISTRY ABB=ON  PLU=ON  75695-93-1/CRN
L6      1 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN/CN
L7      37 SEA FILE=REGISTRY ABB=ON  PLU=ON  75330-75-5/CRN
L8      17 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN?/CN
L17     1 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLIPIZID?/CN
L18     18 SEA FILE=REGISTRY ABB=ON  PLU=ON  29094-61-9/CRN
L20     91 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L2 OR L3)
L21     4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L4 OR L5)
L22     53 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L6 OR L7 OR L8)
L23     19 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L17 OR L18)
L27     167 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23)
L29     8 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
L30     1 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM/CN
L31     102 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM?/CN
L33     28 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
      CELLULOSE?/CN
L34     2 SEA FILE=REGISTRY ABB=ON  PLU=ON  PROPYLENE GLYCOL ALGINATE?/CN

L36     1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINATE/CN
L37     133 SEA FILE=REGISTRY ABB=ON  PLU=ON  9005-38-3/CRN
L38     137 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 OR L36 OR L37
L39     87 SEA FILE=REGISTRY ABB=ON  PLU=ON  11138-66-2/CRN
L40     111 SEA FILE=REGISTRY ABB=ON  PLU=ON  L30 OR L31 OR L39
L41     1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
      CELLULOSE/CN

```

| | | | | | |
|------|-------|-------------------|--------|--------|--|
| L42 | 129 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 9004-65-3/CRN |
| L43 | 151 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L33 OR L41 OR L42 |
| L44 | 6 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (130392-34-6/CRN OR 9005-37-2/CRN) |
| L45 | 8 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L34 OR L44 |
| L67 | 57253 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | MEDLINE/LC |
| L70 | 6 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L27 AND L67 |
| L73 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L38 AND L67 |
| L76 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L40 AND L67 |
| L79 | 3 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L43 AND L67 |
| L82 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L45 AND L67 |
| L94 | 18551 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | L70 |
| L95 | 19109 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | NIFEDIPINE |
| L96 | 1475 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | ISRADIPINE |
| L97 | 4043 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | LOVASTATIN |
| L98 | 713 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | GLIPIZIDE |
| L99 | 10 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | L73 |
| L100 | 663 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | SODIUM ALGINATE |
| L101 | 5653 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | ALGINATE |
| L102 | 263 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | L76 |
| L103 | 372 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | XANTHAN GUM |
| L104 | 655 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | L79 |
| L105 | 4774 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | METHYLCELLULOSE |
| L106 | 458 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | HYDROXYPROPYLMETHYLCELLULOSE |
| L107 | 13 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | L82 |
| L108 | 5243 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | PROPYLENE GLYCOL |
| L109 | 0 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | (L94 OR L95 OR L96 OR L97 OR L98) AND (L99 OR L100 OR L101) AND (L102 OR L103) AND (L104 OR L105 OR L106) AND (L107 OR L108) |

=> d stat que L110

| | | | | | |
|-----|-----|-------------------|--------|--------|-----------------------------------|
| L2 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | NIFEDIPINE/CN |
| L3 | 90 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 21829-25-4/CRN |
| L4 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | ISRADIPINE/CN |
| L5 | 3 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 75695-93-1/CRN |
| L6 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | LOVASTATIN/CN |
| L7 | 37 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 75330-75-5/CRN |
| L8 | 17 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | LOVASTATIN?/CN |
| L17 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | GLIPIZID?/CN |
| L18 | 18 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 29094-61-9/CRN |
| L20 | 91 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L2 OR L3) |
| L21 | 4 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L4 OR L5) |
| L22 | 53 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L6 OR L7 OR L8) |
| L23 | 19 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L17 OR L18) |
| L27 | 167 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L20 OR L21 OR L22 OR L23) |
| L29 | 8 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINAT?/CN |
| L30 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM/CN |
| L31 | 102 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM?/CN |
| L33 | 28 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYLCELLULOSE?/CN |
| L36 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINATE/CN |
| L37 | 133 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 9005-38-3/CRN |
| L38 | 137 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L29 OR L36 OR L37 |
| L39 | 87 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 11138-66-2/CRN |
| L40 | 111 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L30 OR L31 OR L39 |
| L41 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYLCELLULOSE/CN |
| L42 | 129 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 9004-65-3/CRN |
| L43 | 151 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L33 OR L41 OR L42 |

| | | | | | | |
|------|-------|-----|---------------|--------|--------|---|
| L67 | 57253 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | MEDLINE/LC |
| L70 | 6 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L27 AND L67 |
| L73 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L38 AND L67 |
| L76 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L40 AND L67 |
| L79 | 3 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L43 AND L67 |
| L94 | 18551 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | L70 |
| L95 | 19109 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | NIFEDIPINE |
| L96 | 1475 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | ISRADIPINE |
| L97 | 4043 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | LOVASTATIN |
| L98 | 713 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | GLIPIZIDE |
| L99 | 10 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | L73 |
| L100 | 663 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | SODIUM ALGINATE |
| L101 | 5653 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | ALGINATE |
| L102 | 263 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | L76 |
| L103 | 372 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | XANTHAN GUM |
| L104 | 655 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | L79 |
| L105 | 4774 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | METHYLCELLULOSE |
| L106 | 458 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | HYDROXYPROPYLMETHYLCELLULOSE |
| L110 | 0 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | (L94 OR L95 OR L96 OR L97 OR L98) AND (L99 OR L100 OR L101) AND (L102 OR L103) AND (L104 OR L105 OR L106) |

=> d stat que L111

| | | | | | | |
|------|-------|-----|---------------|--------|--------|---|
| L29 | 8 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINAT?/CN |
| L30 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM/CN |
| L31 | 102 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM?/CN |
| L33 | 28 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE?/CN |
| L34 | 2 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | PROPYLENE GLYCOL ALGINATE?/CN |
| L36 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINATE/CN |
| L37 | 133 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 9005-38-3/CRN |
| L38 | 137 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L29 OR L36 OR L37 |
| L39 | 87 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 11138-66-2/CRN |
| L40 | 111 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L30 OR L31 OR L39 |
| L41 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE/CN |
| L42 | 129 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 9004-65-3/CRN |
| L43 | 151 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L33 OR L41 OR L42 |
| L44 | 6 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (130392-34-6/CRN OR 9005-37-2 /CRN) |
| L45 | 8 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L34 OR L44 |
| L67 | 57253 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | MEDLINE/LC |
| L73 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L38 AND L67 |
| L76 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L40 AND L67 |
| L79 | 3 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L43 AND L67 |
| L82 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L45 AND L67 |
| L99 | 10 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | L73 |
| L100 | 663 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | SODIUM ALGINATE |
| L101 | 5653 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | ALGINATE |
| L102 | 263 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | L76 |
| L103 | 372 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | XANTHAN GUM |
| L104 | 655 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | L79 |
| L105 | 4774 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | METHYLCELLULOSE |
| L106 | 458 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | HYDROXYPROPYLMETHYLCELLULOSE |
| L107 | 13 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | L82 |
| L108 | 5243 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | PROPYLENE GLYCOL |
| L111 | 0 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | (L99 OR L100 OR L101) AND (L102 OR L103) AND (L104 OR L105 OR L106) AND (L107 OR L108) |

=> d stat que L121

| | | | | | | |
|------|-------|-----|---------------|--------|--------|--|
| L2 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | NIFEDIPINE/CN |
| L3 | 90 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 21829-25-4/CRN |
| L4 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | ISRADIPINE/CN |
| L5 | 3 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 75695-93-1/CRN |
| L6 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | LOVASTATIN/CN |
| L7 | 37 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 75330-75-5/CRN |
| L8 | 17 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | LOVASTATIN?/CN |
| L17 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | GLIPIZID?/CN |
| L18 | 18 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 29094-61-9/CRN |
| L20 | 91 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L2 OR L3) |
| L21 | 4 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L4 OR L5) |
| L22 | 53 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L6 OR L7 OR L8) |
| L23 | 19 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L17 OR L18) |
| L27 | 167 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L20 OR L21 OR L22 OR L23) |
| L29 | 8 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINAT?/CN |
| L30 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM/CN |
| L31 | 102 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM?/CN |
| L33 | 28 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE?/CN |
| L34 | 2 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | PROPYLENE GLYCOL ALGINATE?/CN |
| L36 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINATE/CN |
| L37 | 133 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 9005-38-3/CRN |
| L38 | 137 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L29 OR L36 OR L37 |
| L39 | 87 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 11138-66-2/CRN |
| L40 | 111 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L30 OR L31 OR L39 |
| L41 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE/CN |
| L42 | 129 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 9004-65-3/CRN |
| L43 | 151 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L33 OR L41 OR L42 |
| L44 | 6 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (130392-34-6/CRN OR 9005-37-2 /CRN) |
| L45 | 8 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L34 OR L44 |
| L67 | 57253 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | MEDLINE/LC |
| L70 | 6 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L27 AND L67 |
| L73 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L38 AND L67 |
| L76 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L40 AND L67 |
| L79 | 3 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L43 AND L67 |
| L82 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L45 AND L67 |
| L94 | 18551 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | L70 |
| L95 | 19109 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | NIFEDIPINE |
| L96 | 1475 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | ISRADIPINE |
| L97 | 4043 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | LOVASTATIN |
| L98 | 713 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | GLIPIZIDE |
| L99 | 10 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | L73 |
| L100 | 663 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | SODIUM ALGINATE |
| L101 | 5653 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | ALGINATE |
| L102 | 263 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | L76 |
| L103 | 372 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | XANTHAN GUM |
| L104 | 655 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | L79 |
| L105 | 4774 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | METHYLCELLULOSE |
| L106 | 458 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | HYDROXYPROPYLMETHYLCELLULOSE |
| L107 | 13 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | L82 |
| L108 | 5243 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | PROPYLENE GLYCOL |
| L112 | 426 | SEA | FILE=MEDLINE | ABB=ON | PLU=ON | (ADALAT/BI OR BAY-A-1040/BI OR BAY-1040/BI OR CORDIPIN/BI OR CORDIPINE/BI OR CORINFAR/BI OR FENIGIDIN/BI OR INFEDIPIN/BI OR KORINFAR/BI OR "MONOHYDROCHL |

ORIDE, NIFEDIPINE"/BI OR NIFANGIN/BI OR "NIFEDIPINE MONOHYDROCHLORIDE"/BI OR NIFEDIPINE-GTIS/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI)

L114 19161 SEA FILE=MEDLINE ABB=ON PLU=ON L95 OR L112
L115 382 SEA FILE=MEDLINE ABB=ON PLU=ON (DYNACIRC/BI OR "ISRADIPINE, (+)-ISOMER"/BI OR "ISRADIPINE, (R)-ISOMER"/BI OR "ISRADIPINE, (S)-ISOMER"/BI OR LOMIR/BI OR "PN 200-110"/BI OR "PN 205 033"/BI OR "PN 205 034"/BI OR "PN 205-033"/BI OR "PN 205-034"/BI OR "PN 205033"/BI OR "PN 205034"/BI OR PN-200-110/BI OR PN-205-033/BI OR PN-205-034/BI OR PN205033/BI OR PN205034/BI)
L116 1595 SEA FILE=MEDLINE ABB=ON PLU=ON L96 OR L115
L117 404 SEA FILE=MEDLINE ABB=ON PLU=ON ("LOVASTATIN, (1 ALPHA(S*))-ISOMER"/BI OR "LOVASTATIN, 1 ALPHA-ISOMER (WITHOUT R*/S* NOTATION)"/BI OR "MK 803"/BI OR MK-803/BI OR MK803/BI OR MEVACOR/BI OR MEVINOLIN/BI OR "MONACOLIN K"/BI)
L118 4139 SEA FILE=MEDLINE ABB=ON PLU=ON L97 OR L117
L119 29 SEA FILE=MEDLINE ABB=ON PLU=ON ("ALPHAPHARM BRAND OF GLIPIZIDE"/BI OR "GLIBENESE BRAND OF GLIPIZIDE"/BI OR GLIDIAZINAMIDE/BI OR GLUCOTROL/BI OR GLUPITEL/BI OR GLYDIAZINAMIDE/BI OR GLYPIDIZINE/BI OR "K 4024"/BI OR K-4024/BI OR K4024/BI OR "KENFARMA BRAND OF GLIPIZIDE"/BI OR "LACER BRAND OF GLIPIZIDE"/BI OR "LILLY BRAND OF GLIPIZIDE"/BI OR MELIZIDE/BI OR MINDIAB/BI OR MINIDIAB/BI OR MINODIAB/BI OR OZIDIA/BI OR "PFIZER BRAND OF GLIPIZIDE"/BI OR "PHARMACIA BRAND OF GLIPIZIDE"/BI OR "PYRAZINECARBOXAMIDE, N-(2-(4-(((CYCLOHEXYLAMINO) CARBONYL) AMINO) SULFONYL) PHENYL) ETHYL)-5-METHYL-"/BI)
L120 723 SEA FILE=MEDLINE ABB=ON PLU=ON L98 OR L119
L121 0 SEA FILE=MEDLINE ABB=ON PLU=ON (L94 OR L114 OR L116 OR L118 OR L120) AND (L99 OR L100 OR L101) AND (L102 OR L103) AND (L104 OR L105 OR L106) AND (L107 OR L108)

=> file embase

FILE 'EMBASE' ENTERED AT 18:03:59 ON 07 MAR 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE COVERS 1974 TO 7 Mar 2007 (20070307/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d stat que L143

L2 1 SEA FILE=REGISTRY ABB=ON PLU=ON NIFEDIPINE/CN
L3 90 SEA FILE=REGISTRY ABB=ON PLU=ON 21829-25-4/CRN
L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON ISRADIPINE/CN
L5 3 SEA FILE=REGISTRY ABB=ON PLU=ON 75695-93-1/CRN
L6 1 SEA FILE=REGISTRY ABB=ON PLU=ON LOVASTATIN/CN
L7 37 SEA FILE=REGISTRY ABB=ON PLU=ON 75330-75-5/CRN
L8 17 SEA FILE=REGISTRY ABB=ON PLU=ON LOVASTATIN?/CN
L17 1 SEA FILE=REGISTRY ABB=ON PLU=ON GLIPIZID?/CN
L18 18 SEA FILE=REGISTRY ABB=ON PLU=ON 29094-61-9/CRN
L20 91 SEA FILE=REGISTRY ABB=ON PLU=ON (L2 OR L3)
L21 4 SEA FILE=REGISTRY ABB=ON PLU=ON (L4 OR L5)
L22 53 SEA FILE=REGISTRY ABB=ON PLU=ON (L6 OR L7 OR L8)
L23 19 SEA FILE=REGISTRY ABB=ON PLU=ON (L17 OR L18)
L27 167 SEA FILE=REGISTRY ABB=ON PLU=ON (L20 OR L21 OR L22 OR L23)
L29 8 SEA FILE=REGISTRY ABB=ON PLU=ON SODIUM ALGINAT?/CN

| | | | | | |
|------|-------|-------------------|--------|--------|--|
| L30 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM/CN |
| L31 | 102 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM?/CN |
| L33 | 28 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE?/CN |
| L36 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINATE/CN |
| L37 | 133 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 9005-38-3/CRN |
| L38 | 137 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L29 OR L36 OR L37 |
| L39 | 87 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 11138-66-2/CRN |
| L40 | 111 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L30 OR L31 OR L39 |
| L41 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE/CN |
| L42 | 129 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 9004-65-3/CRN |
| L43 | 151 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L33 OR L41 OR L42 |
| L68 | 30841 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | EMBASE/LC |
| L71 | 6 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L27 AND L68 |
| L74 | 3 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L38 AND L68 |
| L77 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L40 AND L68 |
| L80 | 3 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L43 AND L68 |
| L95 | 19109 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | NIFEDIPINE |
| L96 | 1475 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | ISRADIPINE |
| L97 | 4043 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | LOVASTATIN |
| L98 | 713 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | GLIPIZIDE |
| L100 | 663 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | SODIUM ALGINATE |
| L101 | 5653 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | ALGINATE |
| L105 | 4774 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | METHYLCELLULOSE |
| L106 | 458 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | HYDROXYPROPYLMETHYLCELLULOSE |
| L123 | 46607 | SEA FILE=EMBASE | ABB=ON | PLU=ON | (L71 OR (L95 OR L96 OR L97 OR L98)) |
| L124 | 3286 | SEA FILE=EMBASE | ABB=ON | PLU=ON | (ADALAT/BI OR "ADALAT CRONO"/BI OR "ADALAT PA"/BI OR "ADALAT RETARD"/BI OR ADALATE/BI OR ALDIPIN/BI OR ANGIBLOC/BI OR APONIFED/BI OR APRICAL/BI OR "APRICAL RETARD"/BI OR "BAY 1040"/BI OR "BAY A 1040"/BI OR "BAY A1040"/BI OR BAY1040/BI OR CALCIGARD/BI OR CHRONADALAT/BI OR CHRONADALATE/BI OR CORACTEN/BI OR CORDAFEN/BI OR CORDAFLEX/B I OR CORDICANT/BI OR CORDIPIN/BI OR CORINFAR/BI OR COROTREND/BI OR DEPIN/BI OR "DIMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2 NITROPHENYL) PYRIDINE 3,5 DICARBOXYLATE"/BI OR DURANIFIN/BI OR ECODIPIN/BI OR EMABERIN/BI OR FENIGIDIN/BI OR HERLAT/BI OR INFEDIPINE/BI OR MIFEDIPINE/BI OR MODERAT/BI OR MYOGARD/BI OR NIFANGIN/BI OR NIFEDICOR/BI OR "NIFEDICOR GOCCE"/BI OR NIFEDINE/BI OR NIFEDIPAT/BI OR NIFEHEXAL/BI OR NIFELAT/BI OR NIFENSAR/BI OR NIFEPIDINE/BI OR NIFICAL/BI OR NIFICARD/BI OR NOVONIFEDIN/BI OR PHENYGLIDINE/BI OR PIDILAT/BI OR "PIDILAT RETARD"/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI OR RONIAN/BI OR SEPAMIT/BI OR SLOFEDIPINE/BI OR "SLOFEDIPINE XL"/BI OR UNIDIPINE/BI OR ZENUSIN/BI) |
| L125 | 1049 | SEA FILE=EMBASE | ABB=ON | PLU=ON | (ISRODIPINE/BI OR LOMIR/BI OR "PK 200110"/BI OR "PN 200 110"/BI OR "PN 200-110"/BI OR "PN 200110"/BI OR "PN 200110 N"/BI OR "PN 205033"/BI OR "PN 205034"/BI OR "PN200 110"/BI OR PN200-110/BI OR PN200110/BI OR PRESCAL/BI OR "SDZ 200 110"/BI OR VASCAL/BI) |
| L126 | 2955 | SEA FILE=EMBASE | ABB=ON | PLU=ON | (ALTOCOR/BI OR ALTOPREV/BI OR ARTEIN/BI OR "L 654969"/BI OR LIPIVAS/BI OR LOVACOL/BI OR LOVASTATIN/BI OR MEVACOR/BI OR MEVINACOR/BI OR "MK 0803"/BI OR "MK 803"/BI OR MK0803/BI OR MK803/BI OR "MONACOLIN K"/BI OR "MONAKOLIN K"/BI OR "MSD 803"/BI OR NEOLIPID/BI) |
| L127 | 524 | SEA FILE=EMBASE | ABB=ON | PLU=ON | ("CP 28,720"/BI OR "CP 28720"/BI OR "CP28,720"/BI OR CP28720/BI OR GLIBENESE/BI OR GLIBINESE/BI OR GLIBIZIDE/BI OR GLIDIAZINAMIDE/BI OR GLUCATROL/ BI OR GLUCOTROL/BI OR "GLUCOTROL XL"/BI OR GLYDIAZENAMIDE/BI |

OR GLYDIAZIAMIDE/BI OR GLYDIAZINAMIDE/BI OR GLYPIZIDE/BI OR "K 4024"/BI OR MINIDIAB/BI OR MINODIAB/BI)

L128 46760 SEA FILE=EMBASE ABB=ON PLU=ON (L123 OR L124 OR L125 OR L126 OR L127)

L129 13985 SEA FILE=EMBASE ABB=ON PLU=ON (ALGIN/BI OR ALGINATE/BI OR "ALGINATE SODIUM"/BI OR ALGINATES/BI OR "ALGINIC GULURONIC ACID"/BI OR "BLUEPRINT RAPID"/BI OR COLOURGEL/BI OR "G-C FAST SET"/BI OR "G-C VERICOL AROMA"/BI OR KALGINATE/BI OR KELACID/BI OR "KELCOGEL LV"/BI OR KELGIN/BI OR KELTONE/BI OR "KERR ALGINATE"/BI OR "MANUGEL DJX"/BI OR "MANUGEL DMB"/BI OR MINUS/BI OR NORALGIN/BI OR NORGINE/BI OR POLYMANNURONATE/BI OR "POLYMANNURONIC ACID"/BI OR "POLYMANNURONIC GULURONIC ACID"/BI OR PROTANAL/BI OR PSOTHANOL/BI OR "SODIUM ALGINATE"/BI OR "SODIUM POLYMANNURONATE"/BI OR SORBALGON/BI OR "ZELGAN GREEN"/BI OR "ZELGAN PINK"/BI)

L130 6223 SEA FILE=EMBASE ABB=ON PLU=ON L74 OR (L100 OR L101)

L131 15293 SEA FILE=EMBASE ABB=ON PLU=ON (L129 OR L130)

L132 649 SEA FILE=EMBASE ABB=ON PLU=ON L77 OR XANTHAN GUM

L133 699 SEA FILE=EMBASE ABB=ON PLU=ON XANTHAN OR KELTROL OR RHODIGEL 23

L134 699 SEA FILE=EMBASE ABB=ON PLU=ON (L132 OR L133)

L135 6010 SEA FILE=EMBASE ABB=ON PLU=ON L80 OR (L105 OR L106)

L136 1239 SEA FILE=EMBASE ABB=ON PLU=ON (ADATOCEL/BI OR CONTACTOL/BI OR GONIOSOL/BI OR "HYDROXYPROPYL METHYL CELLULOSE"/BI OR "HYDROXYPROPYL METHYLCELLULOSE"/BI OR "HYDROXYPROPYLMETHYL CELLULOSE"/BI OR HYPROMELLOSE/BI OR "ISOPTO TEARS"/BI OR ISOPTONATURAL/BI OR ISOPTOPLAIN/BI OR ISOPTOTEARS/BI OR "K 8515"/BI OR LUBAFAX/BI OR "METHOCEL E 15"/BI OR "METHOCEL EFK"/BI OR "METHOCEL K100M"/BI OR "METHOCEL K15M"/BI OR "METHOCEL K4M"/BI OR "METHOLOSE TC 5"/BI OR "METHYLHYDROXYPROPYL CELLULOSE"/BI OR METHYLHYDROXYPROPYLCELLULOSE/BI OR METOLOSE/BI OR OCCUCOAT/BI OR OCUCOAT/BI OR "PHARMACOAT 603"/BI OR "PHARMACOAT 606"/BI OR ULTRATEARS/BI)

L137 6060 SEA FILE=EMBASE ABB=ON PLU=ON (L135 OR L136)

L143 2 SEA FILE=EMBASE ABB=ON PLU=ON L128 AND L131 AND L134 AND L137

=> s L143 not L153

L186 2 L143 NOT L153

=> file biosis

FILE 'BIOSIS' ENTERED AT 18:04:37 ON 07 MAR 2007

Copyright (c) 2007 The Thomson Corporation

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 28 February 2007 (20070228/ED)

=> d stat. que L167

L2 1 SEA FILE=REGISTRY ABB=ON PLU=ON NIFEDIPINE/CN

L3 90 SEA FILE=REGISTRY ABB=ON PLU=ON 21829-25-4/CRN

L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON ISRADIPINE/CN

L5 3 SEA FILE=REGISTRY ABB=ON PLU=ON 75695-93-1/CRN

L6 1 SEA FILE=REGISTRY ABB=ON PLU=ON LOVASTATIN/CN

L7 37 SEA FILE=REGISTRY ABB=ON PLU=ON 75330-75-5/CRN

L8 17 SEA FILE=REGISTRY ABB=ON PLU=ON LOVASTATIN?/CN

| | | | | | |
|------|--------|-------------------|--------|--------|---|
| L17 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | GLIPIZID?/CN |
| L18 | 18 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 29094-61-9/CRN |
| L20 | 91 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L2 OR L3) |
| L21 | 4 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L4 OR L5) |
| L22 | 53 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L6 OR L7 OR L8) |
| L23 | 19 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L17 OR L18) |
| L27 | 167 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (L20 OR L21 OR L22 OR L23) |
| L29 | 8 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINAT?/CN |
| L30 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM/CN |
| L31 | 102 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM?/CN |
| L33 | 28 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE?/CN |
| L34 | 2 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | PROPYLENE GLYCOL ALGINATE?/CN |
| L36 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINATE/CN |
| L37 | 133 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 9005-38-3/CRN |
| L38 | 137 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L29 OR L36 OR L37 |
| L39 | 87 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 11138-66-2/CRN |
| L40 | 111 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L30 OR L31 OR L39 |
| L41 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE/CN |
| L42 | 129 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | 9004-65-3/CRN |
| L43 | 151 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L33 OR L41 OR L42 |
| L44 | 6 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | (130392-34-6/CRN OR 9005-37-2 /CRN) |
| L45 | 8 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L34 OR L44 |
| L68 | 30841 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | EMBASE/LC |
| L69 | 196582 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | BIOSIS/LC |
| L72 | 11 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L27 AND L69 |
| L74 | 3 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L38 AND L68 |
| L77 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L40 AND L68 |
| L78 | 3 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L40 AND L69 |
| L80 | 3 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L43 AND L68 |
| L81 | 5 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L43 AND L69 |
| L84 | 1 | SEA FILE=REGISTRY | ABB=ON | PLU=ON | L45 AND L69 |
| L95 | 19109 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | NIFEDIPINE |
| L96 | 1475 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | ISRADIPINE |
| L97 | 4043 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | LOVASTATIN |
| L98 | 713 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | GLIPIZIDE |
| L100 | 663 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | SODIUM ALGINATE |
| L101 | 5653 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | ALGINATE |
| L105 | 4774 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | METHYLCELLULOSE |
| L106 | 458 | SEA FILE=MEDLINE | ABB=ON | PLU=ON | HYDROXYPROPYLMETHYLCELLULOSE |
| L125 | 1049 | SEA FILE=EMBASE | ABB=ON | PLU=ON | (ISRODIPINE/BI OR LOMIR/BI OR "PK 200110"/BI OR "PN 200 110"/BI OR "PN 200-110"/BI OR "PN 200110"/BI OR "PN 200110 N"/BI OR "PN 205033"/BI OR "PN 205034"/BI OR "PN200 110"/BI OR PN200-110/BI OR PN200110/BI OR PRESCAL/BI OR "SDZ 200 110"/BI OR VASCAL/BI) |
| L126 | 2955 | SEA FILE=EMBASE | ABB=ON | PLU=ON | (ALTOCOR/BI OR ALTOPREV/BI OR ARTEIN/BI OR "L 654969"/BI OR LIPIVAS/BI OR LOVACOL/BI OR LOVASTATIN/BI OR MEVACOR/BI OR MEVINACOR/BI OR "MK 0803"/BI OR "MK 803"/BI OR MK0803/BI OR MK803/BI OR "MONACOLIN K"/BI OR "MONAKOLIN K"/BI OR "MSD 803"/BI OR NEOLIPID/BI) |
| L127 | 524 | SEA FILE=EMBASE | ABB=ON | PLU=ON | ("CP 28,720"/BI OR "CP 28720"/BI OR "CP28,720"/BI OR CP28720/BI OR GLIBENESE/BI OR GLIBINESE/BI OR GLIBIZIDE/BI OR GLIDIAZINAMIDE/BI OR GLUCATROL/ BI OR GLUCOTROL/BI OR "GLUCOTROL XL"/BI OR GLYDIAZENAMIDE/BI OR GLYDIAZIAMIDE/BI OR GLYDIAZINAMIDE/BI OR GLYPIZIDE/BI OR "K 4024"/BI OR MINIDIAB/BI OR MINODIAB/BI) |
| L129 | 13985 | SEA FILE=EMBASE | ABB=ON | PLU=ON | (ALGIN/BI OR ALGINATE/BI OR |

"ALGINATE SODIUM"/BI OR ALGINATES/BI OR "ALGINIC GULURONIC ACID"/BI OR "BLUEPRINT RAPID"/BI OR COLOURGEL/BI OR "G-C FAST SET"/BI OR "G-C VERICOL AROMA"/BI OR KALGINATE/BI OR KELACID/BI OR "KELCOGEL LV"/BI OR KELGIN/BI OR KELTONE/BI OR "KERR ALGINATE"/BI OR "MANUGEL DJX"/BI OR "MANUGEL DMB"/BI OR MINUS/BI OR NORALGIN/BI OR NORGINE/BI OR POLYMANNURONATE/BI OR "POLYMANNURONIC ACID"/BI OR "POLYMANNURONIC GULURONIC ACID"/BI OR PROTANAL/BI OR PSOTHANOL/BI OR "SODIUM ALGINATE"/BI OR "SODIUM POLYMANNURONATE"/BI OR SORBALGON/BI OR "ZELGAN GREEN"/BI OR "ZELGAN PINK"/BI)

L130 6223 SEA FILE=EMBASE ABB=ON PLU=ON L74 OR (L100 OR L101)

L132 649 SEA FILE=EMBASE ABB=ON PLU=ON L77 OR XANTHAN GUM

L133 699 SEA FILE=EMBASE ABB=ON PLU=ON XANTHAN OR KELTROL OR RHODIGEL 23

L135 6010 SEA FILE=EMBASE ABB=ON PLU=ON L80 OR (L105 OR L106)

L136 1239 SEA FILE=EMBASE ABB=ON PLU=ON (ADATOCEL/BI OR CONTACTOL/BI OR GONIOSOL/BI OR "HYDROXYPROPYL METHYL CELLULOSE"/BI OR "HYDROXYPROPYL METHYLCELLULOSE"/BI OR "HYDROXYPROPYLMETHYL CELLULOSE"/BI OR HYPROMELLOSE/BI OR "ISOPTO TEARS"/BI OR ISOPTONATURAL/BI OR ISOPTOPLAIN/BI OR ISOPTOTEARS/BI OR "K 8515"/BI OR LUBAFAX/BI OR "METHOCEL E 15"/BI OR "METHOCEL EFK"/BI OR "METHOCEL K100M"/BI OR "METHOCEL K15M"/BI OR "METHOCEL K4M"/BI OR "METHOLOSE TC 5"/BI OR "METHYLHYDROXYPROPYL CELLULOSE"/BI OR METHYLHYDROXYPROPYLCELLULOSE/BI OR METOLOSE/BI OR OCCUCOAT/BI OR OCUCOAT/BI OR "PHARMACOAT 603"/BI OR "PHARMACOAT 606"/BI OR ULTRATEARS/BI)

L137 6060 SEA FILE=EMBASE ABB=ON PLU=ON (L135 OR L136)

L139 23 SEA FILE=EMBASE ABB=ON PLU=ON "ALGINIC ACID PROPYLENE GLYCOL ESTER"+UF/CT

L140 26 SEA FILE=EMBASE ABB=ON PLU=ON ("PROPYLENE GLYCOL ALGINATE"/BI OR "PROPYLENEGLYCOL ALGINATE"/BI)

L141 34 SEA FILE=EMBASE ABB=ON PLU=ON (L139 OR L140)

L157 25683 SEA FILE=BIOSIS ABB=ON PLU=ON L72 OR (L95 OR L96 OR L97 OR L98)

L158 422 SEA FILE=BIOSIS ABB=ON PLU=ON (ADALAT/BI OR "ADALAT CRONO"/BI OR "ADALAT PA"/BI OR "ADALAT RETARD"/BI OR ADALATE/BI OR ALDIPIN/BI OR ANGIBLOC/BI OR APONIFED/BI OR APRICAL/BI OR "APRICAL RETARD"/BI OR "BAY 1040"/BI OR "BAY A 1040"/BI OR "BAY A1040"/BI OR BAY1040/BI OR CALCIGARD/BI OR CHRONADALAT/BI OR CHRONADALATE/BI OR CORACTEN/BI OR CORDAFEN/BI OR CORDAFLEX/B I OR CORDICANT/BI OR CORDIPIN/BI OR CORINFAR/BI OR COROTREND/BI OR DEPIN/BI OR "DIMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2 NITROPHENYL) PYRIDINE 3,5 DICARBOXYLATE"/BI OR DURANIFIN/BI OR ECODIPIN/BI OR EMABERIN/BI OR FENIGIDIN/BI OR HERLAT/BI OR INFEDIPINE/BI OR MIFEDIPINE/BI OR MODERAT/BI OR MYOGARD/BI OR NIFANGIN/BI OR NIFEDICOR/BI OR "NIFEDICOR GOCCE"/BI OR NIFEDINE/BI OR NIFEDIPAT/BI OR NIFEHEXAL/BI OR NIFELAT/BI OR NIFENSAR/BI OR NIFEPIDINE/BI OR NIFICAL/BI OR NIFICARD/BI OR NOVONIFEDIN/BI OR PHENYIGIDINE/BI OR PIDILAT/BI OR "PIDILAT RETARD"/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI OR RONIAN/BI OR SEPAMIT/BI OR SLOFEDIPINE/BI OR "SLOFEDIPINE XL"/BI OR UNIDIPINE/BI OR ZENUSIN/BI)

L159 4086 SEA FILE=BIOSIS ABB=ON PLU=ON (L125 OR L126 OR L127)

L160 26142 SEA FILE=BIOSIS ABB=ON PLU=ON (L157 OR L158 OR L159)

L161 23308 SEA FILE=BIOSIS ABB=ON PLU=ON (L129 OR L130)

L162 1552 SEA FILE=BIOSIS ABB=ON PLU=ON (L132 OR L133)

L163 1071 SEA FILE=BIOSIS ABB=ON PLU=ON L78

L164 1552 SEA FILE=BIOSIS ABB=ON PLU=ON (L162 OR L163)

L165 4435 SEA FILE=BIOSIS ABB=ON PLU=ON L137 OR L81

L166 96 SEA FILE=BIOSIS ABB=ON PLU=ON L84 OR L141

L167 0 SEA FILE=BIOSIS ABB=ON PLU=ON L160 AND L161 AND L164 AND
 L165 AND L166

=> file uspatfull

FILE 'USPATFULL' ENTERED AT 18:04:52 ON 07 MAR 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Mar 2007 (20070306/PD)

FILE LAST UPDATED: 6 Mar 2007 (20070306/ED)

HIGHEST GRANTED PATENT NUMBER: US7188369

HIGHEST APPLICATION PUBLICATION NUMBER: US2007050874

CA INDEXING IS CURRENT THROUGH 6 Mar 2007 (20070306/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Mar 2007 (20070306/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006

=> d stat que L184

L173 67 SEA FILE=USPATFULL ABB=ON PLU=ON (WO2004037226/PN OR
 EP331385/PN OR EP616508/PN OR EP782846/PN OR AU2003274655/PN
 OR CA2054822/PN OR CA2411153/PN OR CA2503380/PN OR EP1150722/PN
 OR EP1296656/PN OR EP1299499/PN OR EP1558222/PN OR EP241178/PN
 OR EP484186/PN OR EP740528/PN OR EP812545/PN OR EP983326/PN
 OR US2002012680/PN OR US2002032171/PN OR US2006057204/PN OR
 US6267985/PN OR US6294192/PN OR US6451339/PN OR US6703044/PN
 OR US6761903/PN OR WO2002000201/PN OR WO2002005620/PN OR
 WO2002005660/PN OR WO2002005661/PN OR WO2003080056/PN OR
 WO2003090693/PN OR WO2004113042/PN OR WO2005046363/PN OR
 WO2005107713/PN OR WO9517104/PN OR AT103492/PN OR AT180170/PN
 OR AT188118/PN OR AT203148/PN OR AT228776/PN OR AT235228/PN OR
 AT254157/PN OR AT305802/PN OR AT334662/PN OR AT338800/PN OR
 AU2000063445/PN OR AU2001013246/PN OR AU2003213020/PN OR
 AU2003218058/PN OR AU2003230719/PN OR AU2003234240/PN OR
 AU2003237944/PN OR AU2003297561/PN OR AU2004249662/PN OR
 AU2004289248/PN OR AU2005230362/PN OR AU590403/PN OR AU618932/P
 N OR AU657706/PN OR AU667471/PN OR AU683713/PN OR AU688837/PN
 OR AU713127/PN OR AU725810/PN OR AU731072/PN OR AU740326/PN OR
 AU753760/PN OR AU754917/PN OR AU772345/PN OR AU782828/PN OR
 AU8172030/PN OR AU8770616/PN OR AU8770617/PN OR AU9176742/PN
 OR AU9186961/PN OR AU9220020/PN OR AU9513020/PN OR AU9514318/PN
 OR AU9673269/PN OR AU9724856/PN OR AU9856271/PN OR AU9879126/P
 N OR AU9888405/PN OR AU9892840/PN OR AU9910043/PN OR AU9929241/
 PN OR AU9956852/PN OR BG64100/PN OR BR2001008145/PN OR
 BR2001012014/PN OR BR2004015741/PN OR BR9809674/PN OR BR9913227
 /PN OR CA1164264/PN OR CA1300515/PN OR CA2069759/PN OR
 CA2177713/PN OR CA2188331/PN OR CA2200620/PN OR CA2269769/PN
 OR CA2291040/PN OR CA2309380/PN OR CA2338688/PN OR CA2361847/PN
 OR CA2388610/PN OR CA2397832/PN OR CA2414161/PN OR CA2414166/P
 N OR CA24141

L174 6797 SEA FILE=USPATFULL ABB=ON PLU=ON NIFEDIPINE

L175 1469 SEA FILE=USPATFULL ABB=ON PLU=ON ISRADIPINE

L176 5820 SEA FILE=USPATFULL ABB=ON PLU=ON LOVASTATIN

L177 2595 SEA FILE=USPATFULL ABB=ON PLU=ON GLIPIZIDE

L178 15 SEA FILE=USPATFULL ABB=ON PLU=ON L173 AND (L174 OR L175 OR
 L176 OR L177)

L182 8 SEA FILE=REGISTRY ABB=ON PLU=ON (9005-38-3/BI OR 11138-66-2/B
 I OR 9004-65-3/BI OR 9005-37-2/BI OR 9050-31-1/BI OR 71138-97-1
 /BI OR 70535-77-2/BI OR 497236-18-7/BI)

L183 9847 SEA FILE=USPATFULL ABB=ON PLU=ON L182

L184 9 SEA FILE=USPATFULL ABB=ON PLU=ON L183 AND L178

=> s L184 not L170

L187 9 L184 NOT L170

=> => file caplus

FILE 'CAPLUS' ENTERED AT 18:05:40 ON 07 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Mar 2007 VOL 146 ISS 11

FILE LAST UPDATED: 6 Mar 2007 (20070306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L55

| | | | | | | |
|-----|-------|-----|---------------|--------|--------|---------------------------------------|
| L2 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | NIFEDIPINE/CN |
| L3 | 90 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 21829-25-4/CRN |
| L4 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | ISRADIPINE/CN |
| L5 | 3 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 75695-93-1/CRN |
| L6 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | LOVASTATIN/CN |
| L7 | 37 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 75330-75-5/CRN |
| L8 | 17 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | LOVASTATIN?/CN |
| L17 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | GLIPIZID?/CN |
| L18 | 18 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 29094-61-9/CRN |
| L20 | 91 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L2 OR L3) |
| L21 | 4 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L4 OR L5) |
| L22 | 53 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L6 OR L7 OR L8) |
| L23 | 19 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L17 OR L18) |
| L27 | 167 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | (L20 OR L21 OR L22 OR L23) |
| L28 | 12370 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | L27 |
| L29 | 8 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINAT?/CN |
| L30 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM/CN |
| L31 | 102 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | XANTHAN GUM?/CN |
| L33 | 28 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | HYDROXYPROPYL METHYL CELLULOSE?/CN |
| L34 | 2 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | PROPYLENE GLYCOL ALGINATE?/CN |
| L36 | 1 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | SODIUM ALGINATE/CN |
| L37 | 133 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 9005-38-3/CRN |
| L38 | 137 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L29 OR L36 OR L37 |
| L39 | 87 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | 11138-66-2/CRN |
| L40 | 111 | SEA | FILE=REGISTRY | ABB=ON | PLU=ON | L30 OR L31 OR L39 |

L41 1 SEA FILE=REGISTRY ABB=ON PLU=ON HYDROXYPROPYL METHYL
 CELLULOSE/CN
 L42 129 SEA FILE=REGISTRY ABB=ON PLU=ON 9004-65-3/CRN
 L43 151 SEA FILE=REGISTRY ABB=ON PLU=ON L33 OR L41 OR L42
 L44 6 SEA FILE=REGISTRY ABB=ON PLU=ON (130392-34-6/CRN OR 9005-37-2
 /CRN)
 L45 8 SEA FILE=REGISTRY ABB=ON PLU=ON L34 OR L44
 L46 1 SEA FILE=REGISTRY ABB=ON PLU=ON L38 AND (L40 OR L43 OR L45)
 L47 1 SEA FILE=REGISTRY ABB=ON PLU=ON L40 AND (L43 OR L45)
 L49 62 SEA FILE=CAPLUS ABB=ON PLU=ON L38 AND L40 AND L43 AND L45
 L50 1 SEA FILE=CAPLUS ABB=ON PLU=ON L46 AND L43 AND L45
 L51 0 SEA FILE=CAPLUS ABB=ON PLU=ON L38 AND L47 AND L45
 L52 0 SEA FILE=CAPLUS ABB=ON PLU=ON L46 AND L47 AND L45
 L53 1 SEA FILE=CAPLUS ABB=ON PLU=ON L46 AND L45
 L54 0 SEA FILE=CAPLUS ABB=ON PLU=ON L47 AND L45
 L55 4 SEA FILE=CAPLUS ABB=ON PLU=ON (L49 OR L50 OR L51 OR L52 OR
 L53 OR L54) AND L28

=> d stat que L60

L29 8 SEA FILE=REGISTRY ABB=ON PLU=ON SODIUM ALGINAT?/CN
 L30 1 SEA FILE=REGISTRY ABB=ON PLU=ON XANTHAN GUM/CN
 L31 102 SEA FILE=REGISTRY ABB=ON PLU=ON XANTHAN GUM?/CN
 L33 28 SEA FILE=REGISTRY ABB=ON PLU=ON HYDROXYPROPYL METHYL
 CELLULOSE?/CN
 L34 2 SEA FILE=REGISTRY ABB=ON PLU=ON PROPYLENE GLYCOL ALGINATE?/CN

 L36 1 SEA FILE=REGISTRY ABB=ON PLU=ON SODIUM ALGINATE/CN
 L37 133 SEA FILE=REGISTRY ABB=ON PLU=ON 9005-38-3/CRN
 L38 137 SEA FILE=REGISTRY ABB=ON PLU=ON L29 OR L36 OR L37
 L39 87 SEA FILE=REGISTRY ABB=ON PLU=ON 11138-66-2/CRN
 L40 111 SEA FILE=REGISTRY ABB=ON PLU=ON L30 OR L31 OR L39
 L41 1 SEA FILE=REGISTRY ABB=ON PLU=ON HYDROXYPROPYL METHYL
 CELLULOSE/CN
 L42 129 SEA FILE=REGISTRY ABB=ON PLU=ON 9004-65-3/CRN
 L43 151 SEA FILE=REGISTRY ABB=ON PLU=ON L33 OR L41 OR L42
 L44 6 SEA FILE=REGISTRY ABB=ON PLU=ON (130392-34-6/CRN OR 9005-37-2
 /CRN)
 L45 8 SEA FILE=REGISTRY ABB=ON PLU=ON L34 OR L44
 L46 1 SEA FILE=REGISTRY ABB=ON PLU=ON L38 AND (L40 OR L43 OR L45)
 L47 1 SEA FILE=REGISTRY ABB=ON PLU=ON L40 AND (L43 OR L45)
 L49 62 SEA FILE=CAPLUS ABB=ON PLU=ON L38 AND L40 AND L43 AND L45
 L50 1 SEA FILE=CAPLUS ABB=ON PLU=ON L46 AND L43 AND L45
 L51 0 SEA FILE=CAPLUS ABB=ON PLU=ON L38 AND L47 AND L45
 L52 0 SEA FILE=CAPLUS ABB=ON PLU=ON L46 AND L47 AND L45
 L53 1 SEA FILE=CAPLUS ABB=ON PLU=ON L46 AND L45
 L54 0 SEA FILE=CAPLUS ABB=ON PLU=ON L47 AND L45
 L56 14331 SEA FILE=CAPLUS ABB=ON PLU=ON NIFEDIPINE/BI
 L57 908 SEA FILE=CAPLUS ABB=ON PLU=ON ISRADIPINE/BI
 L58 3338 SEA FILE=CAPLUS ABB=ON PLU=ON LOVASTATIN/BI
 L59 1072 SEA FILE=CAPLUS ABB=ON PLU=ON GLIPIZIDE/BI
 L60 4 SEA FILE=CAPLUS ABB=ON PLU=ON (L56 OR L57 OR L58 OR L59) AND
 (L49 OR L50 OR L51 OR L52 OR L53 OR L54)

=> s L55 or L60

L188 4 L55 OR L60

=> dup rem L188 L186 L187

FILE 'CAPLUS' ENTERED AT 18:06:15 ON 07 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 18:06:15 ON 07 MAR 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 18:06:15 ON 07 MAR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L188
PROCESSING COMPLETED FOR L186
PROCESSING COMPLETED FOR L187
L189 14 DUP REM L188 L186 L187 (1 DUPLICATE REMOVED)
 ANSWERS '1-4' FROM FILE CAPLUS
 ANSWERS '5-6' FROM FILE EMBASE
 ANSWERS '7-14' FROM FILE USPATFULL

=> d ibib abs hitind hitstr L189 1-4; d iall L189 5-6; d ibib abs kwic hitstr L189
7-14

L189 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2003:319266 CAPLUS Full-text
DOCUMENT NUMBER: 138:343857
TITLE: Pharmaceutical formulations and systems for improved
 absorption and multistage release of active agents
INVENTOR(S): Chen, Feng-Jing; Venkateshwaran, Srinivasan; Krill,
 Steven L.; Patel, Mahesh V.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 55 pp., Cont.-in-part of U.S.
 Ser. No. 898,553.
 CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|---|----------|-----------------|----------|
| US 2003077297 | A1 | 20030424 | US 2002-74687 | 20020211 |
| US 6294192 | B1 | 20010925 | US 1999-258654 | 19990226 |
| US 6267985 | B1 | 20010731 | US 1999-345615 | 19990630 |
| US 6248363 | B1 | 20010619 | US 1999-447690 | 19991123 |
| US 2003064097 | A1 | 20030403 | US 2001-800593 | 20010306 |
| US 6569463 | B2 | 20030527 | | |
| US 2002032171 | A1 | 20020314 | US 2001-877541 | 20010608 |
| US 6761903 | B2 | 20040713 | | |
| US 2002012680 | A1 | 20020131 | US 2001-898553 | 20010702 |
| US 6451339 | B2 | 20020917 | | |
| WO 2003068186 | A1 | 20030821 | WO 2003-US4195 | 20030211 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| AU 2003213020 | A1 | 20030904 | AU 2003-213020 | 20030211 |

PRIORITY APPLN. INFO.:

| | |
|----------------|-------------|
| US 1999-258654 | A1 19990226 |
| US 1999-345615 | A2 19990630 |
| US 1999-447690 | A3 19991123 |
| US 2001-800593 | A2 20010306 |
| US 2001-877541 | A2 20010608 |
| US 2001-898553 | A2 20010702 |
| US 1999-375636 | A2 19990817 |
| US 2000-751968 | A2 20001229 |
| US 2002-74687 | A 20020211 |
| WO 2003-US4195 | W 20030211 |

AB The present invention pertains to pharmaceutical formulations and systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction of active agent is solubilized in the vehicle, with the suspended fraction representing about 5 weight % to about 80 weight % of the active agent and the second fraction representing about 20 weight % to about 95 weight % of the active agent. One or more addnl. active agents, which may be fully solubilized, partially solubilized, or suspended, may also be present. The first and second fractions of the active agent may or may not have different release profiles. Generally, a significant fraction of the solubilized drug will release rapidly, providing for rapid onset, while the suspended drug may be formulated for delayed and/or sustained release. A pharmaceutical suspension contained isotretinoin 40, soybean oil 200, Maisine 35-1 100, and Lutrol F68 100 mg.

IC ICM A61K009-00

INCL 424400000

CC 63-6 (Pharmaceuticals)

IT 50-27-1, Estriol 50-28-2, 17 β -Estradiol, biological studies
 50-35-1, Thalidomide 50-50-0, 17 β -Estradiol benzoate 51-98-9,
 Norethindrone acetate 52-76-6, Lynestrenol 53-16-7, Estrone,
 biological studies 54-11-5, Nicotine 57-63-6, Ethynylestradiol
 57-83-0, Progesterone, biological studies 68-22-4, Norethindrone
 68-23-5, Norethynodrel 68-96-2, Hydroxyprogesterone 71-58-9,
 Medroxyprogesterone acetate 72-33-3, Mestranol 79-10-7D, Acrylic acid,
 polymers 79-41-4D, Methacrylic acid, polymers 79-64-1, Dimethisterone
 128-13-2, Ursodeoxycholic Acid 152-43-2, Quinestrol 297-76-7,
 Ethynodiol diacetate 302-22-7, Chlormadinone acetate 302-23-8,
 Hydroxyprogesterone acetate 313-06-4, 17 β -Estradiol cypionate
 427-51-0, Cyproterone acetate 432-60-0, Allylestrenol 434-03-7,
 Ethisterone 481-97-0, Estrone sulfate 514-61-4, Normethisterone
 514-68-1, Estriol succinate 566-65-4 595-33-5, Megestrol acetate
 630-56-8, Hydroxyprogesterone caproate 637-07-0, Clofibrate 797-63-7,
 Levonorgestrel 848-21-5, Norgestrienone 882-09-7, Clofibric acid
 901-93-9, Estrone acetate 977-79-7, Medrogestone 979-32-8,
 17 β -Estradiol valerate 1318-93-0, Montmorillonite, biological
 studies 1323-54-2, Acetoxypregnenolone 1327-43-1, Magnesium aluminum
 silicate 1335-30-4, Aluminum silicate 1343-88-0, Magnesium silicate
 1405-86-3, Glycyrrhizin 1743-60-8 1951-25-3, Amiodarone 2098-66-0,
 Cyproterone 2529-45-5, Flurogestone acetate 2919-66-6, Melengestrol
 acetate 3137-73-3, Anagestone acetate 3434-88-6, 17 β -Estradiol
 diacetate 3562-63-8, Megestrol 4759-48-2, Isotretinoin 4956-37-0
 5779-47-5, Ethynylestradiol 3-acetate 5934-04-3, Ethynylestradiol
 3-benzoate 6533-00-2, Norgestrel 7280-37-7, Piperazine estrone sulfate
 9000-07-1, Carrageenan 9000-30-0, Guar gum 9000-40-2, Locust bean gum
 9000-65-1, Tragacanth 9000-69-5, Pectin 9002-18-0, Agar 9003-39-8,
 Polyvinyl pyrrolidone 9004-32-4, Sodium carboxymethylcellulose
 9004-57-3, Ethylcellulose 9004-58-4, Ethyl hydroxyethylcellulose
 9004-59-5, Ethyl methylcellulose 9004-64-2, Hydroxypropyl cellulose
 9004-65-3, Hydroxypropyl methylcellulose 9004-67-5,
 Methylcellulose 9005-25-8, Starch, biological studies 9005-37-2

, Propylene glycol alginate 9005-38-3, Sodium alginate
 9063-38-1, Sodium starch glycolate 11138-66-2, Xanthan gum
 12173-47-6, Hectorite 12174-11-7, Attapulgate 14291-86-2 14929-11-4,
 Simfibrate 21829-25-4, Nifedipine 23288-49-5,
 Probucol 25189-83-7, Poly(N-vinyl caprolactam) 25322-68-3,
 Polyethylene glycol 25812-30-0, Gemfibrozil 30299-08-2, Clinofibrate
 31637-97-5, Etofibrate 31694-55-0 31980-29-7, Nicofibrate
 35189-28-7, Norgestimate 39386-78-2, Tamarind gum 41859-67-0,
 Bezafibrate 42017-89-0, Fenofibric acid 42408-82-2, Butorphanol
 42597-57-9, Ronifibrate, biological studies 49562-28-9, Fenofibrate
 52214-84-3, Ciprofibrate 53694-15-8, Polyoxyethylene sorbitol
 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel 55285-45-5,
 Pirifibrate 55937-99-0, Beclobrate 60282-87-3, Gestodene 61748-93-4
 61931-73-5, Ethoxylated glucose 68693-11-8, Modafinil 69047-39-8,
 Binifibrate 73963-72-1, Cilostazol 76547-98-3, Lisinopril
 82626-48-0, Zolpidem 91161-71-6, Terbinafine 95233-18-4, Atovaquone
 99614-02-5, Ondansetron 103062-96-0 107753-78-6, Zafirlukast
 144034-80-0, Rizatriptan 151319-34-5, Zaleplon 159989-64-7, Nelfinavir
 161814-49-9, Amprenavir 162011-90-7, Rofecoxib 163222-33-1, Ezetimibe
 169590-42-5, Celecoxib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulations and systems for improved absorption and
 multistage release of active agents)

IT 9004-65-3, Hydroxypropyl methylcellulose 9005-37-2,
 Propylene glycol alginate 9005-38-3, Sodium alginate
 11138-66-2, Xanthan gum 21829-25-4, Nifedipine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulations and systems for improved absorption and
 multistage release of active agents)

RN 9004-65-3 CAPLUS

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified

CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1


CMF C H4 O

H₃C—OH

CM 3

CRN 57-55-6

CMF C3 H8 O2



RN 9005-37-2 CAPLUS
 CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9005-32-7
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
 CMF C3 H8 O2




RN 9005-38-3 CAPLUS
 CN Alginic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11138-66-2 CAPLUS
 CN Xanthan gum (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 21829-25-4 CAPLUS
 CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 3,5-dimethyl ester (CA INDEX NAME)



L189 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1123805 CAPLUS Full-text
 DOCUMENT NUMBER: 143:411049
 TITLE: Sustained-release formulation for oral administration

of HMG-Co A reductase inhibitor and method for the preparation thereof

INVENTOR(S) :

Woo, Jong-Soo; Yi, Hong-Gi; Chi, Moon-Hyuk; Ryu, Jae-Kuk; Jung, Si-Young; Kim, Yong-Il

PATENT ASSIGNEE(S) :

Hanmi Pharm. Co., Ltd., S. Korea

SOURCE :

PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE :

Patent

LANGUAGE :

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2005097194 | A1 | 20051020 | WO 2005-KR1021 | 20050408 |
| W: | | | | |
| AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: | | | | |
| BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

| | | | | |
|---------------|----|----------|-----------------|----------|
| KR 2005099583 | A | 20051013 | KR 2004-24734 | 20040410 |
| AU 2005230362 | A1 | 20051020 | AU 2005-230362 | 20050408 |
| CA 2562418 | A1 | 20051020 | CA 2005-2562418 | 20050408 |
| EP 1744782 | A1 | 20070124 | EP 2005-733408 | 20050408 |

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.:

| | | |
|----------------|---|----------|
| KR 2004-24734 | A | 20040410 |
| WO 2005-KR1021 | W | 20050408 |

AB The sustained release formulation for oral administration of an HMG-CoA reductase inhibitor of the present invention can be easily and economically prepared and is capable of maintaining a constant drug level in blood by slowly releasing the HMG-CoA reductase inhibitor at a uniform rate for 24 h. Accordingly, the sustained release formulation of the present invention can be effectively used for lowering blood cholesterol and triglyceride levels. A sustained-release tablet contained lovastatin 60, vitamin E TPGS 20, BHT 2, HPMC-2910 50, sodium alginate 36, xanthan gum 150, locust bean gum 50, propylene glycol ester alginate 30, HPMC-2208 110, kofovidone 35, light anhydrous silicic acid 10, and magnesium stearate 2 mg. Effects of tablets on lowering cholesterol and triglyceride levels in hyperlipidemic rats is shown.

IC ICM A61K047-00

ICS A61P009-10

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

ST sustained release oral pharmaceutical HMGCo A reductase inhibitor;

lovastatin sustained release oral pharmaceutical tablet

IT 73573-88-3, Mevastatin 75330-75-5, Lovastatin

79902-63-9, Velostatin 81093-37-0, Pravastatin 81093-37-0D,

Pravastatin, lactones 93957-54-1, Fluvastatin 134523-00-5,

Atorvastatin 143201-11-0, Rivastatin 145599-86-6, Cerivastatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(sustained-release formulation for oral administration of hmg-coa reductase inhibitor and method for preparation thereof)

IT 50-81-7, Ascorbic acid, biological studies 89-65-6, Erythorbic acid

128-37-0, Butylated hydroxy toluene, biological studies 9000-40-2,
Locust bean gum 9002-96-4 9004-65-3, Hydroxypropyl methyl
cellulose 9004-99-3, Polyoxyethylene stearic acid ester
9005-37-2, Propylene glycol alginate 9005-38-3, Sodium
alginate 11138-66-2, Xanthan gum 25013-16-5,
Butylatedhydroxyanisole 106392-12-5, Ethylene glycol propylene glycol
block copolymer

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sustained-release formulation for oral administration of hmg-coa
reductase inhibitor and method for preparation thereof)


IT 75330-75-5, *Lovastatin*

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(sustained-release formulation for oral administration of hmg-coa
reductase inhibitor and method for preparation thereof)

RN 75330-75-5 CAPLUS

CN Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-
dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-
naphthalenyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 9004-65-3, Hydroxypropyl methyl cellulose 9005-37-2,
Propylene glycol alginate 9005-38-3, Sodium alginate
11138-66-2, Xanthan gum

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sustained-release formulation for oral administration of hmg-coa
reductase inhibitor and method for preparation thereof)

RN 9004-65-3 CAPLUS

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified

CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2


CRN 67-56-1

CMF C H4 O

H₃C—OH

CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 CAPLUS
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9005-38-3 CAPLUS
CN Alginic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11138-66-2 CAPLUS
CN Xanthan gum (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L189 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:757454 CAPLUS Full-text
DOCUMENT NUMBER: 139:250344
TITLE: Process for producing drug solid dispersion
INVENTOR(S): Nakano, Tomio; Izumi, Shogo
PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan; Imoto Machinery Co.,
Ltd.

SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2003077827 | A1 | 20030925 | WO 2003-JP3226 | 20030318 |
| W: CA, CN, JP, KR, RU, US | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR | | | | |

PRIORITY APPLN. INFO.: JP 2002-75541 A 20020319

AB Disclosed is a process for producing a drug solid dispersion. In particular, a process for producing a drug solid dispersion, comprising effecting compression and shearing of a material to be kneaded by rotation of disk and further effecting spiral transfer of the material by rotation of spiral screw to thereby produce a kneaded material, wherein a drug solid dispersion composed of at least a pharmaceutically acceptable polymer carrier and a drug is produced by kneading extruder that is so constructed that, in a valley portion between rotary disk and a stationary disk, the material is extruded toward the periphery by a boundary portion of the two disks and fed outward through the interstice provided between the circumference of the rotary disk and an internal surface of cylinder. A solid dispersion of the present invention was prepared from *nifedipine* 20 g and hydroxypropyl Me cellulose acetate succinate (AQOAT) 100 g.

IC ICM A61J003-06

CC 63-6 (Pharmaceuticals)

IT 53-86-1, Indomethacine 57-41-0, Phenytoin 79-41-4D, Methacrylic acid, copolymers 126-07-8, Griseofulvin 1508-65-2, Oxybutynin hydrochloride 7585-39-9, β -Cyclodextrin 9000-01-5, Gum arabic 9000-65-1, Tragacanth 9002-18-0, Agar 9002-89-5, Polyvinyl alcohol 9003-39-8, Polyvinyl pyrrolidone 9004-32-4, Carboxymethyl cellulose sodium salt 9004-38-0, Cellulose Acetate phthalate 9004-53-9, Dextrin 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, TC-5R 9004-67-5, Methyl cellulose 9005-25-8, α -Starch, biological studies 9005-37-2, Propylene glycol alginate 9005-38-3, Sodium alginate 9032-42-2, Hydroxyethyl methyl cellulose 9050-31-1, Hydroxypropyl methyl cellulose phthalate 9057-02-7, Pullulan 9063-38-1, Sodium Carboxymethyl starch 10016-20-3, α -Cyclodextrin 11138-66-2, Xanthan gum 17465-86-0, γ -Cyclodextrin 21829-25-4, *Nifedipine* 25086-89-9, N-Vinyl pyrrolidone vinyl acetate copolymer 25212-88-8, Eudragit L100-55 25322-68-3, Macrogol 37353-59-6, Hydroxymethyl cellulose 54527-84-3, Nicardipine hydrochloride 71138-97-1, AQOAT

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(process for producing drug solid dispersion with polymer carriers)

IT 9004-65-3, TC-5R 9005-37-2, Propylene glycol alginate 9005-38-3, Sodium alginate 9050-31-1, Hydroxypropyl methyl cellulose phthalate 11138-66-2, Xanthan gum 21829-25-4, *Nifedipine* 71138-97-1, AQOAT

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(process for producing drug solid dispersion with polymer carriers)

RN 9004-65-3 CAPLUS

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

$\text{H}_3\text{C}-\text{OH}$

CM 3

CRN 57-55-6
CMF C3 H8 O2

$\begin{array}{c} \text{OH} \\ | \\ \text{H}_3\text{C}-\text{CH}-\text{CH}_2-\text{OH} \end{array}$

RN 9005-37-2 CAPLUS
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2

$\begin{array}{c} \text{OH} \\ | \\ \text{H}_3\text{C}-\text{CH}-\text{CH}_2-\text{OH} \end{array}$

RN 9005-38-3 CAPLUS
CN Alginic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9050-31-1 CAPLUS

CN Cellulose, hydrogen 1,2-benzenedicarboxylate, 2-hydroxypropyl methyl ether
(9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified


CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 88-99-3


CMF C8 H6 O4



CM 3

CRN 67-56-1


CMF C H4 O



CM 4

CRN 57-55-6

CMF C3 H8 O2




RN 11138-66-2 CAPLUS

CN Xanthan gum (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 21829-25-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-
, 3,5-dimethyl ester (CA INDEX NAME)




RN 71138-97-1 CAPLUS

CN Cellulose, 2-hydroxypropyl methyl ether, acetate hydrogen butanedioate
(9CI) (CA INDEX NAME)

CM 1

CRN 110-15-6


CMF C4 H6 O4



CM 2

CRN 64-19-7

CMF C2 H4 O2



CM 3

CRN 9004-65-3

CMF C3 H8 O2 . x C H4 O . x Unspecified

CM 4

CRN 9004-34-6

CMF Unspecified

CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 5

CRN 67-56-1


CMF C H4 O

H₃C—OH

CM 6

CRN 57-55-6

CMF C3 H8 O2



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L189 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:319681 CAPLUS Full-text

DOCUMENT NUMBER: 134:331629

TITLE: Oral transmucosal drug dosage using solid solution

INVENTOR(S): Zhang, Hao; Croft, Jed

PATENT ASSIGNEE(S): Anesta Corp., USA

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2001030288 | A1 | 20010503 | WO 2000-US28113 | 20001012 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| US 6264981 | B1 | 20010724 | US 1999-428071 | 19991027 |
| CA 2388610 | A1 | 20010503 | CA 2000-2388610 | 20001012 |
| EP 1242013 | A1 | 20020925 | EP 2000-972083 | 20001012 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | |
| JP 2003512402 | T | 20030402 | JP 2001-532709 | 20001012 |
| PRIORITY APPLN. INFO.: | | | US 1999-428071 | A 19991027 |
| | | | WO 2000-US28113 | W 20001012 |

AB The present invention is directed toward formulation and method for oral transmucosal delivery of a pharmaceutical. The invention provides a drug formulation comprising a solid pharmaceutical agent in solid solution with a dissoln. agent. The formulation is administered into a patient's oral cavity, delivering the pharmaceutical agent by absorption through a patient's oral

mucosal tissue. The formulation and method provide for improved oral mucosal delivery of the pharmaceutical agent. Oral transmucosal formulation containing piroxicam 2, mannitol 10, Emdex 86.7, sodium hydroxide 0.24, and magnesium stearate 1% was prepared. The C_{max} and AUC of the drug was two fold of the wet granulation formulation and it was absorbed into the blood stream faster.

IC ICM A61F013-02
ICS A61K009-20; A61K009-68
CC 63-6 (Pharmaceuticals)
IT 50-02-2, Dexamethasone 50-28-2, Estradiol, biological studies 50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 50-70-4, Sorbitol, biological studies 50-81-7, Vitamin C, biological studies 50-99-7, Dextrose, biological studies 51-30-9, Isoproterenol hydrochloride 51-43-4, Epinephrine 51-61-6, Dopamine, biological studies 54-11-5, Nicotine 54-31-9, Furosemide 55-63-0, Nitroglycerin 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 57-83-0, Progesterone, biological studies 58-22-0, Testosterone 58-38-8, Prochlorperazine 58-55-9, Theophylline, biological studies 58-82-2, Bradykinin 59-41-6, Bretylium 59-92-7, Levodopa, biological studies 60-79-7, Ergonovine 63-12-7, Benzquinamide 63-42-3, Lactose 67-52-7, 2,4,6(1H,3H,5H)-Pyrimidinetrione 69-65-8, Mannitol 71-50-1, Acetate, biological studies 76-74-4, Pentobarbital 76-75-5, Thiopental 77-10-1, Phencyclidine 77-27-0, Thiamylal 77-86-1, Tris 87-99-0, Xylitol 94-24-6, Tetracaine 97-53-0, Eugenol 107-43-7, Trimethylglycine 110-16-7, Maleic acid, biological studies 113-15-5, Ergotamine 129-51-1, Oxytocic 134-03-2, Sodium ascorbate 137-58-6, Lidocaine 138-56-7, Trimethobenzamide 151-83-7, Methohexital 317-34-0, Aminophylline 361-37-5, Methysergide 364-62-5, Metoclopramide 437-38-7, Fentanyl 465-65-6, Naloxone 479-18-5, Dyphylline 495-40-9, Butyrophenone 511-12-6, Dihydroergotamine 525-66-6, Propranolol 530-08-5, Isoetharine 548-73-2, Droperidol 569-65-3, Meclizine 585-86-4, Lactitol 586-06-1, Metaproterenol 604-75-1, Oxazepam 652-67-5, Isosorbide 721-50-6, Prilocaine 846-49-1, Lorazepam 1400-61-9, Nystatin 1406-18-4, Vitamin E 1421-14-3, Propanidid 2078-54-8, Propofol 3385-03-3, Flunisolide 3715-17-1, Tartrate, biological studies 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4499-40-5, Oxtriphylline, biological studies 6740-88-1, Ketamine 7440-70-2, Calcium, biological studies 9000-30-0, Guar gum 9000-65-1, Tragacanth 9002-60-2, Adrenocorticotrophic hormone, biological studies 9002-64-6, Parathyroid hormone 9002-72-6, Growth hormone 9002-89-5, Polyvinyl alcohol 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-53-9, Dextrin 9004-57-3, Ethylcellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-37-2, Propylene glycolalginat 9005-38-3, Sodium alginate 9005-49-6, Heparin, biological studies 9007-12-9, Calcitonin 9041-90-1, Angiotensin I 9050-36-6, Maltodextrin 9063-38-1, Sodium starch glycolate 11000-17-2, Vasopressin 11103-57-4, Vitamin A 11138-66-2, Xanthan gum 12794-10-4, Benzodiazepine 15078-28-1, Nitroprusside 16679-58-6, Desmopressin 17560-51-9, Metolazone 18559-94-9, Albuterol 21829-25-4, Nifedipine 23031-25-6, Terbutaline 23593-75-1, Clotrimazole 25322-68-3, Polyethylene glycol 25322-68-3D, alkyl ethers 28860-95-9, Carbidopa 28911-01-5, Triazolam 33125-97-2, Etomidate 36322-90-4, Piroxicam 36894-69-6, Labetalol 38396-39-3, Bupivacaine 39404-33-6, Dextrates 42200-33-9, Nadolol 51384-51-1, Metoprolol 54182-58-0, Sucralfate 54767-75-8, Suloctidil 56030-54-7, Sufentanil 59467-70-8, Midazolam 59708-52-0, Carfentanil 60617-12-1, β -Endorphin 61380-40-3, Lofentanil 62571-86-2, Captopril

71195-58-9, Alfentanil 75847-73-3, Enalapril 81147-92-4, Esmolol
103628-46-2, Sumatriptan 106392-12-5, Poloxamer

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral transmucosal drug dosage using solid solution)

IT 9004-65-3, Hydroxypropyl methylcellulose 9005-37-2,
Propylene glycolalginate 9005-38-3, Sodium alginate
11138-66-2, Xanthan gum 21829-25-4, *Nifedipine*

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral transmucosal drug dosage using solid solution)

RN 9004-65-3 CAPLUS

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified

CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1

CMF C H4 O

H₃C—OH

CM 3

CRN 57-55-6

CMF C3 H8 O2

OH
|
H₃C—CH—CH₂—OH

RN 9005-37-2 CAPLUS

CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7

CMF Unspecified


CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6

CMF C3 H8 O2




RN 9005-38-3 CAPLUS
CN Alginic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11138-66-2 CAPLUS
CN Xanthan gum (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 21829-25-4 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 3,5-dimethyl ester (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L189 ANSWER 5 OF 14 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2006359876 EMBASE Full-text
TITLE: Buccal bioadhesive drug delivery - A promising option for orally less efficient drugs.
AUTHOR: Sudhakar Y.; Kuotsu K.; Bandyopadhyay A.K.
CORPORATE SOURCE: A.K. Bandyopadhyay, Buccal Adhesive Research Laboratory, Division of Pharmaceutics, Department of Pharmaceutical Technology, Kolkata, 700032, India. akbju@yahoo.com
SOURCE: Journal of Controlled Release, (10 Aug 2006) Vol. 114, No. 1, pp. 15-40. .
Refs: 208
ISSN: 0168-3659 CODEN: JCREEC
PUBLISHER IDENT.: S 0168-3659(06)00202-1
COUNTRY: Netherlands
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 037 Drug Literature Index
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 23 Aug 2006

Last Updated on STN: 23 Aug 2006

ABSTRACT: Rapid developments in the field of molecular biology and gene technology resulted in generation of many macromolecular drugs including peptides, proteins, polysaccharides and nucleic acids in great number possessing superior pharmacological efficacy with site specificity and devoid of untoward and toxic effects. However, the main impediment for the oral delivery of these drugs as potential therapeutic agents is their extensive presystemic metabolism, instability in acidic environment resulting into inadequate and erratic oral absorption. Parenteral route of administration is the only established route that overcomes all these drawbacks associated with these orally less/inefficient drugs. But, these formulations are costly, have least patient compliance, require repeated administration, in addition to the other hazardous effects associated with this route. Over the last few decades pharmaceutical scientists throughout the world are trying to explore transdermal and transmucosal routes as an alternative to injections. Among the various transmucosal sites available, mucosa of the buccal cavity was found to be the most convenient and easily accessible site for the delivery of therapeutic agents for both local and systemic delivery as retentive dosage forms, because it has expanse of smooth muscle which is relatively immobile, abundant vascularization, rapid recovery time after exposure to stress and the near absence of langerhans cells. Direct access to the systemic circulation through the internal jugular vein bypasses drugs from the hepatic first pass metabolism leading to high bioavailability. Further, these dosage forms are self-administrable, cheap and have superior patient compliance. Developing a dosage form with the optimum pharmacokinetics is a promising area for continued research as it is enormously important and intellectually challenging. With the right dosage form design, local environment of the mucosa can be controlled and manipulated in order to optimize the rate of drug dissolution and permeation. A rational approach to dosage form design requires a complete understanding of the physicochemical and biopharmaceutical properties of the drug and excipients. Advances in experimental and computational methodologies will be helpful in shortening the processing time from formulation design to clinical use. This paper aims to review the developments in the buccal adhesive drug delivery systems to provide basic principles to the young scientists, which will be useful to circumvent the difficulties associated with the formulation design. .COPYRGT. 2006 Elsevier B.V. All rights reserved.

CONTROLLED TERM: Medical Descriptors:
*drug delivery system
cheek mucosa
mucus
saliva
drug absorption
hydrogen bond
disulfide bond
electricity
hydrophobicity
covalent bond
quantitative analysis
qualitative analysis
drug formulation
basement membrane
biocompatibility
physical chemistry
drug release
thermodynamics
drug penetration
drug transport
drug bioavailability
human

nonhuman
review
priority journal
Drug Descriptors:

CONTROLLED TERM:

*penetration enhancing agent: PR, pharmaceuticals
*drug carrier: PR, pharmaceuticals
polycarbophil: PR, pharmaceuticals
carboxymethylcellulose: PR, pharmaceuticals
hydroxypropylcellulose: PR, pharmaceuticals
hydroxypropylmethylcellulose: PR, pharmaceuticals
hydroxyethylcellulose: PR, pharmaceuticals
xanthan: PR, pharmaceuticals
guar gum: PR, pharmaceuticals
chitosan: PR, pharmaceuticals
carrageenan: PR, pharmaceuticals
alginic acid: PR, pharmaceuticals
polycaprolactone: PR, pharmaceuticals
polystyrene: PR, pharmaceuticals
edetic acid: PR, pharmaceuticals
citric acid: PR, pharmaceuticals
salicylate sodium: PR, pharmaceuticals
dodecyl sulfate sodium: PR, pharmaceuticals
polyoxyethylene: PR, pharmaceuticals
glycocholate sodium: PR, pharmaceuticals
taurodeoxycholic acid: PR, pharmaceuticals
glycodeoxycholic acid: PR, pharmaceuticals
ketoprofen: BD, buccal drug administration
ketoprofen: PR, pharmaceuticals
nifedipine: BD, buccal drug administration
nifedipine: PR, pharmaceuticals
propranolol derivative: BD, buccal drug administration
propranolol derivative: PR, pharmaceuticals
diltiazem: BD, buccal drug administration
diltiazem: PR, pharmaceuticals
miconazole: BD, buccal drug administration
miconazole: PR, pharmaceuticals
ergotamine: BD, buccal drug administration
ergotamine: PR, pharmaceuticals
polymer: PR, pharmaceuticals
unindexed drug

CAS REGISTRY NO.:

(polycarbophil) 9003-97-8; (carboxymethylcellulose)
8050-38-2, 9000-11-7, 9004-32-4, 9050-04-8;
(hydroxypropylcellulose) 9004-64-2; (
hydroxypropylmethylcellulose) 9004-65-3;
(hydroxyethylcellulose) 9004-62-0; (**xanthan**)
11138-66-2; (guar gum) 9000-30-0; (chitosan)
9012-76-4; (carrageenan) 9000-07-1, 9049-05-2, 9061-82-9,
9064-57-7; (alginic acid) 28961-37-7, 29894-36-8,
9005-32-7, **9005-38-3;** (polycaprolactone)
24980-41-4, 25248-42-4; (polystyrene) 9003-53-6; (edetic
acid) 150-43-6, 60-00-4; (citric acid) 126-44-3, 5949-29-1,
77-92-9, 8002-14-0; (salicylate sodium) 54-21-7; (dodecyl
sulfate sodium) 151-21-3; (glycocholate sodium) 863-57-0;
(taurodeoxycholic acid) 1180-95-6, 516-50-7;
(glycodeoxycholic acid) 16409-34-0, 360-65-6; (ketoprofen)
22071-15-4, 57495-14-4; (**nifedipine**)
21829-25-4; (diltiazem) 33286-22-5, 42399-41-7;
(miconazole) 22916-47-8; (ergotamine) 113-15-5, 52949-35-6

reserved on STN

ACCESSION NUMBER: 1997171083 EMBASE Full-text
DOCUMENT NUMBER: 1997171083
TITLE: Mucoadhesive drug delivery systems.
AUTHOR: Ahuja A.; Khar R.K.; Ali J.
CORPORATE SOURCE: A. Ahuja, Department of Pharmaceutics, Faculty of Pharmacy,
Jamia Hamdard, New Delhi 110062, India
SOURCE: Drug Development and Industrial Pharmacy, (1997) Vol. 23,
No. 5, pp. 489-515. .
Refs: 144
ISSN: 0363-9045 CODEN: DDIPD8
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 030 Pharmacology
037 Drug Literature Index
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 10 Jul 1997
Last Updated on STN: 10 Jul 1997

ABSTRACT: Mucoadhesion in drug delivery systems has recently gained interest among pharmaceutical scientists as a means of promoting dosage form residence time as well as improving intimacy of contact with various absorptive membranes of the biological system. Besides acting as platforms for sustained-release dosage forms, bioadhesive polymers can themselves exert some control over the rate and amount of drug release, and thus contribute to the therapeutic advantage of such systems. This paper describes some aspects of bioadhesion such as mucus layer, mucoadhesion, and theories of bioadhesion to explain the adhesion mechanism. The factors important to mucoadhesion, the methods used to study bioadhesion, and bioadhesive polymers are described. The methods that evaluate the mucoadhesive dosage forms and finally the bioadhesive drug delivery systems designed for several therapeutic purposes are presented.

CONTROLLED TERM: Medical Descriptors:
*drug adsorption
*membrane binding
*mucosa
bioavailability
drug delivery system
drug design
drug release
human
review
theory
Drug Descriptors:
*alginic acid
*carbopol 934
*carbopol 940
*carboxymethylcellulose
*chitosan
*gelatin
*guar gum
*hydroxyethylcellulose
*hydroxypropylcellulose
*hydroxypropylmethylcellulose
*pectin
*polyacrylic acid
*polycarboxophil
*polymer
*starch

***xanthan**

beclometasone dipropionate: PR, pharmaceuticals
beclometasone dipropionate: PK, pharmacokinetics
budesonide
buprenorphine: PR, pharmaceuticals
buprenorphine: PK, pharmacokinetics
cetylpyridinium salt: PR, pharmaceuticals
cetylpyridinium salt: PK, pharmacokinetics
diltiazem: PK, pharmacokinetics
diltiazem: PR, pharmaceuticals
fluoride sodium: PK, pharmacokinetics
fluoride sodium: PR, pharmaceuticals
glyceryl trinitrate: PK, pharmacokinetics
glyceryl trinitrate: PR, pharmaceuticals
insulin: PR, pharmaceuticals
insulin: PK, pharmacokinetics
isosorbide dinitrate: PR, pharmaceuticals
isosorbide dinitrate: PK, pharmacokinetics
ketoprofen: PK, pharmacokinetics
ketoprofen: PR, pharmaceuticals
lidocaine: PR, pharmaceuticals
lidocaine: PK, pharmacokinetics
metoclopramide: PK, pharmacokinetics
metoclopramide: PR, pharmaceuticals
metronidazole: PR, pharmaceuticals
metronidazole: PK, pharmacokinetics
 nifedipine: PK, pharmacokinetics
 nifedipine: PR, pharmaceuticals
prochlorperazine: PR, pharmaceuticals
prochlorperazine: PK, pharmacokinetics
propranolol: PR, pharmaceuticals
propranolol: PK, pharmacokinetics
replens
retinoic acid: PK, pharmacokinetics
retinoic acid: PR, pharmaceuticals
triamcinolone acetonide: PR, pharmaceuticals
triamcinolone acetonide: PK, pharmacokinetics
unindexed drug
verapamil: PK, pharmacokinetics
verapamil: PR, pharmaceuticals
unclassified drug

CAS REGISTRY NO.: (alginic acid) 28961-37-7, 29894-36-8, 9005-32-7,
9005-38-3; (carbopol 934) 9007-16-3; (carbopol 940)
76050-42-5; (carboxymethylcellulose) 8050-38-2, 9000-11-7,
9004-32-4, 9050-04-8; (chitosan) 9012-76-4; (gelatin)
9000-70-8; (guar gum) 9000-30-0; (hydroxyethylcellulose)
9004-62-0; (hydroxypropylcellulose) 9004-64-2; (
hydroxypropylmethylcellulose) 9004-65-3;
(pectin) 9000-69-5; (polyacrylic acid) 74350-43-9,
87003-46-1, 9003-01-4, 9003-04-7; (polycarbophil)
9003-97-8; (starch) 9005-25-8, 9005-84-9; (**xanthan**
) 11138-66-2; (beclometasone dipropionate)
5534-09-8; (budesonide) 51333-22-3; (buprenorphine)
52485-79-7, 53152-21-9; (cetylpyridinium salt) 123-03-5,
140-72-7, 2349-55-5, 7773-52-6; (diltiazem) 33286-22-5,
42399-41-7; (fluoride sodium) 51668-54-3, 7681-49-4,
79933-27-0; (glyceryl trinitrate) 55-63-0; (insulin)
9004-10-8; (isosorbide dinitrate) 87-33-2; (ketoprofen)
22071-15-4, 57495-14-4; (lidocaine) 137-58-6, 24847-67-4,
56934-02-2, 73-78-9; (metoclopramide) 12707-59-4,

2576-84-3, 364-62-5, 7232-21-5; (metronidazole) 39322-38-8,
443-48-1; (*nifedipine*) 21829-25-4;
(prochlorperazine) 58-38-8; (propranolol) 13013-17-7,
318-98-9, 3506-09-0, 4199-09-1, 525-66-6; (retinoic acid)
302-79-4; (triamcinolone acetonide) 76-25-5; (verapamil)
152-11-4, 52-53-9

CHEMICAL NAME: Rhinocort; Replens

L189 ANSWER 7 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2003:152382 USPATFULL Full-text
TITLE: Pharmaceutical dosage forms for highly hydrophilic
materials
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
Krill, Steven L., Danbury, CT, UNITED STATES
Venkateshvaran, Srinivasan, Salt Lake City, UT, UNITED
STATES
PATENT ASSIGNEE(S): LIPOCINE, INC. (U.S. corporation)

| | NUMBER | KIND | DATE | |
|-----------------------|---|------|----------|------|
| PATENT INFORMATION: | US 2003104048 | A1 | 20030605 | <-- |
| APPLICATION INFO.: | US 2002-158206 | A1 | 20020529 | (10) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2001-898553, filed on 2 Jul 2001, GRANTED, Pat. No. US 6451339 Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192 Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985 | | | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | THORPE NORTH WESTERN, 8180 SOUTH 700 EAST, SUITE 200, P.O. BOX 1219, SANDY, UT, 84070 | | | |
| NUMBER OF CLAIMS: | 37 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| NUMBER OF DRAWINGS: | 1 Drawing Page(s) | | | |
| LINE COUNT: | 2976 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical dosage forms having a highly hydrophilic fill material and a shell encapsulating the fill material are disclosed and described. Generally, the shell has at least one plasticizing agent therein in order to provide the shell with an effective plasticity. In one aspect, the shell may have included therein an amount of plasticizing agent that is sufficient to provide the shell with an effective plasticity upon migration of a portion of the plasticizing agent into the fill material. In another aspect, the plasticizing agent may have a solubility in the fill material of less than about 10% w/w. In yet another aspect, a combination of a plasticizing agent, and a plasticizing agent having a solubility in the fill material of less than about 10% w/w, may be presented in a total amount sufficient to provide the shell with an effective plasticity upon migration of plasticizing agent into the fill material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2003104048 A1 20030605 <--

DETD [0129] Lipid-regulating agents that are generally classified as hydrophobic include HMG CoA reductase inhibitors such as atorvastatin, simvastatin, fluvastatin, pravastatin, **lovastatin**, cerivastatin, rosuvastatin, and pitavastatin, as well as other lipid-lowering ("antihyperlipidemic") agents such as bezafibrate, beclobate, binifibrate, ciprofibrate, clinofibrate, clofibrate, clofibril.

DETD . . . amlodipine, benazepril, benidipine, candesartan, captopril, carvedilol, darodipine, dilitazem, diazoxide, doxazosin, enalapril, epleronone, eposartan, felodipine, fenoldopam, fosinopril, guanabenz, iloprost, imidapril, irbesartan, **isradipine**, lercardinipine, lisinopril, losartan, mibefradil, minoxidil, nebivolol, nicardipine, **nifedipine**, nimodipine, nisoldipine, olmesartan, omapatrilat, phenoxybenzamine, pindolol, prazosin, quinapril, reserpine, semotiadil, sitaxsentan, terazosin, telmisartan, trandolapril, and valsartan.

DETD [0133] Anti-diabetic agents include, by way of example, acetohehexamide, chlorpropamide, ciglitazone, farglitazar, glibenclamide, gliclazide, **glipizide**, glucagon, glyburide, glymepiride, miglitol, pioglitazone, nateglinide, pimagedine, repaglinide, rosiglitazone, tolazamide, tolbutamide, triampterine, and troglitazone.

DETD [0149] Anti-diabetics, such as acetohehexamide, chlorpropamide, farglitazar, glibenclamide, gliclazide, **glipizide**, glimepiride, miglitol, nateglinide, pimagedine, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide, troglitazone, and voglibose;

DETD . . . and cardiac inotropes such as amrinone, digoxin, digitoxin, enoximone, lanatoside C, medigoxin, and milrinone; calcium channel blockers such as verapamil, **nifedipine**, nicardipene, felodipine, **isradipine**, nimodipine, amlodipine and diltiazem; beta-blockers such as acebutolol, alprenolol, atenolol, labetalol, metoprolol, nadolol, oxyprenolol, pindolol, propafenone, propranolol, esmolol, sotalol, timolol, . . .

DETD . . . acid sources, esomeprazole, estradiol, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, fluconazole, flurbiprofen, fluvastatin, fosphenytoin, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, **glipizide**, glyburide, glimepiride, griseofulvin, halofantrine, ibuprofen, irbesartan, irinotecan, isosorbide dinitrate, isotretinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lansoprazole, leflunomide, lisinopril, loperamide, loratadine, **lovastatin**, L-thyroxine, lutein, lycopene, medroxyprogesterone, mifepristone, mefloquine, megestrol acetate, methadone, methoxsalen, metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine, naratriptan, nelfinavir, **nifedipine**, nisoldipine, nilutamide, nitrofurantoin, nizatidine, omeprazole, oprelvekin, oxaprozin, paclitaxel, pantoprazole, paracalcitol, paroxetine, pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone, probucol, progesterone, pseudoephedrine, pyridostigmine, . . .

DETD . . . of lipid-regulating agents, e.g., (a) a fibrate and a statin, such as fenofibrate and atorvastatin, fenofibrate and simvastatin, fenofibrate and **lovastatin**, or fenofibrate and pravastatin; (b) a fibrate and nicotinic acid, such as fenofibrate and niacin; and (c) a statin and a nicotinic acid, such as **lovastatin** and niacin;

DETD . . . and rosiglitazone, (b) a fibrate and an insulin stimulant such as a sulfonylurea, e.g., fenofibrate and glimepiride, or fenofibrate and **glipizide**, a statin and and insulin sensitizer such as a thiazolidinedione, e.g., **lovastatin** and pioglitazone, simvastatin and rosiglitazone, pravastatin and pioglitazone, or the like;

DETD . . . as glyburide combined with acarbose, (ii) acarbose and a meglitinide such as repaglinide, (iii) miglitol and a sulfonylurea such as *glipizide*, or (iv) acarbose and a thiazolidinedione such as pioglitazone;

DETD . . . a diuretic agent such as losartan and hydrochlorothiazide; a combination of a calcium channel blocker and a β -blocker such as *nifedipine* and atenolol; and a combination of a calcium channel blocker and an ACE inhibitor such as felodipine and ramipril;

DETD . . . combinations of an antihypertensive agent and an antidiabetic agent, such as an ACE inhibitor and a sulfonylurea, e.g., irbesartan and *glipizide*;

DETD [0193] combinations of a lipid-regulating agent and a drug for treating coronary artery disease, e.g., fenofibrate and ezetimibe, or *lovastatin* and ezetimibe; and

COMMAND INTERRUPTED

REENTER FILE 'CAPLUS, EMBASE, USPATFULL'

AND TRY AGAIN, OR ENTER '?' FOR MORE INFORMATION.

Your command did not complete due to a temporary system problem. To recover, reenter the file you are in now. Then, any command that is normally available to you may be used. No cost summary for the current file will be displayed. After reentering the current file you may retry your command. Also, you may wish to SAVE your search query. This can be done in any file. If you cannot access your current file, or if your command fails a second time, notify the Help Desk. Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or by using the SEND command in STNMAIL file.

=> d ibib abs kwic hitstr L189 7-14

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> => d ibib abs kwic hitstr L189 7-14

YOU HAVE REQUESTED DATA FROM FILE 'EMBASE, USPATFULL, CAPLUS' - CONTINUE? (Y)/N:y

DETD [0193] combinations of a lipid-regulating agent and a drug for treating coronary artery disease, e.g., fenofibrate and ezetimibe, or *lovastatin* and ezetimibe; and

L189 ANSWER 7 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2003:152382 USPATFULL Full-text

TITLE: Pharmaceutical dosage forms for highly hydrophilic materials

INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
Krill, Steven L., Danbury, CT, UNITED STATES
Venkateshvaran, Srinivasan, Salt Lake City, UT, UNITED STATES

PATENT ASSIGNEE(S): LIPOCINE, INC. (U.S. corporation)

| | NUMBER | KIND | DATE | |
|-----------------------|--|-------|----------|------|
| | ----- | ----- | ----- | |
| PATENT INFORMATION: | US 2003104048 | A1 | 20030605 | <-- |
| APPLICATION INFO.: | US 2002-158206 | A1 | 20020529 | (10) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2001-898553, filed on 2 Jul 2001, GRANTED, Pat. No. US 6451339 | | | |

Continuation of Ser. No. US 1999-258654, filed on 26
Feb 1999, GRANTED, Pat. No. US 6294192
Continuation-in-part of Ser. No. US 2001-877541, filed
on 8 Jun 2001, PENDING Continuation-in-part of Ser. No.
US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No.
US 6267985

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THORPE NORTH WESTERN, 8180 SOUTH 700 EAST, SUITE 200,
P.O. BOX 1219, SANDY, UT, 84070
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2976
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical dosage forms having a highly hydrophilic fill material and a shell encapsulating the fill material are disclosed and described. Generally, the shell has at least one plasticizing agent therein in order to provide the shell with an effective plasticity. In one aspect, the shell may have included therein an amount of plasticizing agent that is sufficient to provide the shell with an effective plasticity upon migration of a portion of the plasticizing agent into the fill material. In another aspect, the plasticizing agent may have a solubility in the fill material of less than about 10% w/w. In yet another aspect, a combination of a plasticizing agent, and a plasticizing agent having a solubility in the fill material of less than about 10% w/w, may be presented in a total amount sufficient to provide the shell with an effective plasticity upon migration of plasticizing agent into the fill material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2003104048 A1 20030605 <--
DETD [0129] Lipid-regulating agents that are generally classified as hydrophobic include HMG CoA reductase inhibitors such as atorvastatin, simvastatin, fluvastatin, pravastatin, *lovastatin*, cerivastatin, rosuvastatin, and pitavastatin, as well as other lipid-lowering ("antihyperlipidemic") agents such as bezafibrate, beclobate, binifibrate, ciprofibrate, clinofibrate, clofibrate, clofibril.
DETD . . . amlodipine, benazepril, benidipine, candesartan, captopril, carvedilol, darodipine, dilitazem, diazoxide, doxazosin, enalapril, epleronone, eposartan, felodipine, fenoldopam, fosinopril, guanabenz, iloprost, imidapril, irbesartan, *isradipine*, lercardinipine, lisinopril, losartan, mibefradil, minoxidil, nebivolol, nicardipine, *nifedipine*, nimodipine, nisoldipine, olmesartan, omapatrilat, phenoxybenzamine, pindolol, prazosin, quinapril, reserpine, semotiadil, sitaxsentan, terazosin, telmisartan, trandolapril, and valsartan.
DETD [0133] Anti-diabetic agents include, by way of example, acetoexamide, chlorpropamide, ciglitazone, farglitazar, glibenclamide, gliclazide, *glipizide*, glucagon, glyburide, glymepiride, miglitol, pioglitazone, nateglinide, pimagedine, repaglinide, rosiglitazone, tolazamide, tolbutamide, triampterine, and troglitazone.
DETD [0149] Anti-diabetics, such as acetoexamide, chlorpropamide, farglitazar, glibenclamide, gliclazide, *glipizide*, glimepiride, miglitol, nateglinide, pimagedine, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide, troglitazone, and voglibose;
DETD . . . and cardiac inotropes such as amrinone, digoxin, digitoxin, enoximone, lanatoside C, medigoxin, and milrinone; calcium channel blockers such as verapamil, *nifedipine*, nicardipene,

felodipine, **isradipine**, nimodipine, amlodipine and diltiazem;
beta-blockers such as acebutolol, alprenolol, atenolol, labetalol,
metoprolol, nadolol, oxyprenolol, pindolol, propafenone, propranolol,
esmolol, sotalol, timolol, . . .

DETD . . . acid sources, esomeprazole, estradiol, etodolac, etoposide,
famotidine, fenofibrate, fentanyl, fexofenadine, finasteride,
fluconazole, flurbiprofen, fluvastatin, fosphenytoin, frovatriptan,
furazolidone, gabapentin, gemfibrozil, glibenclamide, **glipizide**
, glyburide, glimepiride, griseofulvin, halofantrine, ibuprofen,
irbesartan, irinotecan, isosorbide dinitrate, isotretinoin,
itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine,
lansoprazole, leflunomide, lisinopril, loperamide, loratadine,
lovastatin, L-thyroxine, lutein, lycopene, medroxyprogesterone,
mifepristone, mefloquine, megestrol acetate, methadone, methoxsalen,
metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone,
montelukast, nabumetone, nalbuphine, naratriptan, nelfinavir,
nifedipine, nisoldipine, nilutamide, nitrofurantoin, nizatidine,
omeprazole, oprevelkin, oxaprozin, paclitaxel, pantoprazole,
paracalcitol, paroxetine, pentazocine, pioglitazone, pizofetin,
pravastatin, prednisolone, probucol, progesterone, pseudoephedrine,
pyridostigmine, . . .

DETD . . . of lipid-regulating agents, e.g., (a) a fibrate and a statin,
such as fenofibrate and atorvastatin, fenofibrate and simvastatin,
fenofibrate and **lovastatin**, or fenofibrate and pravastatin;
(b) a fibrate and nicotinic acid, such fenofibrate and niacin; and (c) a
statin and a nicotinic acid, such as **lovastatin** and niacin;

DETD . . . and rosiglitazone, (b) a fibrate and an insulin stimulant such
as a sulfonylurea, e.g., fenofibrate and glimepiride, or fenofibrate and
glipizide, a statin and and insulin sensitizer such as a
thiazolidinedione, e.g., **lovastatin** and pioglitazone,
simvastatin and rosiglitazone, pravastatin and pioglitazone, or the
like;

DETD . . . as glyburide combined with acarbose, (ii) acarbose and a
meglitinide such as repaglinide, (iii) miglitol and a sulfonylurea such
as **glipizide**, or (iv) acarbose and a thiazolidinedione such as
pioglitazone;

DETD . . . a diuretic agent such as losartan and hydrochlorothiazide; a
combination of a calcium channel blocker and a β -blocker such as
nifedipine and atenolol; and a combination of a calcium channel
blocker and an ACE inhibitor such as felodipine and ramipril;

DETD . . . combinations of an antihypertensive agent and an antidiabetic
agent, such as an ACE inhibitor and a sulfonylurea, e.g., irbesartan and
glipizide;

DETD [0193] combinations of a lipid-regulating agent and a drug for treating
coronary artery disease, e.g., fenofibrate and ezetimibe, or
lovastatin and ezetimibe; and

IT 56-81-5, Glycerin, biological studies 57-48-7, D-Fructose, biological
studies 57-83-0, Progesterone, biological studies 59-02-9,
 α -Tocopherol 69-65-8, D-Mannitol 102-76-1, Triacetin
1318-93-0, Montmorillonite, biological studies 1327-43-1, Magnesium
aluminum silicate 1335-30-4, Aluminum silicate 1343-88-0, Magnesium
silicate 1405-86-3, Glycyrrhizin 9000-01-5, Acacia gum 9000-07-1,
Carrageenan 9000-30-0, Guar gum 9000-40-2, Locust bean gum
9000-65-1, Tragacanth 9000-69-5, Pectin 9002-18-0, Agar 9002-96-4,
TPGS 9003-39-8, Povidone 9004-32-4, Sodium carboxymethyl cellulose
9004-57-3, Ethyl cellulose 9004-58-4, Ethyl hydroxyethyl cellulose
9004-59-5, Ethyl methyl cellulose 9004-64-2, Hydroxypropyl cellulose
9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl
cellulose 9005-25-8, Starch, biological studies 9005-25-8D, Starch,
hydrolyzates, hydrogenated **9005-37-2**, Propylene glycol alginate

9005-38-3, Sodium alginate 9063-38-1, Sodium starch glycolate
11138-66-2, Xanthan gum 12173-47-6, Hectorite 12174-11-7,
Attapulgate 25322-68-3, PEG 400 25618-55-7, Polyglycerol
39386-78-2, Tamarind gum 49562-28-9, Fenofibrate 82626-48-0, Zolpidem
96081-19-5, Anidrisorb 35/70 99614-02-5, Ondansetron 103628-46-2,
Sumatriptan 106392-12-5, Lutrol F68 151319-34-5, Zaleplon
156259-68-6, Capmul MCM

(encapsulation of fill material containing drug and carrier of hydrophilic surfactant)

IT 9004-65-3, Hydroxypropyl methyl cellulose 9005-37-2,
Propylene glycol alginate 9005-38-3, Sodium alginate
11138-66-2, Xanthan gum

(encapsulation of fill material containing drug and carrier of hydrophilic surfactant)

RN 9004-65-3 USPATFULL

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified

CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1

CMF C H4 O

H₃C—OH

CM 3

CRN 57-55-6

CMF C3 H8 O2

OH
|
H₃C—CH—CH₂—OH

RN 9005-37-2 USPATFULL

CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7


CMF Unspecified

CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9005-38-3 USPATFULL
CN Alginic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

RN 11138-66-2 USPATFULL
CN Xanthan gum (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

L189 ANSWER 8 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2003:92739 USPATFULL Full-text
TITLE: SOLID CARRIERS FOR IMPROVED DELIVERY OF HYDROPHOBIC
ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES

| | NUMBER | KIND | DATE | |
|--|---|------|----------|-----|
| PATENT INFORMATION: | US 2003064097 | A1 | 20030403 | <-- |
| | US 6569463 | B2 | 20030527 | |
| APPLICATION INFO.: | US 2001-800593 | A1 | 20010306 | (9) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363 | | | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025 | | | |
| NUMBER OF CLAIMS: | 91 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| NUMBER OF DRAWINGS: | 4 Drawing Page(s) | | | |
| LINE COUNT: | 3863 | | | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | | | |

AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2003064097 A1 20030403
US 6569463 B2 20030527

<--

DETD . . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, **glipizide**, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irbesartan, irinotecan, isosorbide dinitrate, isotreinoïn, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, lisinopril, loperamide, loratadine, **lovastatin**, L-thyroxine, lutein, lycopene, medroxyprogesterone, mifepristone, mefloquine, megestrol acetate, methadone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine, naratriptan, nelfinavir, **nifedipine**, nilsolidipine, nilutanide, nitrofurantoin, nizatidine, omeprazole, oprevelkin, osteradiol, oxaprozin, paclitaxel, paricalcitol, paroxetine, pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone, probucol, progesterone, pseudo-ephedrine, pyridostigmine, . . .

DETD . . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furzolidone, gabapentin, gemfibrozil, glibenclamide, **glipizide**, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irinotecan, isotreinoïn, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, loperamide, loratadine, **lovastatin**, L-thyroxine, lutein, lycopene, mifepristone, mefloquine, megestrol acetate, methdone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, mitoxantrone, mmedroxyprogestrone, montelukast, nabumetone, nalbuphine, naratriptan, . . .

DETD . . . dihyrotachysterol, efavirenz, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fexofenadine, finasteride, flucanazole, flurbiprofen, fosphenytion, frovatriptan, furzolidone, glibenclamide, **glipizide**, glyburide, glymepride, ibuprofen, irinotecan, isotreinoïn, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, loperamide, loratadine, **lovastatin**, L-thyroxine, lutein, lycopene, medroxyprogesterone, mifepristone, megestrol acetate, methoxsalen, metronidazole, metronidazole, miconazole, miglitol, mitoxantrone, montelukast, nabumetone, naratriptan, nelfinavir, nilutanide, nitrofurantoin, nizatidine, . . .

DETD . . . active ingredients include: amlodipine, amprenavir, atorvastatin, atovaquone, celecoxib, cisapride, coenzyme Q10, cyclosporine, famotidine, fenofibrate, fexofenadine, finasteride, ibuprofen, itraconazole, lanosprazole, loratadine, **lovastatin**, megestrol acetate, montelukast, nabumetone, nizatidine, omeprazole, oxaprozin, paclitaxel, paricalcitol, pioglitazone, pranlukast, progesterone, pseudo-ephedrine, rabeprazole, rapamycin, refocoxib, repaglinide, rimexolone, ritanovir, rosiglitazone, . . .

DETD [0313]

EXAMPLE 19

| Component | Amount (g) |
|-----------|------------|
|-----------|------------|

Lovastatin

20

| | |
|------------------------------|-----|
| Coenzyme Q10 | 50 |
| PEG-40 stearate | 150 |
| Glycerol monolaurate | 50 |
| Non-pareil seed (25/30 mesh) | 200 |

CLM What is claimed is:

. . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, **glipizide**, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irbesartan, irinotecan, isosorbide dinitrate, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, lisinopril, loperamide, loratadine, **lovastatin**, L-thyroxine, lutein, lycopene, medroxyprogesterone, mifepristone, mefloquine, megesterol acetate, methadone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine, naratriptan, nelfinavir, **nifedipine**, nilsolidipine, nilutamide, nitrofurantoin, nizatidine, omeprazole, oprelvekin, osteradiol, oxaprozin, paclitaxel, paricalcitol, paroxetine, pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone, probucol, progesterone, pseudo-ephedrine, pyridostigmine, . . .

. . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furzolidone, gabapentin, gemfibrozil, glibenclamide, **glipizide**, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irinotecan, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, loperamide, loratadine, **lovastatin**, L-thyroxine, lutein, lycopene, mifepristone, mefloquine, megesterol acetate, methdone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, mitoxantrone, mmedroxyprogesterone, montelukast, nabumetone, nalbuphine, naratriptan, . . .

. . . dihyrotachysterol, efavirenz, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fexofenadine, finasteride, flucanazole, flurbiprofen, fosphenytion, frovatriptan, furzolidone, glibenclamide, **glipizide**, glyburide, glymepride, ibuprofen, irinotecan, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, loperamide, loratadine, **lovastatin**, L-thyroxine, lutein, lycopene, medroxyprogesterone, mifepristone, megesterol acetate, methoxsalen, metronidazole, metronidazole, miconazole, miglitol, mitoxantrone, montelukast, nabumetone, naratriptan, nelfinavir, nilutamide, nitrofurantoin, nizatidine, . . .

. . . group consisting of amlodipine, amprenavir, atorvastatin, atovaquone, celecoxib, cisapride, coenzyme Q10, cyclosporine, famotidine, fenofibrate, fexofenadine, finasteride, ibuprofen, itraconazole, lanosprazole, loratadine, **lovastatin**, megesterol acetate, montelukast, nabumetone, nizatidine, omeprazole, oxaprozin, paclitaxel, paricalcitol, pioglitazone, pranlukast, progesterone, pseudo-ephedrine, rabeprazole, rapamycin, refocoxib, repaglinide, rimexolone, ritanovir, rosiglitazone, . . .

. . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, **glipizide**, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irbesartan, irinotecan, isosorbide dinitrate, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, . . .

lisinopril, loperamide, loratadine, **lovastatin**, L-thyroxine, lutein, lycopene, medroxyprogesterone, mifepristone, mefloquine, megesterol acetate, methadone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine, naratriptan, nelfinavir, **nifedipine**, nilsolidipine, nilutamide, nitrofurantoin, nizatidine, omeprazole, oprelvekin, osteradiol, oxaprozin, paclitaxel, paricalcitol, paroxetine, pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone, probucol, progesterone, pseudo-ephedrine, pyridostigmine, . . .

. . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furzolidone, gabapentin, gemfibrozil, glibenclamide, **glipizide**, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irinotecan, isotretinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lansoprazole, leflunomide, loperamide, loratadine, **lovastatin**, L-thyroxine, lutein, lycopene, mifepristone, mefloquine, megesterol acetate, methadone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, mitoxantrone, medroxyprogesterone, montelukast, nabumetone, nalbuphine, naratriptan, .

. . . dihydrotachysterol, efavirenz, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fexofenadine, finasteride, flucanazole, flurbiprofen, fosphenytion, frovatriptan, furzolidone, glibenclamide, **glipizide**, glyburide, glymepride, ibuprofen, irinotecan, isotretinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lansoprazole, leflunomide, loperamide, loratadine, **lovastatin**, L-thyroxine, lutein, lycopene, medroxyprogesterone, mifepristone, megesterol acetate, methoxsalen, metronidazole, metronidazole, miconazole, miglitol, mitoxantrone, montelukast, nabumetone, naratriptan, nelfinavir, nilutamide, nitrofurantoin, nizatidine, . . .

. . . group consisting of amlodipine, amprenavir, atorvastatin, atovaquone, celecoxib, cisapride, coenzyme Q10, cyclosporine, famotidine, fenofibrate, fexofenadine, finasteride, ibuprofen, itraconazole, lansoprazole, loratadine, **lovastatin**, megesterol acetate, montelukast, nabumetone, nizatidine, omeprazole, oxaprozin, paclitaxel, paricalcitol, pioglitazone, pranlukast, progesterone, pseudo-ephedrine, rabeprazole, rapamycin, refocoxib, repaglinide, rimexolone, ritanovir, rosiglitazone, . . .

IT 50-14-6, Ergocalciferol 50-21-5D, Lactic acid, glycerides 50-24-8, Prednisolone 50-28-2, EStradiol, biological studies 50-70-4, Sorbitol, biological studies 51-48-9, L-Thyroxine, biological studies 52-01-7, Spironolactone 55-98-1, Busulphan 56-81-5, 1,2,3-Propanetriol, biological studies 56-81-5D, Glycerol, polyethylene fatty acid esters 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-55-6D, Propylene glycol, ethers 57-83-0, Progesterone, biological studies 57-88-5, Cholesterol, biological studies 57-88-5D, Cholesterol, polyoxyethylene derivs. 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 64-17-5, Ethanol, biological studies 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-63-0, Isopropanol, biological studies 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 69-65-8, Mannitol 71-36-3, Butanol, biological studies 76-57-3, Codeine 76-99-3, Methadone 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl citrate 77-92-9D, Citric acid, diglycerides 77-93-0, Triethylcitrate 77-94-1, Tributylcitrate 81-24-3 81-25-4 83-44-3 87-33-2, Isosorbide dinitrate 87-69-4D, Tartaric acid, glycerides,

biological studies 90-82-4, Pseudoephedrine 100-51-6,
 Benzenemethanol, biological studies 102-76-1, Triacetin 104-31-4,
 Benzonatate 105-37-3, Ethyl propionate 105-54-4, Ethyl butyrate
 105-60-2, biological studies 105-60-2D, Caprolactam, N-Alkyl derivs.
 106-32-1, Ethyl caprylate 107-21-1, 1,2-Ethanediol, biological studies
 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6,
 Crodamol EO 111-90-0, Transcutol 112-80-1, 9-Octadecenoic acid (9Z)-,
 biological studies 113-15-5, Ergotamine 113-92-8, Chlorpheniramine
 115-77-5, biological studies 115-83-3, Pentaerythrityl Tetra stearate
 124-07-2, Octanoic acid, biological studies 125-84-8, Aminogluthethimide
 126-07-8, Griseofulvin 127-19-5, Dimethylacetamide 128-13-2
 141-22-0 142-18-7, Glyceryl monolaurate 142-62-1, Hexanoic acid,
 biological studies 142-91-6, Isopropyl palmitate 143-07-7, Dodecanoic
 acid, biological studies 151-41-7, Lauryl sulfate 155-97-5,
 Pyridostigmine 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide
 298-57-7, Cinnarizine 298-81-7, Methoxsalen 300-62-9, Amphetamine
 302-79-4, Tretinoin 303-49-1, Clomipramine 321-64-2, Tacrine
 334-48-5, Decanoic acid 359-83-1, Pentazocine 360-65-6 378-44-9,
 Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1,
 Metronidazole 463-40-1 474-25-9 475-31-0 511-12-6,
 Dihydroergotamine 516-35-8 516-50-7 520-85-4, Medroxyprogesterone
 542-28-9, δ -Valerolactone 544-35-4, Ethyl linoleate 544-63-8,
 Tetradecanoic acid, biological studies 577-11-7, Sodium docusate
 595-33-5 616-45-5, Pyrrolidone 616-45-5D, Pyrrolidone, N-Alkyl
 derivs. 623-84-7, Propylene glycol diacetate 640-79-9 675-20-7,
 2-Piperidone 872-50-4, N-Methylpyrrolidone, biological studies
 1134-47-0, Baclofen 1331-12-0, Propylene glycol monoacetate
 1335-71-3, Propylene glycol oleate 1338-39-2, Arlacel 20 1338-43-8,
 Span 80 1397-89-3, Amphotericin B 1406-16-2, Vitamin D 1406-18-4,
 Vitamin E 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol
 2687-91-4, N-Ethylpyrrolidone 2687-94-7 2687-96-9 3068-88-0,
 β -Butyrolactone 3445-11-2 4419-39-0, Beclomethasone 4759-48-2,
 Isotretinoin 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl isosorbide
 7261-97-4, Dantrolene 7488-99-5, α Carotene 7664-93-9D,
 Sulfuric acid, salts alkyl derivs., biological studies 7689-03-4,
 Camptothecin 8007-43-0, Sorbitan sesquioleate 9002-89-5,
 Polyvinylalcohol 9002-92-0, Brij 30 9002-96-4 9003-39-8,
 Polyvinylpyrrolidone 9004-65-3, Hydroxypropyl methylcellulose
 9004-74-4, Methoxy polyethylene glycol 9004-81-3, Polyoxyethylene
 laurate 9004-95-9, Polyoxyethylene cetyl ether 9004-96-0, PEG-32
 oleate 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3,
 Polyoxyethylene stearate 9005-00-9, Polyoxyethylene stearyl ether
 9005-02-1, Polyoxyethylene dilaurate 9005-07-6, Polyoxyethylene
 dioleate 9005-08-7, Polyoxyethylene distearate 9005-32-7D, Alginic
 acid, salts 9005-37-2, Propylene glycol alginate 9005-63-4D,
 Polyoxyethylene sorbitan, derivs. 9005-63-4D, Polyoxyethylene sorbitan,
 fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80
 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, PLUROLLEQUECC497
 9011-21-6, Polyoxyethylene glyceryl stearate 9016-45-9 9036-19-5
 10238-21-8, Glyburide 10540-29-1, Tamoxifen 11103-57-4, Vitamin A
 11140-04-8, Imwitor 988 12001-79-5, Vitamin K 12619-70-4,
 Cyclodextrin 12619-70-4D, Cyclodextrin, derivs. 12619-70-4D,
 Cyclodextrin, hydroxypropyl ethers 13081-97-5, Pentaerythrityl di
 stearate 14440-80-3, Stearoyl-2-lactylate 14605-22-2 15307-86-5,
 Diclofenac 15574-96-6, Pizotifen 15686-51-8, Clemastine 15687-27-1,
 Ibuprofen 18559-94-9, Albuterol 19356-17-3, Calcifediol 20594-83-6,
 Nalbuphine 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4,
 Nifedipine 22882-95-7, Isopropyl linoleate 22916-47-8, Miconazole
 23288-49-5, Probuco1 25168-73-4, Sucrose monostearate 25265-75-2,

Butanediol 25322-68-3 25322-69-4, Polypropylene glycol 25339-99-5,
 Sucrose monolaurate 25523-97-1, Dexchlorpheniramine 25618-55-7D,
 Polyglycerol, fatty acid esters 25637-84-7, Glyceryl dioleate
 25637-97-2, Sucrose dipalmitate 25812-30-0, Gemfibrozil 26266-57-9,
 Sorbitan monopalmitate 26266-58-0, Sorbitan Trioleate 26402-22-2,
 Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8,
 Sucrose monopalmitate 27154-43-4D, Piperidone, N-Alkyl derivs.
 27195-16-0, Sucrose distearate 27203-92-5, TRamadol 27638-00-2,
 Glyceryl dilaurate 29094-61-9, Glipizide 29767-20-2, Teniposide
 31692-85-0, Glycofurol 32222-06-3, Calcitriol 33069-62-4, Paclitaxel
 33419-42-0, Etoposide 34911-55-2, Bupropion 36354-80-0, Glyceryl
 dicaprylate 37321-62-3, Lauroglycol 38304-91-5, Minoxidil
 41340-25-4, Etodolac 42924-53-8, Nabumetone 43200-80-2, Zopiclone
 49562-28-9, Fenofibrate 49697-38-3, Rimexolone 51333-22-3, Budesonide
 51481-61-9, Cimetidine 51938-44-4, Sorbitan sesquisteate
 52581-71-2, Volpo 3 53123-88-9, Sirolimus 53168-42-6, Myvacet 9-45
 53179-11-6, Loperamide 53230-10-7, Mefloquine 53988-07-1, Glyceryl
 dicaprate 54392-26-6, Sorbitan monoisostearate 54965-21-8,
 Albendazole 55079-83-9, Acitretin 55142-85-3, Ticlopidine
 57107-97-8, Polyoxyethylene glyceryl oleate 59467-70-8, Midazolam
 59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61379-65-5,
 Rifapentine 61869-08-7 62013-04-1, Dirithromycin 62356-64-3
 63590-64-7, Terazosin 63612-50-0, Nilutamide 63675-72-9, Nisoldipine
 65271-80-9, Mitoxantrone

(pharmaceutical compns. and methods for improved delivery of
 hydrophobic therapeutic agents)

IT 9004-65-3, Hydroxypropyl methylcellulose 9005-37-2,

Propylene glycol alginate

(pharmaceutical compns. and methods for improved delivery of
 hydrophobic therapeutic agents)

RN 9004-65-3 USPATFULL

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified

CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1


CMF C H4 O

H₃C—OH

CM 3

CRN 57-55-6

CMF C3 H8 O2



RN 9005-37-2 USPATFULL
 CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9005-32-7
 CMF Unspecified
 CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6
 CMF C3 H8 O2



L189 ANSWER 9 OF 14 USPATFULL on STN
 ACCESSION NUMBER: 2002:55008 USPATFULL Full-text
 TITLE: Clear oil-containing pharmaceutical compositions
 containing a therapeutic agent
 INVENTOR(S): Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
 Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
 Fikstad, David T., Salt Lake City, UT, UNITED STATES

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 2002032171 | A1 | 20020314 |
| | US 6761903 | B2 | 20040713 |
| APPLICATION INFO.: | US 2001-877541 | A1 | 20010608 (9) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985 | | |
| | Continuation-in-part of Ser. No. US 2000-751968, filed on 29 Dec 2000, PENDING Continuation-in-part of Ser. No. US 1999-375636, filed on 17 Aug 1999, GRANTED, Pat. No. US 6309663 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | APPLICATION | | |
| LEGAL REPRESENTATIVE: | Mark A. Wilson, REED & ASSOCIATES, 3282 Alpine Road, Portola Valley, CA, 94028 | | |
| NUMBER OF CLAIMS: | 205 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 4418 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a carrier,

where the carrier is formed from a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the carrier forms a clear, aqueous dispersion of the triglyceride and surfactants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2002032171 A1 20020314 <--
US 6761903 B2 20040713

DETD . . . propionate, fluvastatin, foscarnet sodium, fosinopril, fosphenytoin, fosphenytoin sodium, frovatriptan, frusemide, fumagillin, furazolidone, furosemide, furzolidone, gabapentin, gancyclovir, gemfibrozil, gentamycin, glibenclamide, gliclazide, *glipizide*, glucagon, glybenclamide, glyburide, glyceryl trinitrate, glymepiride, glymepride, granisetron, granulocyte stimulating factor, grepafloxacin, griseofulvin, guanabenz, guanabenz acetate, halofantrine, halofantrine HCl, haloperidol, hydrocortisone, hyoscyamine, ibufenac, ibuprofen, imipenem, indinavir, indivir, indomethacin, insulin, interleukin-3, irbesartan, irinotecan, isosorbide dinitrate, isosorbide mononitrate, isotretinoin, isoxazole, *isradipine*, itraconazole, ivermectin, ketoconazole, ketoprofen, ketorolac, ketotifen, labetalol, lamivudine, lamotrigine, lanatoside C, lanosprazole, leflunomide, levofloxacin, levothyroxine, lisinopril, lomefloxacin, lomustine, loperamide, loratadine, lorazepam, lorefloxacin, lormetazepam, losartan, *lovastatin*, L-thyroxine, lysuride, lysuride maleate, maprotiline, maprotiline HCl, mazindol, mebendazole, meclofenamic acid, meclozine, meclozine HCl, medazepam, medigoxin, medroxyprogesterone acetate, mefenamic acid, . . . nalbuphine, nalidixic acid, naproxen, naratriptan, naratriptan HCl, natamycin, nedocromil sodium, nefazodone, nelfinavir, nerteporfin, neutontin, nevirapine, nicardipine, nicardipine HCl, nicotine, nicoumalone, *nifedipine*, nilutamide, nimesulide, nimodipine, nimorazole, nisoldipine, nitrazepam, nitrofurantoin, nitrofurazone, nizatidine, non-essential fatty acids, norethisterone, norfloxacin, norgestrel, nortriptyline HCl, nystatin, oestradiol, . . .

IT 50-70-4, Sorbitol, biological studies 50-70-4D, Sorbitol, esters 50-78-2, Aspirin 56-81-5, Glycerol, biological studies 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-55-6, Propylene glycol, biological studies 57-55-6D, 1,2-Propanediol, cyclodextrin ethers 58-32-2, Dipyrindamole 58-95-7, α -Tocopherol acetate 59-02-9, α -Tocopherol 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 64-17-5, Ethanol, biological studies 67-63-0, Isopropanol, biological studies 77-89-4, Acetyl triethyl citrate 77-90-7, Acetyl tributyl citrate 77-93-0, Triethyl citrate 77-94-1, Tributyl citrate 81-24-3 81-25-4 81-81-2, Warfarin 83-44-3 87-69-4D, Tartaric acid, esters 87-78-5, Mannitol 100-51-6, Benzyl alcohol, biological studies 102-76-1, Triacetin 105-37-3, Ethyl propionate 105-54-4, Ethyl butyrate 105-60-2, ϵ -Caprolactam, biological studies 105-60-2D, ϵ -Caprolactam, derivs. 106-32-1, Ethyl caprylate 107-21-1, Ethylene glycol, biological studies 107-21-1D, Ethylene glycol, esters 107-88-0, 1,3-Butanediol 110-27-0, Isopropyl myristate 111-62-6, Ethyl oleate 111-90-0, Transcutol 112-80-1, Oleic acid, biological studies 115-77-5, Pentaerythritol, biological studies 115-77-5D, Pentaerythritol, esters 115-83-3, Pentaerythritol tetrastearate 118-71-8, Maltol 119-13-1, δ -Tocopherol 122-32-7, Glyceryl trioleate 124-07-2, Octanoic acid, biological studies 127-19-5, Dimethylacetamide 128-13-2 141-22-0 142-62-1, Hexanoic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Lauric

acid, biological studies 148-03-8, β -Tocopherol 151-41-7, Lauryl
 sulfate 334-48-5, Decanoic acid 360-65-6 434-13-9 463-40-1
 474-25-9 475-31-0 490-23-3, β -Tocotrienol 502-44-3,
 ϵ -Caprolactone 516-35-8 516-50-7 537-40-6, Glyceryl
 trilinoleate 538-23-8, Glyceryl tricaprilate 538-24-9, Glyceryl
 trilaurate 541-15-1D, Carnitine, esters with fatty acids, salts
 544-35-4, Ethyl linoleate 544-63-8, Myristic acid, biological studies
 555-43-1, Glyceryl tristearate 577-11-7, Sodium docusate 616-45-5,
 2-Pyrrolidone 616-45-5D, 2-Pyrrolidone, derivs. 621-70-5, Glyceryl
 tricaproate 621-71-6, Glyceryl tricaprinate 623-84-7, Propylene glycol
 diacetate 640-79-9 675-20-7, 2-Piperidone 675-20-7D, 2-Piperidone,
 derivs. 823-22-3, δ -Caprolactone 872-50-4, N-Methylpyrrolidone,
 biological studies 1331-12-0, Propylene glycol monoacetate 1338-39-2,
 Sorbitan monolaurate 1338-41-6, Sorbitan monostearate 1338-43-8,
 Sorbitan monooleate 1398-61-4, Chitin 1406-18-4, Vitamin E
 1721-51-3, α -Tocotrienol 1935-18-8, Palmitoylcarnitine
 2466-77-5, Lauroylcarnitine 2687-91-4, N-Ethylpyrrolidone 2687-94-7,
 N-Octylpyrrolidone 2687-96-9, N-Lauryl-2-pyrrolidone 3068-88-0,
 β -Butyrolactone 3416-24-8, Glucosamine 3445-11-2 4345-03-3,
 α -Tocopherol succinate 5306-85-4, Dimethyl isosorbide
 6493-05-6, Pentoxifylline 6990-06-3, Fusidic acid 7616-22-0,
 γ -Tocopherol 7664-93-9D, Sulfuric acid, alkyl esters, salts
 8007-43-0, Sorbitan sesquioleate 9002-89-5, Polyvinylalcohol
 9002-92-0, Polyethylene glycol lauryl ether 9002-96-4 9003-39-8,
 Polyvinylpyrrolidone 9003-39-8D, PVP, conjugates with
 phosphatidylethanolamines 9004-34-6D, Cellulose, derivs. 9004-54-0,
 Dextran, biological studies 9004-57-3, Ethyl cellulose 9004-61-9,
 Hyaluronic acid 9004-65-3, Hydroxypropyl methyl cellulose
 9004-67-5, Methyl cellulose 9004-74-4, Methoxy polyethylene glycol
 9004-81-3, Polyethylene glycol monolaurate 9004-95-9, Polyethylene
 glycol cetyl ether 9004-96-0, Polyethylene glycol oleate 9004-98-2,
 Polyethylene glycol oleyl ether 9004-99-3, Polyethylene glycol
 monostearate 9005-00-9, Polyethylene glycol stearyl ether 9005-02-1,
 Polyethylene glycol dilaurate 9005-07-6, Polyethylene glycol dioleate
 9005-08-7, Polyethylene glycol distearate 9005-25-8, Starch, biological
 studies 9005-32-7D, Alginic acid, salts 9005-37-2, Propylene
 glycol alginate 9005-49-6, Heparin, biological studies 9005-64-5,
 Polysorbate 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40
 9005-67-8, Tween 60 9007-27-6, Chondroitin 9007-48-1, Polyglyceryl
 oleate 9009-32-9, Polyglyceryl stearate 9014-63-5, Xylan 9016-45-9,
 Polyethylene glycol nonyl phenyl ether 9041-08-1, Heparin sodium
 9050-30-0, Heparan sulfate 9050-36-6, Maltodextrin 9062-73-1,
 Polyethylene glycol sorbitan laurate 9062-90-2, Polyethylene glycol
 sorbitan oleate 10041-19-7 11140-04-8, Imwitor 988 12619-70-4,
 Cyclodextrin 12619-70-4D, Cyclodextrin, hydroxypropyl ethers
 12772-47-3, Pentaerythritol oleate 13027-26-4, δ -Tocopherol
 acetate 13081-97-5, Pentaerythritol distearate 13552-80-2, Glyceryl
 triundecanoate 14101-61-2, γ -Tocotrienol 14440-80-3, Stearoyl-2
 Lactylate 14465-68-0, Glyceryl trilinolenate 14605-22-2 22373-05-3,
 β -Tocopherol acetate 22373-06-4, γ -Tocopherol acetate
 22882-95-7, Isopropyl linoleate 25168-73-4, Sucrose monostearate
 25249-06-3, Polygalacturonic acid 25322-68-3D, ethers or esters
 25322-69-4D, Polypropylene glycol, esters 25339-99-5, Sucrose
 monolaurate 25612-59-3, δ -Tocotrienol 25618-55-7D,
 Polyglycerol, esters with fatty acids 25637-97-2, Sucrose dipalmitate
 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan trioleate
 26446-38-8, Sucrose monopalmitate 26658-19-5, Sorbitan tristearate
 27195-16-0, Sucrose distearate 27321-96-6, Polyethylene glycol

cholesteryl ether 29874-09-7, Myristoylcarnitine 29894-36-8,
 Polymannuronic acid 31692-85-0, Glycofurol 31694-55-0D, AMD triesters
 with fatty acids 35296-72-1, Butanol 36291-32-4, Citric acid
 monoglyceride 37270-89-6, Nadroparin calcium 51938-44-4, Sorbitan
 sesquistearate 53168-42-6, Myvacet 9-45 54392-26-6, Sorbitan
 monoisostearate 55142-85-3, Ticlid 56451-84-4 57307-93-4,
 Pentaerythritol caprylate 61725-93-7, Polyglyceryl distearate
 61752-68-9, Sorbitan tetrastearate 64480-66-6, Glycoursodeoxycholic
 acid 68818-37-1, Pentaerythritol decanoate 68958-64-5, Polyethylene
 glycol glyceryl trioleate 69070-98-0 70226-44-7, Heparan
 73963-72-1, Cilostazol 74504-64-6, Polyglyceryl laurate 75634-40-1,
 Dermatan 83138-62-9, Polyglyceryl isostearate 88662-03-7
 93790-70-6, Cholylsarcosine 93790-72-8, N-Methyltaurocholic acid
 98913-68-9, Pentaerythritol isostearate 106392-12-5, Polyethylene
 glycol-polypropylene glycol block copolymer 110540-43-7, Polyglyceryl
 pentaoleate 113665-84-2, Clopidogrel 128254-89-7 128254-90-0
 128286-20-4 146478-45-7, Polyglyceryl dioleate 148796-42-3
 150372-93-3, Polyoxyethylene glyceryl laurate 162011-90-7, Rofecoxib
 181695-72-7, Valdecocix 198470-84-7, Parecoxib 208666-87-9, Captex
 810D 256923-73-6, γ -Tocotrienol acetate 300583-65-7
 300583-68-0 403815-06-5 403815-07-6 403815-12-3 403821-12-5,
 Polyglyceryl trioleate 403838-29-9

(clear oil-containing pharmaceutical compns. containing therapeutic agent)

IT 9004-65-3, Hydroxypropyl methyl cellulose 9005-37-2,

Propylene glycol alginate

(clear oil-containing pharmaceutical compns. containing therapeutic agent)

RN 9004-65-3 USPATFULL

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified

CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1


CMF C H4 O

H₃C-OH

CM 3

CRN 57-55-6

CMF C3 H8 O2



RN 9005-37-2 USPATFULL
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6
CMF C3 H8 O2



L189 ANSWER 10 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2002:21845 USPATFULL Full-text
TITLE: Compositions and methods for improved delivery of lipid
regulating agents
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES

| | NUMBER | KIND | DATE | |
|-----------------------|--|------|----------|-----|
| PATENT INFORMATION: | US 2002012680 | A1 | 20020131 | <-- |
| | US 6451339 | B2 | 20020917 | |
| APPLICATION INFO.: | US 2001-898553 | A1 | 20010702 | (9) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192 | | | |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025 | | | |
| NUMBER OF CLAIMS: | 140 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| NUMBER OF DRAWINGS: | 1 Drawing Page(s) | | | |
| LINE COUNT: | 3604 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to triglyceride-free pharmaceutical compositions for delivery of hydrophobic therapeutic agents. Compositions of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the surfactants containing the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2002012680 A1 20020131 <--
US 6451339 B2 20020917

DETD [0092] anti-diabetics, such as acetohexamide, chlorpropamide, glibenclamide, gliclazide, **glipizide**, glymepride, miglitol, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide and troglitazone;

DETD . . . benidipine, benezepril, candesartan, captopril, darodipine, dilitazem HCl, diazoxide, doxazosin HCl, elanapril, eposartan losartan, mesylate, felodipine, fenolclopam, fosinopril, guanabenz acetate, irbesartan, **isradipine**, lisinopril, minoxidil, nicardipine HCl, **nifedipine**, nimodipine, nisolidipine, phenoxybenzamine HCl, prazosin HCl, quinapril, reserpine, terazosin HCl, telmisartan, and valsartan;

CLM What is claimed is:

. . . nelfinavir, efavirenz, dicoumarol, tirofibrin, cilostazol, ticlidopine, clopidrogel, oprelvekin, paroxetine, sertraline, venlafaxine, bupropion, clomipramine, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, **glipizide**, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, lisinopril, benezepril, **nifedipine**, nilsolidipine, telmisartan, irbesartan, eposartan, valsartan, candesartan, minoxidil, terazosin, halofantrine, mefloquine, dihydroergotamine, ergotamine, frovatriptan, pizofetin, sumatriptan, zolmitriptan, naratriptan, rizatriptan, aminogluthemide, busulphan, . . .

. . . montelukast, azithromycin, ciprofloxacin, clarithromycin, dirithromycin, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, **glipizide**, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, halofantrine, . . .

. . . amiodarone, zileuton, zafirlukast, albuterol, montelukast, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, **glipizide**, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, nitrofurantoin, dihydroergotamine, ergotamine, frovatriptan, pizofetin, zolmitriptan, pseudo-ephedrine, . . .

. . . nelfinavir, efavirenz, dicoumarol, tirofibrin, cilostazol, ticlidopine, clopidrogel, oprelvekin, paroxetine, sertraline, venlafaxine, bupropion, clomipramine, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, **glipizide**, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, lisinopril, benezepril, **nifedipine**, nilsolidipine, telmisartan, irbesartan, eposartan, valsartan, candesartan, minoxidil, terazosin, halofantrine, mefloquine, dihydroergotamine, ergotamine, frovatriptan, pizofetin, sumatriptan, zolmitriptan, naratriptan, rizatriptan, aminogluthemide, busulphan, . . .

. . . montelukast, azithromycin, ciprofloxacin, clarithromycin, dirithromycin, rifabutine, rifapentine, trovafloxacin, baclofen,

ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosiglitazone, troglitazone, glyburide, **glipizide**, glibenclamide, carbamazepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, halofantrine, . . .
 . . . amiodarone, zileuton, zafirlukast, albuterol, montelukast, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosiglitazone, troglitazone, glyburide, **glipizide**, glibenclamide, carbamazepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, nitrofurantoin, dihydroergotamine, ergotamine, frovatriptan, pizofetin, zolmitriptan, pseudo-ephedrine, . . .

IT 50-14-6, Ergocalciferol 50-21-5D, Lactic acid, glycerides 50-24-8, Prednisolone 50-28-2, EStradiol, biological studies 50-70-4, Sorbitol, biological studies 51-48-9, L-Thyroxine, biological studies 52-01-7, Spironolactone 55-98-1, Busulphan 56-81-5, 1,2,3-Propanetriol, biological studies 56-81-5D, Glycerol, polyethylene fatty acid esters 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-55-6D, Propylene glycol, ethers 57-83-0, Progesterone, biological studies 57-88-5, Cholesterol, biological studies 57-88-5D, Cholesterol, polyoxyethylene derivs. 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 64-17-5, Ethanol, biological studies 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-63-0, Isopropanol, biological studies 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 69-65-8, Mannitol 71-36-3, Butanol, biological studies 76-57-3, Codeine 76-99-3, Methadone 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl citrate 77-92-9D, Citric acid, diglycerides 77-93-0, Triethylcitrate 77-94-1, Tributylcitrate 81-24-3 81-25-4 83-44-3 87-33-2, Isosorbide dinitrate 87-69-4D, Tartaric acid, glycerides, biological studies 90-82-4, Pseudoephedrine 100-51-6, Benzenemethanol, biological studies 102-76-1, Triacetin 104-31-4, Benzonatate 105-37-3, Ethyl propionate 105-54-4, Ethyl butyrate 105-60-2, biological studies 105-60-2D, Caprolactam, N-Alkyl derivs. 106-32-1, Ethyl caprylate 107-21-1, 1,2-Ethenediol, biological studies 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6, Crodamol EO 111-90-0, Transcutol 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 113-15-5, Ergotamine 113-92-8, Chlorpheniramine 115-77-5, biological studies 115-83-3, Pentaerythrityl Tetra stearate 124-07-2, Octanoic acid, biological studies 125-84-8, Aminogluthethimide 126-07-8, Griseofulvin 127-19-5, Dimethylacetamide 128-13-2 141-22-0 142-18-7, Glyceryl monolaurate 142-62-1, Hexanoic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Dodecanoic acid, biological studies 151-41-7, Lauryl sulfate 155-97-5, Pyridostigmine 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide 298-57-7, Cinnarizine 298-81-7, Methoxsalen 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 321-64-2, Tacrine 334-48-5, Decanoic acid 359-83-1, Pentazocine 360-65-6 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 463-40-1 474-25-9 475-31-0 511-12-6, Dihydroergotamine 516-35-8 516-50-7 520-85-4, Medroxyprogesterone 542-28-9, δ -Valerolactone 544-35-4, Ethyl linoleate 544-63-8, Tetradecanoic acid, biological studies 577-11-7, Sodium docusate 595-33-5 616-45-5, Pyrrolidone 616-45-5D, Pyrrolidone, N-Alkyl derivs. 623-84-7, Propylene glycol diacetate 640-79-9 675-20-7,

2-Piperidone 872-50-4, N-Methylpyrrolidone, biological studies
 1134-47-0, Baclofen 1331-12-0, Propylene glycol monoacetate
 1335-71-3, Propylene glycol oleate 1338-39-2, Arlacel 20 1338-43-8,
 Span 80 1397-89-3, Amphotericin B 1406-16-2, Vitamin D 1406-18-4,
 Vitamin E 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol
 2687-91-4, N-Ethylpyrrolidone 2687-94-7 2687-96-9 3068-88-0,
 β -Butyrolactone 3445-11-2 4419-39-0, Beclomethasone 4759-48-2,
 Isotretinoin 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl isosorbide
 7261-97-4, Dantrolene 7488-99-5, α Carotene 7664-93-9D,
 Sulfuric acid, salts alkyl derivs., biological studies 7689-03-4,
 Camptothecin 8007-43-0, Sorbitan sesquioleate 9002-89-5,
 Polyvinylalcohol 9002-92-0, Brij 30 9002-96-4 9003-39-8,
 Polyvinylpyrrolidone 9004-65-3, Hydroxypropyl methylcellulose
 9004-74-4, Methoxy polyethylene glycol 9004-81-3, Polyoxyethylene
 laurate 9004-95-9, Polyoxyethylene cetyl ether 9004-96-0, PEG-32
 oleate 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3,
 Polyoxyethylene stearate 9005-00-9, Polyoxyethylene stearyl ether
 9005-02-1, Polyoxyethylene dilaurate 9005-07-6, Polyoxyethylene
 dioleate 9005-08-7, Polyoxyethylene distearate 9005-32-7D, Alginate
 acid, salts 9005-37-2, Propylene glycol alginate 9005-63-4D,
 Polyoxyethylene sorbitan, derivs. 9005-63-4D, Polyoxyethylene sorbitan,
 fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80
 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, PLUROLEIQUECC497
 9011-21-6, Polyoxyethylene glyceryl stearate 9016-45-9 9036-19-5
 10238-21-8, Glyburide 10540-29-1, Tamoxifen 11103-57-4, Vitamin A
 11140-04-8, Imwitor 988 12001-79-5, Vitamin K 12619-70-4,
 Cyclodextrin 12619-70-4D, Cyclodextrin, derivs. 12619-70-4D,
 Cyclodextrin, hydroxypropyl ethers 13081-97-5, Pentaerythrityl di
 stearate 14440-80-3, Stearoyl-2-lactylate 14605-22-2 15307-86-5,
 Diclofenac 15574-96-6, Pizotifen 15686-51-8, Clemastine 15687-27-1,
 Ibuprofen 18559-94-9, Albuterol 19356-17-3, Calcifediol 20594-83-6,
 Nalbuphine 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4,
 Nifedipine 22882-95-7, Isopropyl linoleate 22916-47-8, Miconazole
 23288-49-5, Probuco 25168-73-4, Sucrose monostearate 25265-75-2,
 Butanediol 25322-68-3 25322-69-4, Polypropylene glycol 25339-99-5,
 Sucrose monolaurate 25523-97-1, Dexchlorpheniramine 25618-55-7D,
 Polyglycerol, fatty acid esters 25637-84-7, Glyceryl dioleate
 25637-97-2, Sucrose dipalmitate 25812-30-0, Gemfibrozil 26266-57-9,
 Sorbitan monopalmitate 26266-58-0, Sorbitan Trioleate 26402-22-2,
 Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8,
 Sucrose monopalmitate 27154-43-4D, Piperidone, N-Alkyl derivs.
 27195-16-0, Sucrose distearate 27203-92-5, Tramadol 27638-00-2,
 Glyceryl dilaurate 29094-61-9, Glipizide 29767-20-2, Teniposide
 31692-85-0, Glycofurol 32222-06-3, Calcitriol 33069-62-4, Paclitaxel
 33419-42-0, Etoposide 34911-55-2, Bupropion 36354-80-0, Glyceryl
 dicaprylate 37321-62-3, Lauroglycol 38304-91-5, Minoxidil
 41340-25-4, Etodolac 42924-53-8, Nabumetone 43200-80-2, Zopiclone
 49562-28-9, Fenofibrate 49697-38-3, Rimexolone 51333-22-3, Budesonide
 51481-61-9, Cimetidine 51938-44-4, Sorbitan sesquisteate
 52581-71-2, Volpo 3 53123-88-9, Sirolimus 53168-42-6, Myvacet 9-45
 53179-11-6, Loperamide 53230-10-7, Mefloquine 53988-07-1, Glyceryl
 dicaprate 54392-26-6, Sorbitan monoisostearate 54965-21-8,
 Albendazole 55079-83-9, Acitretin 55142-85-3, Ticlopidine
 57107-97-8, Polyoxyethylene glyceryl oleate 59467-70-8, Midazolam
 59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61379-65-5,
 Rifapentine 61869-08-7 62013-04-1, Dirithromycin 62356-64-3
 63590-64-7, Terazosin 63612-50-0, Nilutamide 63675-72-9, Nisoldipine
 65271-80-9, Mitoxantrone

(pharmaceutical compns. and methods for improved delivery of
 hydrophobic therapeutic agents)

IT 9004-65-3, Hydroxypropyl methylcellulose 9005-37-2,
Propylene glycol alginate
(pharmaceutical compns. and methods for improved delivery of
hydrophobic therapeutic agents)

RN 9004-65-3 USPATFULL

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified

CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1

CMF C H4 O

$\text{H}_3\text{C}-\text{OH}$

CM 3

CRN 57-55-6

CMF C3 H8 O2

$\begin{array}{c} \text{OH} \\ | \\ \text{H}_3\text{C}-\text{CH}-\text{CH}_2-\text{OH} \end{array}$

RN 9005-37-2 USPATFULL

CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7

CMF Unspecified

CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6

CMF C3 H8 O2

$\begin{array}{c} \text{OH} \\ | \\ \text{H}_3\text{C}-\text{CH}-\text{CH}_2-\text{OH} \end{array}$

L189 ANSWER 11 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2001:162866 USPATFULL Full-text
TITLE: Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, United States
Chen, Feng-Jing, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|-----------------------|--|------|----------|-----|
| PATENT INFORMATION: | US 6294192 | B1 | 20010925 | <-- |
| APPLICATION INFO.: | US 1999-258654 | | 19990226 | (9) |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | GRANTED | | | |
| PRIMARY EXAMINER: | Page, Thurman K. | | | |
| ASSISTANT EXAMINER: | Channavajjala, Lakshmi | | | |
| LEGAL REPRESENTATIVE: | Reed, Dianne E. Reed & Associates | | | |
| NUMBER OF CLAIMS: | 74 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| NUMBER OF DRAWINGS: | 1 Drawing Figure(s); 1 Drawing Page(s) | | | |
| LINE COUNT: | 3094 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to triglyceride-free pharmaceutical compositions for delivery of hydrophobic therapeutic agents. Compositions of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the surfactants containing the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6294192 B1 20010925 <--

DETD anti-diabetics, such as acetohexamide, chlorpropamide, glibenclamide, gliclazide, *glipizide*, glimepiride, miglitol, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide and troglitazone;

DETD . . . benidipine, benezepril, candesartan, captopril, darodipine, dilitazem HCl, diazoxide, doxazosin HCl, enalapril, eposartan, losartan mesylate, felodipine, fenoldopam, fosenopril, guanabenz acetate, irbesartan, *isradipine*, lisinopril, minoxidil, nicardipine HCl, *nifedipine*, nimodipine, nisoldipine, phenoxybenzamine HCl, prazosin HCl, quinapril, reserpine, terazosin HCl, telmisartan, and valsartan;

CLM What is claimed is:

. . . nelfinavir, efavirenz, dicournarol, tirofibrin, cilostazol, ticlidopine, clopidrogel, oprelvekin, paroxetine, sertraline, venlafaxine, bupropion, clomipramine, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, *glipizide*, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, lisinopril, benezepril, *nifedipine*, nilsolidipine, telmisartan, irbesartan, eposartan, valsartan, candesartan, minnoxidil, terazosin, halofantrine, mefloquine,

dihydroergotamine, ergotamine, frovatriptan, pizofetin, sumatriptan, zolmitriptan, naratriptan, rizatriptan, aminogluthemide, busulphan, .

montelukast, azithromycin, ciprofloxacin, clarithromycin, dirithromycin, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, *glipizide*, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, halofantrine, . . .

amiodarone, zileuton, zafirlukast, albuterol, montelukast, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, *glipizide*, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, nitrofurantoin, dihydroergotamine, ergotamine, frovatriptan, pizofetin, zolmitriptan, pseudo-ephedrine, . . .

IT 50-14-6, Ergocalciferol 50-21-5D, Lactic acid, glycerides 50-24-8, Prednisolone 50-28-2, Estradiol, biological studies 50-70-4, Sorbitol, biological studies 51-48-9, L-Thyroxine, biological studies 52-01-7, Spironolactone 55-98-1, Busulphan 56-81-5, 1,2,3-Propanetriol, biological studies 56-81-5D, Glycerol, polyethylene fatty acid esters 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-55-6D, Propylene glycol, ethers 57-83-0, Progesterone, biological studies 57-88-5, Cholesterol, biological studies 57-88-5D, Cholesterol, polyoxyethylene derivs. 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 64-17-5, Ethanol, biological studies 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-63-0, Isopropanol, biological studies 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 69-65-8, Mannitol 71-36-3, Butanol, biological studies 76-57-3, Codeine 76-99-3, Methadone 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl citrate 77-92-9D, Citric acid, diglycerides 77-93-0, Triethylcitrate 77-94-1, Tributylcitrate 81-24-3 81-25-4 83-44-3 87-33-2, Isosorbide dinitrate 87-69-4D, Tartaric acid, glycerides 90-82-4, Pseudoephedrine 100-51-6, Benzenemethanol, biological studies 102-76-1, Triacetin 104-31-4, Benzonatate 105-37-3, Ethyl propionate 105-54-4, Ethyl butyrate 105-60-2, biological studies 105-60-2D, Caprolactam, N-Alkyl derivs. 106-32-1, Ethyl caprylate 107-21-1, 1,2-Ethenediol, biological studies 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6, Crodamol EO 111-90-0, Transcutol 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 113-15-5, Ergotamine 113-92-8, Chlorpheniramine 115-77-5, biological studies 115-83-3, Pentaerythrityl Tetra stearate 124-07-2, Octanoic acid, biological studies 125-84-8, Aminogluthethimide 126-07-8, Griseofulvin 127-19-5, Dimethylacetamide 128-13-2 141-22-0 142-18-7, Glyceryl monolaurate 142-62-1, Hexanoic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Dodecanoic acid, biological studies 151-41-7, Lauryl sulfate 155-97-5, Pyridostigmine 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide 298-57-7, Cinnarizine 298-81-7, Methoxsalen 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 321-64-2, Tacrine 334-48-5, Decanoic acid 359-83-1, Pentazocine 360-65-6 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 463-40-1 474-25-9 475-31-0 511-12-6, Dihydroergotamine 516-35-8 516-50-7

520-85-4, Medroxyprogesterone 542-28-9, δ -Valerolactone
 544-35-4, Ethyl linoleate 544-63-8, Tetradecanoic acid, biological
 studies 577-11-7, Sodium docusate 595-33-5 616-45-5, Pyrrolidone
 616-45-5D, Pyrrolidone, N-Alkyl derivs. 623-84-7, Propylene glycol
 diacetate 640-79-9 675-20-7, 2-Piperidone 872-50-4,
 N-Methylpyrrolidone, biological studies 1134-47-0, Baclofen
 1331-12-0, Propylene glycol monoacetate 1335-71-3, Propylene glycol
 oleate 1338-39-2, Arlacel 20 1338-43-8, Span 80 1397-89-3,
 Amphotericin B 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1951-25-3,
 Amiodarone 1972-08-3, Tetrahydrocannabinol 2687-91-4,
 N-Ethylpyrrolidone 2687-94-7 2687-96-9 3068-88-0,
 β -Butyrolactone 3445-11-2 4419-39-0, Beclomethasone 4759-48-2,
 Isotretinoin 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl isosorbide
 7261-97-4, Dantrolene 7488-99-5, α Carotene 7664-93-9D,
 Sulfuric acid, salts alkyl derivs. 7689-03-4, Camptothecin 8007-43-0,
 Sorbitan sesquioleate 9002-89-5, Polyvinylalcohol 9002-92-0, Brij 30
 9002-96-4 9003-39-8, Polyvinylpyrrolidone 9004-65-3,
 Hydroxypropyl methylcellulose 9004-74-4, Methoxy polyethylene glycol
 9004-81-3, Polyoxyethylene laurate 9004-95-9, Polyoxyethylene cetyl
 ether 9004-96-0, PEG-32 oleate 9004-98-2, Polyoxyethylene oleyl ether
 9004-99-3, Polyoxyethylene stearate 9005-00-9, Polyoxyethylene stearyl
 ether 9005-02-1, Polyoxyethylene dilaurate 9005-07-6, Polyoxyethylene
 dioleate 9005-08-7, Polyoxyethylene distearate 9005-32-7D, Alginic
 acid, salts 9005-37-2, Propylene glycol alginate 9005-63-4D,
 Polyoxyethylene sorbitan, derivs. 9005-63-4D, Polyoxyethylene sorbitan,
 fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80
 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, PLUROLIOLEIQUECC497
 9011-21-6, Polyoxyethylene glyceryl stearate 9016-45-9 9036-19-5
 10238-21-8, Glyburide 10540-29-1, Tamoxifen 11103-57-4, Vitamin A
 11140-04-8, Imwitor 988 12001-79-5, Vitamin K 12619-70-4,
 Cyclodextrin 12619-70-4D, Cyclodextrin, derivs. 12619-70-4D,
 Cyclodextrin, hydroxypropyl ethers 13081-97-5, Pentaerythrityl di
 stearate 14440-80-3, Stearoyl-2-lactylate 14605-22-2 15307-86-5,
 Diclofenac 15574-96-6, Pizotifen 15686-51-8, Clemastine 15687-27-1,
 Ibuprofen 18559-94-9, Albuterol 19356-17-3, Calcifediol 20594-83-6,
 Nalbuphine 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4,
 Nifedipine 22882-95-7, Isopropyl linoleate 22916-47-8, Miconazole
 23288-49-5, Probuco 25168-73-4, Sucrose monostearate 25265-75-2,
 Butanediol 25322-68-3 25322-69-4, Polypropylene glycol 25339-99-5,
 Sucrose monolaurate 25523-97-1, Dexchlorpheniramine 25618-55-7D,
 Polyglycerol, fatty acid esters 25637-84-7, Glyceryl dioleate
 25637-97-2, Sucrose dipalmitate 25812-30-0, Gemfibrozil 26266-57-9,
 Sorbitan monopalmitate 26266-58-0, Sorbitan Trioleate 26402-22-2,
 Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8,
 Sucrose monopalmitate 27154-43-4D, Piperidone, N-Alkyl derivs.
 27195-16-0, Sucrose distearate 27203-92-5, Tramadol 27638-00-2,
 Glyceryl dilaurate 29094-61-9, Glipizide 29767-20-2, Teniposide
 31692-85-0, Glycofurol 32222-06-3, Calcitriol 33069-62-4, Paclitaxel
 33419-42-0, Etoposide 34911-55-2, Bupropion 36354-80-0, Glyceryl
 dicaprylate 37321-62-3, Lauroglycol 38304-91-5, Minoxidil
 41340-25-4, Etodolac 42924-53-8, Nabumetone 43200-80-2, Zopiclone
 49562-28-9, Fenofibrate 49697-38-3, Rimexolone 51333-22-3, Budesonide
 51481-61-9, Cimetidine 51938-44-4, Sorbitan sesquisteate
 52581-71-2, Volpo 3 53123-88-9, Sirolimus 53168-42-6, Myvacet 9-45
 53179-11-6, Loperamide 53230-10-7, Mefloquine 53988-07-1, Glyceryl
 dicaprate 54392-26-6, Sorbitan monoisostearate 54965-21-8,
 Albendazole 55079-83-9, Acitretin 55142-85-3, Ticlopidine
 57107-97-8, Polyoxyethylene glyceryl oleate 59467-70-8, Midazolam
 59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61379-65-5;

Rifapentine 61869-08-7 62013-04-1, Dirithromycin 62356-64-3
63590-64-7, Terazosin 63612-50-0, Nilutamide 63675-72-9, Nisoldipine
65271-80-9, Mitoxantrone

(pharmaceutical compns. and methods for improved delivery of
hydrophobic therapeutic agents)

IT 9004-65-3, Hydroxypropyl methylcellulose 9005-37-2,

Propylene glycol alginate

(pharmaceutical compns. and methods for improved delivery of
hydrophobic therapeutic agents)

RN 9004-65-3 USPATFULL

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified

CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1

CMF C H4 O

H₃C—OH

CM 3

CRN 57-55-6

CMF C3 H8 O2

OH
|
H₃C—CH—CH₂—OH

RN 9005-37-2 USPATFULL

CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7

CMF Unspecified


CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6

CMF C3 H8 O2



L189 ANSWER 12 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2001:121093 USPATFULL Full-text
 TITLE: Clear oil-containing pharmaceutical compositions
 INVENTOR(S): Chen, Feng-Jing, Salt Lake City, UT, United States
 Patel, Mahesh V., Salt Lake City, UT, United States
 PATENT ASSIGNEE(S): Lipocine Inc., Salt Lake City, UT, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|-----------------------|-----------------|-------------------|----------|-----|
| PATENT INFORMATION: | US 6267985 | B1 | 20010731 | <-- |
| APPLICATION INFO.: | US 1999-345615 | | 19990630 | (9) |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | GRANTED | | | |
| PRIMARY EXAMINER: | Spear, James M. | | | |
| LEGAL REPRESENTATIVE: | Reed, Dianne E. | Reed & Associates | | |
| NUMBER OF CLAIMS: | 184 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 3767 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a triglyceride and a carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the triglyceride and surfactants. An optional therapeutic agent can be incorporated into the composition, or can be co-administered with the composition. The invention also provides methods of enhancing triglyceride solubility and methods of treatment with therapeutic agents using these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6267985 B1 20010731 <--
 SUMM . . . propionate, fluvastatin, foscamet sodium, fosinopril, fosphenytoin, fosphenytoin sodium, frovatriptan, frusemide, fumagillin, furazolidone, furosemide, furzolidone, gabapentin, gancyclovir, gemfibrozil, gentamycin, glibenclamide, gliclazide, *glipizide*, glucagon, glybenclamide, glyburide, glyceryl trinitrate, glymepiride, glymepride, granisetron, granulocyte stimulating factor, grepafloxacin, griseofulvin, guanabenz, guanabenz acetate, halofantrine, halofantrine HCl, haloperidol, hydrocortisone, hyoscyamine, ibufenac, ibuprofen, imipenem, indinavir, indivir, indomethacin, insulin, interleukin-3, irbesartan, irinotecan, isosorbide dinitrate, isosorbide mononitrate, isotretinoin, isoxazole, *isradipine*, itraconazole, ivermectin, ketoconazole, ketoprofen, ketorolac, ketotifen, labetalol, lamivudine, lamotrigine, lanatoside C, lansoprazole, leflunomide, levofloxacin, levothyroxine, lisinopril, lomefloxacin, lomustine, loperamide, lorazepam, lorazepam, lorefloxacin, lormetazepam, losartan, *lovastatin*, L-thyroxine, lysuride, lysuride maleate, maprotiline, maprotiline HCl, mazindol, mebendazole, meclofenamic acid,

meclozine, meclozine HCl, medazepam, medigoxin, medroxyprogesterone acetate, mefenamic acid, . . . nalbuphine, nalidixic acid, naproxen, naratriptan, naratriptan HCl, natamycin, nedocromil sodium, nefazodone, nelfinavir, nerteporfin, neutontin, nevirapine, nicardipine, nicardipine HCl, nicotine, nicoumalone, **nifedipine**, nilutamide, nimesulide, nimodipine, nimorazole, nisoldipine, nitrazepam, nitrofurantoin, nitrofurazone, nizatidine, non-essential fatty acids, norethisterone, norfloxacin, norgestrel, nortriptyline HCl, nystatin, oestradiol, ofloxacin, . . .

IT 50-14-6, Ergocalciferol 50-21-5D, Lactic acid, glycerides 50-24-8, Prednisolone 50-28-2, EStradiol, biological studies 50-70-4, Sorbitol, biological studies 51-48-9, L-Thyroxine, biological studies 52-01-7, Spironolactone 55-98-1, Busulphan 56-81-5, 1,2,3-Propanetriol, biological studies 56-81-5D, Glycerol, polyethylene fatty acid esters 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-55-6D, Propylene glycol, ethers 57-83-0, Progesterone, biological studies 57-88-5, Cholesterol, biological studies 57-88-5D, Cholesterol, polyoxyethylene derivs. 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 64-17-5, Ethanol, biological studies 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-63-0, Isopropanol, biological studies 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 69-65-8, Mannitol 71-36-3, Butanol, biological studies 76-57-3, Codeine 76-99-3, Methadone 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl citrate 77-92-9D, Citric acid, diglycerides 77-93-0, Triethylcitrate 77-94-1, Tributylcitrate 81-24-3 81-25-4 83-44-3 87-33-2, Isosorbide dinitrate 87-69-4D, Tartaric acid, glycerides, biological studies 90-82-4, Pseudoephedrine 100-51-6, Benzenemethanol, biological studies 102-76-1, Triacetin 104-31-4, Benzonatate 105-37-3, Ethyl propionate 105-54-4, Ethyl butyrate 105-60-2, biological studies 105-60-2D, Caprolactam, N-Alkyl derivs. 106-32-1, Ethyl caprylate 107-21-1, 1,2-Ethanediol, biological studies 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6, Crodamol EO 111-90-0, Transcutol 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 113-15-5, Ergotamine 113-92-8, Chlorpheniramine 115-77-5, biological studies 115-83-3, Pentaerythrityl Tetra stearate 124-07-2, Octanoic acid, biological studies 125-84-8, Aminoglutethimide 126-07-8, Griseofulvin 127-19-5, Dimethylacetamide 128-13-2 141-22-0 142-18-7, Glyceryl monolaurate 142-62-1, Hexanoic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Dodecanoic acid, biological studies 151-41-7, Lauryl sulfate 155-97-5, Pyridostigmine 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide 298-57-7, Cinnarizine 298-81-7, Methoxsalen 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 321-64-2, Tacrine 334-48-5, Decanoic acid 359-83-1, Pentazocine 360-65-6 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 463-40-1 474-25-9 475-31-0 511-12-6, Dihydroergotamine 516-35-8 516-50-7 520-85-4, Medroxyprogesterone 542-28-9, δ -Valerolactone 544-35-4, Ethyl linoleate 544-63-8, Tetradecanoic acid, biological studies 577-11-7, Sodium docusate 595-33-5 616-45-5, Pyrrolidone 616-45-5D, Pyrrolidone, N-Alkyl derivs. 623-84-7, Propylene glycol diacetate 640-79-9 675-20-7, 2-Piperidone 872-50-4, N-Methylpyrrolidone, biological studies 1134-47-0, Baclofen 1331-12-0, Propylene glycol monoacetate 1335-71-3, Propylene glycol oleate 1338-39-2, Arlacel 20 1338-43-8, Span 80 1397-89-3, Amphoteracin B 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol 2687-91-4, N-Ethylpyrrolidone 2687-94-7 2687-96-9 3068-88-0, β -Butyrolactone 3445-11-2 4419-39-0, Beclomethasone 4759-48-2,

Isotretinoin 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl isosorbide 7261-97-4, Dantrolene 7488-99-5, α Carotene 7664-93-9D, Sulfuric acid, salts alkyl derivs., biological studies 7689-03-4, Camptothecin 8007-43-0, Sorbitan sesquioleate 9002-89-5, Polyvinylalcohol 9002-92-0, Brij 30 9002-96-4 9003-39-8, Polyvinylpyrrolidone 9004-65-3, Hydroxypropyl methylcellulose 9004-74-4, Methoxy polyethylene glycol 9004-81-3, Polyoxyethylene laurate 9004-95-9, Polyoxyethylene cetyl ether 9004-96-0, PEG-32 oleate 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3, Polyoxyethylene stearate 9005-00-9, Polyoxyethylene stearyl ether 9005-02-1, Polyoxyethylene dilaurate 9005-07-6, Polyoxyethylene dioleate 9005-08-7, Polyoxyethylene distearate 9005-32-7D, Alginic acid, salts 9005-37-2, Propylene glycol alginate 9005-63-4D, Polyoxyethylene sorbitan, derivs. 9005-63-4D, Polyoxyethylene sorbitan, fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, PLUROLOLEIQUECC497 9011-21-6, Polyoxyethylene glyceryl stearate 9016-45-9 9036-19-5 10238-21-8, Glyburide 10540-29-1, Tamoxifen 11103-57-4, Vitamin A 11140-04-8, Imwitor 988 12001-79-5, Vitamin K 12619-70-4, Cyclodextrin 12619-70-4D, Cyclodextrin, derivs. 12619-70-4D, Cyclodextrin, hydroxypropyl ethers 13081-97-5, Pentaerythrityl di stearate 14440-80-3, Stearoyl-2-lactylate 14605-22-2 15307-86-5, Diclofenac 15574-96-6, Pizotifen 15686-51-8, Clemastine 15687-27-1, Ibuprofen 18559-94-9, Albuterol 19356-17-3, Calcifediol 20594-83-6, Nalbuphine 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22882-95-7, Isopropyl linoleate 22916-47-8, Miconazole 23288-49-5, Probuco 25168-73-4, Sucrose monostearate 25265-75-2, Butanediol 25322-68-3 25322-69-4, Polypropylene glycol 25339-99-5, Sucrose monolaurate 25523-97-1, Dexchlorpheniramine 25618-55-7D, Polyglycerol, fatty acid esters 25637-84-7, Glyceryl dioleate 25637-97-2, Sucrose dipalmitate 25812-30-0, Gemfibrozil 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan Trioleate 26402-22-2, Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8, Sucrose monopalmitate 27154-43-4D, Piperidone, N-Alkyl derivs. 27195-16-0, Sucrose distearate 27203-92-5, TRamadol 27638-00-2, Glyceryl dilaurate 29094-61-9, Glipizide 29767-20-2, Teniposide 31692-85-0, Glycofurol 32222-06-3, Calcitriol 33069-62-4, Paclitaxel 33419-42-0, Etoposide 34911-55-2, Bupropion 36354-80-0, Glyceryl dicaprylate 37321-62-3, Lauroglycol 38304-91-5, Minoxidil 41340-25-4, Etodolac 42924-53-8, Nabumetone 43200-80-2, Zopiclone 49562-28-9, Fenofibrate 49697-38-3, Rimexolone 51333-22-3, Budesonide 51481-61-9, Cimetidine 51938-44-4, Sorbitan sesquisteate 52581-71-2, Volpo 3 53123-88-9, Sirolimus 53168-42-6, Myvacet 9-45 53179-11-6, Loperamide 53230-10-7, Mefloquine 53988-07-1, Glyceryl dicaprate 54392-26-6, Sorbitan monoisostearate 54965-21-8, Albendazole 55079-83-9, Acitretin 55142-85-3, Ticlopidine 57107-97-8, Polyoxyethylene glyceryl oleate 59467-70-8, Midazolam 59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61379-65-5, Rifapentine 61869-08-7 62013-04-1, Dirithromycin 62356-64-3 63590-64-7, Terazosin 63612-50-0, Nilutamide 63675-72-9, Nisoldipine 65271-80-9, Mitoxantrone

(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

IT 9004-65-3, Hydroxypropyl methylcellulose 9005-37-2, Propylene glycol alginate

(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

RN 9004-65-3 USPATFULL

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified

CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1

CMF C H4 O

$\text{H}_3\text{C}-\text{OH}$

CM 3

CRN 57-55-6

CMF C3 H8 O2

$\begin{array}{c} \text{OH} \\ | \\ \text{H}_3\text{C}-\text{CH}-\text{CH}_2-\text{OH} \end{array}$

RN 9005-37-2 USPATFULL

CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7

CMF Unspecified

CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6

CMF C3 H8 O2

$\begin{array}{c} \text{OH} \\ | \\ \text{H}_3\text{C}-\text{CH}-\text{CH}_2-\text{OH} \end{array}$

L189 ANSWER 13 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2001:116589 USPATFULL Full-text

TITLE: Oral transmucosal drug dosage using solid solution

INVENTOR(S): Zhang, Hao, Salt Lake City, UT, United States
Croft, Jed, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Anesta Corporation, Salt Lake City, UT, United States
(U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 6264981 | B1 | 20010724 |
| APPLICATION INFO.: | US 1999-428071 | | 19991027 (9) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | GRANTED | | |
| PRIMARY EXAMINER: | Azpuru, Carlos | | |
| LEGAL REPRESENTATIVE: | Kirton & McConkie, Krieger, Michael F. | | |
| NUMBER OF CLAIMS: | 55 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 3 Drawing Figure(s); 3 Drawing Page(s) | | |
| LINE COUNT: | 1057 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed toward formulation and method for oral transmucosal delivery of a pharmaceutical. The invention provides a drug formulation comprising a solid pharmaceutical agent in solid solution with a dissolution agent. The formulation is administered into a patient's oral cavity, delivering the pharmaceutical agent by absorption through a patient's oral mucosal tissue. The formulation and method provide for improved oral mucosal delivery of the pharmaceutical agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

| | | | |
|---------------|-------------------------|---------|----------|
| PI | US 6264981 | B1 | 20010724 |
| DETD | diuretic | 20-100 | mg |
| isosorbide | angina | 2.5-40 | mg |
| labetalol | antihypertensive | 100-400 | mg |
| lidocaine | antiarrhythmic | 20-250 | mg |
| metolazone | diuretic | 5-50 | mg |
| metoprolol | antihypertensive | 25-100 | mg |
| nadolol | antihypertensive | 40-160 | mg |
| nifedipine | antihypertensive | 10-40 | mg |
| nitroglycerin | antihypertensive/angina | 0.4-1.0 | mg |
| nitroprusside | hypotensive | 10-50 | mg |
| propranolol | antihypertensive/angina | 0.1-50 | mg |

CLM What is claimed is:

... triazolam, droperidol, propanidid, etomidate, propofol, ketamine, diprivan, bretylium, captopril, clonidine, dopamine, enalapril, esmolol, furosemide, isosorbide, labetalol, lidocaine, metolazone, metoprolol, nadolol, **nifedipine**, nitroglycerin, nitroprusside, propranolol, benzquinamide, meclizine, metoclopramide, prochlorperazine, trimethobenzamide, clotrimazole, nystatin, carbidopa, levodopa, sucralfate, albuterol, aminophylline, beclomethasone, dyphylline, epinephrine, flunisolide, isoetharine,...

... triazolam, droperidol, propanidid, etomidate, propofol, ketamine, diprivan, bretylium, captopril, clonidine, dopamine, enalapril, esmolol, furosemide, isosorbide, labetalol, lidocaine, metolazone, metoprolol, nadolol, **nifedipine**, nitroglycerin, nitroprusside, propranolol, benzquinamide, meclizine, metoclopramide, prochlorperazine, trimethobenzamide, clotrimazole, nystatin, carbidopa, levodopa, sucralfate, albuterol, aminophylline, beclomethasone, dyphylline, epinephrine, flunisolide, isoetharine,...

IT 50-02-2, Dexamethasone 50-28-2, Estradiol, biological studies
50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 50-70-4,
Sorbitol, biological studies 50-81-7, Vitamin C, biological studies

-- duplicate

50-99-7, Dextrose, biological studies 51-30-9, Isoproterenol hydrochloride 51-43-4, Epinephrine 51-61-6, Dopamine, biological studies 54-11-5, Nicotine 54-31-9, Furosemide 55-63-0, Nitroglycerin 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 57-83-0, Progesteron, biological studies 58-22-0, Testosterone 58-38-8, Prochlorperazine 58-55-9, Theophylline, biological studies 58-82-2, Bradykinin 59-41-6, Bretylium 59-92-7, Levodopa, biological studies 60-79-7, Ergonovine 63-12-7, Benzquinamide 63-42-3, Lactose 67-52-7, 2,4,6(1H,3H,5H)-Pyrimidinetrione 69-65-8, Mannitol 71-50-1, Acetate, biological studies 76-74-4, Pentobarbital 76-75-5, Thiopental 77-10-1, Phencyclidine 77-27-0, Thiamylal 77-86-1, Tris 87-99-0, Xylitol 94-24-6, Tetracaine 97-53-0, Eugenol 107-43-7, Trimethylglycine 110-16-7, Maleic acid, biological studies 113-15-5, Ergotamine 129-51-1, Oxytocic 134-03-2, Sodium ascorbate 137-58-6, Lidocaine 138-56-7, Trimethobenzamide 151-83-7, Methohexital 317-34-0, Aminophylline 361-37-5, Methysergide 364-62-5, Metoclopramide 437-38-7, Fentanyl 465-65-6, Naloxone 479-18-5, Dyphylline 495-40-9, Butyrophenone 511-12-6, Dihydroergotamine 525-66-6, Propranolol 530-08-5, Isoetharine 548-73-2, Droperidol 569-65-3, Meclizine 585-86-4, Lactitol 586-06-1, Metaproterenol 604-75-1, Oxazepam 652-67-5, Isosorbide 721-50-6, Prilocaine 846-49-1, Lorazepam 1400-61-9, Nystatin 1406-18-4, Vitamin E 1421-14-3, Propofol 2078-54-8, Propofol 3385-03-3, Flunisolide 3715-17-1, Tartrate 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4499-40-5, Oxtriphylline, biological studies 6740-88-1, Ketamine 7440-70-2, Calcium, biological studies 9000-30-0, Guar gum 9000-65-1, Tragacanth 9002-60-2, Adrenocorticotrophic hormone, biological studies 9002-64-6, Parathyroid hormone 9002-72-6, Growth hormone 9002-89-5, Polyvinyl alcohol 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-53-9, Dextrin 9004-57-3, Ethylcellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-37-2, Propylene glycolalginat 9005-38-3, Sodium alginate 9005-49-6, Heparin), biological studies 9007-12-9, Calcitonin 9041-90-1, Angiotensin I 9050-36-6, Maltodextrin 9063-38-1, Sodium starch glycolate 11000-17-2, Vasopressin 11103-57-4, Vitamin A 11138-66-2, Xanthan gum 12794-10-4, Benzodiazepine 15078-28-1, Nitroprusside 16679-58-6, Desmopressin 17560-51-9, Metolazone 18559-94-9, Albuterol 21829-25-4, Nifedipine 23031-25-6, Terbutaline 23593-75-1, Clotrimazole 25322-68-3, Polyethylene glycol 25322-68-3D, alkyl ethers 28860-95-9, Carbidopa 28911-01-5, Triazolam 33125-97-2, Etomidate 36322-90-4, Piroxicam 36894-69-6, Labetalol 38396-39-3, Bupivacaine 39404-33-6, Dextrates 42200-33-9, Nadolol 51384-51-1, Metoprolol 54182-58-0, Sucralfate 54767-75-8, Suloctidil 56030-54-7, Sufentanil 59467-70-8, Midazolam 59708-52-0, Carfentanil 60617-12-1, β -Endorphin 61380-40-3, Lofentanil 62571-86-2, Captopril 71195-58-9, Alfentanil 75847-73-3, Enalapril 81147-92-4, Esmolol 103628-46-2, Sumatriptan 106392-12-5, Poloxamer

(oral transmucosal drug dosage using solid solution)

IT 9004-65-3, Hydroxypropyl methylcellulose 9005-37-2, Propylene glycolalginat 9005-38-3, Sodium alginate 11138-66-2, Xanthan gum

(oral transmucosal drug dosage using solid solution)

RN 9004-65-3 USPATFULL


CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE


CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 USPATFULL
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9005-38-3 USPATFULL
CN Alginic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

RN 11138-66-2 USPATFULL

CN Xanthan gum (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

L189 ANSWER 14 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2001:93131 USPATFULL Full-text
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, United States
Chen, Feng-Jing, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|-----------------------|-----------------|----------------------|-----------------|-----|
| PATENT INFORMATION: | US 6248363 | B1 | 20010619 | <-- |
| APPLICATION INFO.: | US 1999-447690 | | 19991123 | (9) |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | GRANTED | | | |
| PRIMARY EXAMINER: | Spear, James M. | | | |
| LEGAL REPRESENTATIVE: | Reed, Dianne E. | Reed & Associates | | |
| NUMBER OF CLAIMS: | 57 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| NUMBER OF DRAWINGS: | 4 | Drawing Figure(s); 4 | Drawing Page(s) | |
| LINE COUNT: | 3302 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6248363 B1 20010619 <--
DETD . . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, *glipizide*, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irbesartan, irinotecan, isosorbide dinitrate isotreinoine, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, lisinopril, loperamide, loratadine, *lovastatin*, L-thyroxine, lutein, lycopene, medroxyprogesterone, mifepristone, mefloquine, megestrol acetate, methadone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine, naratriptan, nelfinavir, *nifedipine*, nilsolidipine, nilutamide, nitrofurantoin, nizatidine, omeprazole, oprevelkin, osteradiol, oxaprozin, paclitaxel, paricalcitol, paroxetine, pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone, probucol, progesterone, pseudo-ephedrine,

pyridostigmine, . . .

DETD . . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furzolidone, gabapentin, gemfibrozil, glibenclamide, **glipizide**, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irinotecan, isotreinoine, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lansoprazole, leflunomide, loperamide, loratadine, **lovastatin**, L-thyroxine, lutein, lycopene, mefepristone, mefloquine, megestrol acetate, methdone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, mitoxantrone, mmedroxyprogesterone, montelukast, nabumetone, nalbuphine, naratriptan, .

DETD . . . dihyrotachysterol, efavirenz, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fexofenadine, finasteride, flucanazole, flurbiprofen, fosphenytion, frovatriptan, furzolidone, glibenclamide, **glipizide**, glyburide, glymepride, ibuprofen, irinotecan, isotreinoine, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lansoprazole, leflunomide, loperamide, loratadine, **lovastatin**, L-thyroxine, lutein, lycopene, medroxyprogesterone, mefepristone, megestrol acetate, methoxsalen, metronidazole, metronidazole, miconazole, miglitol, mitoxantrone, montelukast, nabumetone, naratriptan, nelfinavir, nilutamide, nitrofurantoin, nizatidine, . . .

DETD . . . active ingredients include: amlodipine, amprenavir, atorvastatin, atovaquone, celecoxib, cisapride, coenzyme Q10, cyclosporine, famotidine, fenofibrate, fexofenadine, finasteride, ibuprofen, itraconazole, lansoprazole, loratadine, **lovastatin**, megestrol acetate, montelukast, nabumetone, nizatidine, omeprazole, oxaprozin, paclitaxel, paricalcitol, pioglitazone, pranlukast, progesterone, pseudo-ephedrine, rabeprazole, rapamycin, refocoxib, repaglinide, rimexolone, ritanovir, rosiglitazone, . . .

DETD Component Amount (g)

| | |
|------------------------------|-----|
| Lovastatin | 20 |
| Coenzyme Q10 | 50 |
| PBG-40 stearate | 150 |
| Glycerol monolaurate | 50 |
| Non-pareil seed (25/30 mesh) | 200 |

IT 50-14-6, Ergocalciferol 50-21-5D, Lactic acid, glycerides 50-24-8, Prednisolone 50-28-2, Estradiol, biological studies 50-70-4, Sorbitol, biological studies 51-48-9, L-Thyroxine, biological studies 52-01-7, Spironolactone 55-98-1, Busulphan 56-81-5, 1,2,3-Propanetriol, biological studies 56-81-5D, Glycerol, polyethylene fatty acid esters 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-55-6D, Propylene glycol, ethers 57-83-0, Progesterone, biological studies 57-88-5, Cholesterol, biological studies 57-88-5D, Cholesterol, polyoxyethylene derivs. 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 64-17-5, Ethanol, biological studies 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-63-0, Isopropanol, biological studies 67-96-9, Dihyrotachysterol 67-97-0, Cholecalciferol 69-65-8, Mannitol 71-36-3, Butanol, biological studies 76-57-3, Codeine 76-99-3, Methadone 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl citrate 77-92-9D, Citric acid, diglycerides 77-93-0, Triethylcitrate 77-94-1, Tributylcitrate 81-24-3 81-25-4 83-44-3 87-33-2, Isosorbide dinitrate 87-69-4D, Tartaric acid, glycerides, biological studies 90-82-4, Pseudoephedrine 100-51-6, Benzenemethanol, biological studies 102-76-1, Triacetin 104-31-4,

Benzonatate 105-37-3, Ethyl propionate 105-54-4, Ethyl butyrate 105-60-2, biological studies 105-60-2D, Caprolactam, N-Alkyl derivs. 106-32-1, Ethyl caprylate 107-21-1, 1,2-Ethanediol, biological studies 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6, Crodamol EO 111-90-0, Transcutol 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 113-15-5, Ergotamine 113-92-8, Chlorpheniramine 115-77-5, biological studies 115-83-3, Pentaerythrityl Tetra stearate 124-07-2, Octanoic acid, biological studies 125-84-8, Aminogluthethimide 126-07-8, Griseofulvin 127-19-5, Dimethylacetamide 128-13-2 141-22-0 142-18-7, Glyceryl monolaurate 142-62-1, Hexanoic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Dodecanoic acid, biological studies 151-41-7, Lauryl sulfate 155-97-5, Pyridostigmine 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide 298-57-7, Cinnarizine 298-81-7, Methoxsalen 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 321-64-2, Tacrine 334-48-5, Decanoic acid 359-83-1, Pentazocine 360-65-6 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 463-40-1 474-25-9 475-31-0 511-12-6, Dihydroergotamine 516-35-8 516-50-7 520-85-4, Medroxyprogesterone 542-28-9, δ -Valerolactone 544-35-4, Ethyl linoleate 544-63-8, Tetradecanoic acid, biological studies 577-11-7, Sodium docusate 595-33-5 616-45-5, Pyrrolidone 616-45-5D, Pyrrolidone, N-Alkyl derivs. 623-84-7, Propylene glycol diacetate 640-79-9 675-20-7, 2-Piperidone 872-50-4, N-Methylpyrrolidone, biological studies 1134-47-0, Baclofen 1331-12-0, Propylene glycol monoacetate 1335-71-3, Propylene glycol oleate 1338-39-2, Arlacel 20 1338-43-8, Span 80 1397-89-3, Amphotericin B 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol 2687-91-4, N-Ethylpyrrolidone 2687-94-7 2687-96-9 3068-88-0, β -Butyrolactone 3445-11-2 4419-39-0, Beclomethasone 4759-48-2, Isotretinoin 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl isosorbide 7261-97-4, Dantrolene 7488-99-5, α Carotene 7664-93-9D, Sulfuric acid, salts alkyl derivs., biological studies 7689-03-4, Camptothecin 8007-43-0, Sorbitan sesquiolate 9002-89-5, Polyvinylalcohol 9002-92-0, Brij 30 9002-96-4 9003-39-8, Polyvinylpyrrolidone 9004-65-3, Hydroxypropyl methylcellulose 9004-74-4, Methoxy polyethylene glycol 9004-81-3, Polyoxyethylene laurate 9004-95-9, Polyoxyethylene cetyl ether 9004-96-0, PEG-32 oleate 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3, Polyoxyethylene stearate 9005-00-9, Polyoxyethylene stearyl ether 9005-02-1, Polyoxyethylene dilaurate 9005-07-6, Polyoxyethylene dioleate 9005-08-7, Polyoxyethylene distearate 9005-32-7D, Alginic acid, salts 9005-37-2, Propylene glycol alginate 9005-63-4D, Polyoxyethylene sorbitan, derivs. 9005-63-4D, Polyoxyethylene sorbitan, fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, PLUROLIOLEIQUECC497 9011-21-6, Polyoxyethylene glyceryl stearate 9016-45-9 9036-19-5 10238-21-8, Glyburide 10540-29-1, Tamoxifen 11103-57-4, Vitamin A 11140-04-8, Imwitor 988 12001-79-5, Vitamin K 12619-70-4, Cyclodextrin 12619-70-4D, Cyclodextrin, derivs. 12619-70-4D, Cyclodextrin, hydroxypropyl ethers 13081-97-5, Pentaerythrityl di stearate 14440-80-3, Stearoyl-2-lactylate 14605-22-2 15307-86-5, Diclofenac 15574-96-6, Pizotifen 15686-51-8, Clemastine 15687-27-1, Ibuprofen 18559-94-9, Albuterol 19356-17-3, Calcifediol 20594-83-6, Nalbuphine 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22882-95-7, Isopropyl linoleate 22916-47-8, Miconazole 23288-49-5, Probuco 25168-73-4, Sucrose monostearate 25265-75-2, Butanediol 25322-68-3 25322-69-4, Polypropylene glycol 25339-99-5, Sucrose monolaurate 25523-97-1, Dexchlorpheniramine 25618-55-7D,

Polyglycerol, fatty acid esters 25637-84-7, Glyceryl dioleate
 25637-97-2, Sucrose dipalmitate 25812-30-0, Gemfibrozil 26266-57-9,
 Sorbitan monopalmitate 26266-58-0, Sorbitan Trioleate 26402-22-2,
 Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8,
 Sucrose monopalmitate 27154-43-4D, Piperidone, N-Alkyl derivs.
 27195-16-0, Sucrose distearate 27203-92-5, TRamadol 27638-00-2,
 Glyceryl dilaurate 29094-61-9, Glipizide 29767-20-2, Teniposide
 31692-85-0, Glycofurol 32222-06-3, Calcitriol 33069-62-4, Paclitaxel
 33419-42-0, Etoposide 34911-55-2, Bupropion 36354-80-0, Glyceryl
 dicaprylate 37321-62-3, Lauroglycol 38304-91-5, Minoxidil
 41340-25-4, Etodolac 42924-53-8, Nabumetone 43200-80-2, Zopiclone
 49562-28-9, Fenofibrate 49697-38-3, Rimexolone 51333-22-3, Budesonide
 51481-61-9, Cimetidine 51938-44-4, Sorbitan sesquistearate
 52581-71-2, Volpo 3 53123-88-9, Sirolimus 53168-42-6, Myvacet 9-45
 53179-11-6, Loperamide 53230-10-7, Mefloquine 53988-07-1, Glyceryl
 dicaprate 54392-26-6, Sorbitan monoisostearate 54965-21-8,
 Albendazole 55079-83-9, Acitretin 55142-85-3, Ticlopidine
 57107-97-8, Polyoxyethylene glyceryl oleate 59467-70-8, Midazolam
 59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61379-65-5,
 Rifapentine 61869-08-7 62013-04-1, Dirithromycin 62356-64-3
 63590-64-7, Terazosin 63612-50-0, Nilutamide 63675-72-9, Nisoldipine
 65271-80-9, Mitoxantrone

(pharmaceutical compns. and methods for improved delivery of
 hydrophobic therapeutic agents)

IT 9004-65-3, Hydroxypropyl methylcellulose 9005-37-2,

Propylene glycol alginate

(pharmaceutical compns. and methods for improved delivery of
 hydrophobic therapeutic agents)

RN 9004-65-3 USPATFULL

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified

CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1


CMF C H4 O

H₃C—OH

CM 3

CRN 57-55-6

CMF C3 H8 O2



RN 9005-37-2 USPATFULL
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6
CMF C3 H8 O2



=> d his full

(FILE 'HOME' ENTERED AT 09:05:03 ON 07 MAR 2007)

FILE 'STNGUIDE' ENTERED AT 09:05:37 ON 07 MAR 2007

FILE 'CAPLUS' ENTERED AT 09:12:51 ON 07 MAR 2007

E US2003-650931 /APPS

L1 1 SEA ABB=ON PLU=ON US2003-650931 /AP
D SCA

FILE 'REGISTRY' ENTERED AT 09:14:08 ON 07 MAR 2007

L2 1 SEA ABB=ON PLU=ON NIFEDIPINE/CN
D SCA

SEL RN

L3 90 SEA ABB=ON PLU=ON 21829-25-4/CRN

L4 1 SEA ABB=ON PLU=ON ISRADIPINE/CN

D SCA

SEL RN

L5 3 SEA ABB=ON PLU=ON 75695-93-1/CRN

D SCA

E LOVASTATIN/CN

L6 1 SEA ABB=ON PLU=ON LOVASTATIN/CN

SEL RN

L7 37 SEA ABB=ON PLU=ON 75330-75-5/CRN

D SCA L6

L8 17 SEA ABB=ON PLU=ON LOVASTATIN?/CN

L9 16 SEA ABB=ON PLU=ON L8 NOT L7

L10 2 SEA ABB=ON PLU=ON L8 AND (L6 OR L7)

D SCA

L11 15 SEA ABB=ON PLU=ON L8 NOT L10

D SCA

E NIFEDIPINE/CN

L12 22 SEA ABB=ON PLU=ON NIFEDIPINE?/CN

L13 5 SEA ABB=ON PLU=ON L12 NOT (L2 OR L3)

D SCA

L14 91 SEA ABB=ON PLU=ON (L2 OR L3)

L15 4 SEA ABB=ON PLU=ON (L4 OR L5)

L16 53 SEA ABB=ON PLU=ON (L6 OR L7 OR L8)

E ISRADIPINE/CN

E GLIPIZIDE/CN

L17 1 SEA ABB=ON PLU=ON GLIPIZID?/CN

D SCA

SEL RN

L18 18 SEA ABB=ON PLU=ON 29094-61-9/CRN

L19 19 SEA ABB=ON PLU=ON (L17 OR L18)

L20 91 SEA ABB=ON PLU=ON (L2 OR L3)

L21 4 SEA ABB=ON PLU=ON (L4 OR L5)

L22 53 SEA ABB=ON PLU=ON (L6 OR L7 OR L8)

L23 19 SEA ABB=ON PLU=ON (L17 OR L18)

L24 0 SEA ABB=ON PLU=ON L20 AND (L21 OR L22 OR L23)

L25 0 SEA ABB=ON PLU=ON L21 AND (L22 OR L23)

L26 0 SEA ABB=ON PLU=ON L22 AND L23

L27 167 SEA ABB=ON PLU=ON (L20 OR L21 OR L22 OR L23)

FILE 'CAPLUS' ENTERED AT 09:28:52 ON 07 MAR 2007

L28 12370 SEA ABB=ON PLU=ON L27

FILE 'REGISTRY' ENTERED AT 09:29:01 ON 07 MAR 2007

E SODIUM ALGINATE/CN
L29 8 SEA ABB=ON PLU=ON SODIUM ALGINAT?/CN
D SCA
E ALGINATE/CN
E XANTHAN GUM/CN
L30 1 SEA ABB=ON PLU=ON XANTHAN GUM/CN
D SCA
L31 102 SEA ABB=ON PLU=ON XANTHAN GUM?/CN
L32 102 SEA ABB=ON PLU=ON (L30 OR L31)
E HYDROXYPROPYL METHYL CELLULOSE/CN
L33 28 SEA ABB=ON PLU=ON HYDROXYPROPYL METHYL CELLULOSE?/CN
E PROPYLENE GLYCOL ALGINATE/CN
L34 2 SEA ABB=ON PLU=ON PROPYLENE GLYCOL ALGINATE?/CN
SEL RN L29
L35 134 SEA ABB=ON PLU=ON (205256-12-8/CRN OR 205256-14-0/CRN OR
225931-01-1/CRN OR 791635-67-1/CRN OR 887259-75-8/CRN OR
9005-38-3/CRN OR 9010-06-4/CRN OR 9061-96-5/CRN)
E SODIUM ALGINATE/CN
L36 1 SEA ABB=ON PLU=ON SODIUM ALGINATE/CN
SEL RN
L37 133 SEA ABB=ON PLU=ON 9005-38-3/CRN
L38 137 SEA ABB=ON PLU=ON L29 OR L36 OR L37
SEL RN L30
L39 87 SEA ABB=ON PLU=ON 11138-66-2/CRN
L40 111 SEA ABB=ON PLU=ON L30 OR L31 OR L39
L41 1 SEA ABB=ON PLU=ON HYDROXYPROPYL METHYL CELLULOSE/CN
SEL RN
L42 129 SEA ABB=ON PLU=ON 9004-65-3/CRN
L43 151 SEA ABB=ON PLU=ON L33 OR L41 OR L42
SEL RN L34
D SCA L34
SEL RN L34
L44 6 SEA ABB=ON PLU=ON (130392-34-6/CRN OR 9005-37-2/CRN)
D SCA
L45 8 SEA ABB=ON PLU=ON L34 OR L44
L46 1 SEA ABB=ON PLU=ON L38 AND (L40 OR L43 OR L45)
D SCA
L47 1 SEA ABB=ON PLU=ON L40 AND (L43 OR L45)
D SCA
L48 0 SEA ABB=ON PLU=ON L43 AND L45
D COST

FILE 'CAPLUS' ENTERED AT 09:55:20 ON 07 MAR 2007

L49 62 SEA ABB=ON PLU=ON L38 AND L40 AND L43 AND L45
L50 1 SEA ABB=ON PLU=ON L46 AND L43 AND L45
L51 0 SEA ABB=ON PLU=ON L38 AND L47 AND L45
L52 0 SEA ABB=ON PLU=ON L46 AND L47 AND L45
L53 1 SEA ABB=ON PLU=ON L46 AND L45
L54 0 SEA ABB=ON PLU=ON L47 AND L45
L55 4 SEA ABB=ON PLU=ON (L49 OR L50 OR L51 OR L52 OR L53 OR L54)
AND L28
D SCA
L56 14331 SEA ABB=ON PLU=ON NIFEDIPINE/BI
L57 908 SEA ABB=ON PLU=ON ISRADIPINE/BI
L58 3338 SEA ABB=ON PLU=ON LOVASTATIN/BI
L59 1072 SEA ABB=ON PLU=ON GLIPIZIDE/BI
L*** DEL 0 S L56-L59 AND L49 L54
L60 4 SEA ABB=ON PLU=ON (L56 OR L57 OR L58 OR L59) AND (L49 OR L50
OR L51 OR L52 OR L53 OR L54)

L61 684024 SEA ABB=ON PLU=ON RELEAS?/BI
L62 2 SEA ABB=ON PLU=ON L60 AND L61
D SCA

FILE 'STNGUIDE' ENTERED AT 10:05:26 ON 07 MAR 2007

FILE 'CAPLUS' ENTERED AT 10:11:05 ON 07 MAR 2007

L63 1615 SEA ABB=ON PLU=ON WOO J?/AU
L64 393 SEA ABB=ON PLU=ON CHI M?/AU
L65 4 SEA ABB=ON PLU=ON L63 AND L64
L66 1 SEA ABB=ON PLU=ON L65 AND L55

FILE 'REGISTRY' ENTERED AT 10:12:11 ON 07 MAR 2007

L67 57253 SEA ABB=ON PLU=ON MEDLINE/LC
L68 30841 SEA ABB=ON PLU=ON EMBASE/LC
L69 196582 SEA ABB=ON PLU=ON BIOSIS/LC
L70 6 SEA ABB=ON PLU=ON L27 AND L67
L71 6 SEA ABB=ON PLU=ON L27 AND L68
L72 11 SEA ABB=ON PLU=ON L27 AND L69
L73 1 SEA ABB=ON PLU=ON L38 AND L67
L74 3 SEA ABB=ON PLU=ON L38 AND L68
L75 6 SEA ABB=ON PLU=ON L38 AND L69
L76 1 SEA ABB=ON PLU=ON L40 AND L67
L77 1 SEA ABB=ON PLU=ON L40 AND L68
L78 3 SEA ABB=ON PLU=ON L40 AND L69
L79 3 SEA ABB=ON PLU=ON L43 AND L67
L80 3 SEA ABB=ON PLU=ON L43 AND L68
L81 5 SEA ABB=ON PLU=ON L43 AND L69
L82 1 SEA ABB=ON PLU=ON L45 AND L67
L83 0 SEA ABB=ON PLU=ON L45 AND L68
L84 1 SEA ABB=ON PLU=ON L45 AND L69
L85 0 SEA ABB=ON PLU=ON L46 AND L67
L86 0 SEA ABB=ON PLU=ON L46 AND L68
L87 0 SEA ABB=ON PLU=ON L46 AND L69
L88 0 SEA ABB=ON PLU=ON L47 AND L67
L89 0 SEA ABB=ON PLU=ON L47 AND L68
L90 0 SEA ABB=ON PLU=ON L47 AND L69
D COST

FILE 'MEDLINE' ENTERED AT 10:41:19 ON 07 MAR 2007

L91 1020 SEA ABB=ON PLU=ON WOO J?/AU
L92 144 SEA ABB=ON PLU=ON CHI M?/AU
L93 0 SEA ABB=ON PLU=ON L91 AND L92
L94 18551 SEA ABB=ON PLU=ON L70
L95 19109 SEA ABB=ON PLU=ON NIFEDIPINE
L96 1475 SEA ABB=ON PLU=ON ISRADIPINE
L97 4043 SEA ABB=ON PLU=ON LOVASTATIN
L98 713 SEA ABB=ON PLU=ON GLIPIZIDE
L99 10 SEA ABB=ON PLU=ON L73
L100 663 SEA ABB=ON PLU=ON SODIUM ALGINATE
D TRIAL 1
D TRIAL 5-10
D TRIAL 100
D TRIAL 101
L101 5653 SEA ABB=ON PLU=ON ALGINATE
L102 263 SEA ABB=ON PLU=ON L76
L103 372 SEA ABB=ON PLU=ON XANTHAN GUM
D TRIAL 50-55
L104 655 SEA ABB=ON PLU=ON L79
D TRIAL 50-53

L105 4774 SEA ABB=ON PLU=ON METHYLCELLULOSE
 L106 458 SEA ABB=ON PLU=ON HYDROXYPROPYLMETHYLCELLULOSE
 L107 13 SEA ABB=ON PLU=ON L82
 D TRIAL 1-13
 L108 5243 SEA ABB=ON PLU=ON PROPYLENE GLYCOL
 L109 0 SEA ABB=ON PLU=ON (L94 OR L95 OR L96 OR L97 OR L98) AND (L99
 OR L100 OR L101) AND (L102 OR L103) AND (L104 OR L105 OR L106)
 AND (L107 OR L108)
 L110 0 SEA ABB=ON PLU=ON (L94 OR L95 OR L96 OR L97 OR L98) AND (L99
 OR L100 OR L101) AND (L102 OR L103) AND (L104 OR L105 OR L106)
 L111 0 SEA ABB=ON PLU=ON (L99 OR L100 OR L101) AND (L102 OR L103)
 AND (L104 OR L105 OR L106) AND (L107 OR L108)
 D COST
 E NIFEDIPINE/CT
 E NIFEDIPINE+ALL/CT
 L112 426 SEA ABB=ON PLU=ON (ADALAT/BI OR BAY-A-1040/BI OR BAY-1040/BI
 OR CORDIPIN/BI OR CORDIPINE/BI OR CORINFAR/BI OR FENIGIDIN/BI
 OR INFEDIPIN/BI OR KORINFAR/BI OR "MONOHYDROCHLORIDE, NIFEDIPIN
 E"/BI OR NIFANGIN/BI OR "NIFEDIPINE MONOHYDROCHLORIDE"/BI OR
 NIFEDIPINE-GTIS/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI)
 L113 52 SEA ABB=ON PLU=ON L112 NOT L95
 L114 19161 SEA ABB=ON PLU=ON L95 OR L112
 E ISRADIPINE+ALL/CT
 L115 382 SEA ABB=ON PLU=ON (DYNACIRC/BI OR "ISRADIPINE, (+-)-ISOMER"/B
 I OR "ISRADIPINE, (R)-ISOMER"/BI OR "ISRADIPINE, (S)-ISOMER"/BI
 OR LOMIR/BI OR "PN 200-110"/BI OR "PN 205 033"/BI OR "PN 205
 034"/BI OR "PN 205-033"/BI OR "PN 205-034"/BI OR "PN 205033"/BI
 OR "PN 205034"/BI OR PN-200-110/BI OR PN-205-033/BI OR
 PN-205-034/BI OR PN205033/BI OR PN205034/BI)
 L116 1595 SEA ABB=ON PLU=ON L96 OR L115
 E LOVASTATIN+ALL/CT
 L*** DEL 4236 S E57-E65/BI
 L117 404 SEA ABB=ON PLU=ON ("LOVASTATIN, (1 ALPHA(S*))-ISOMER"/BI OR
 "LOVASTATIN, 1 ALPHA-ISOMER (WITHOUT R*/S* NOTATION)"/BI OR
 "MK 803"/BI OR MK-803/BI OR MK803/BI OR MEVACOR/BI OR MEVINOLIN
 /BI OR "MONACOLIN K"/BI)
 L118 4139 SEA ABB=ON PLU=ON L97 OR L117
 E GLIPIZIDE+ALL/CT
 L119 29 SEA ABB=ON PLU=ON ("ALPHAPHARM BRAND OF GLIPIZIDE"/BI OR
 "GLIBENESE BRAND OF GLIPIZIDE"/BI OR GLIDIAZINAMIDE/BI OR
 GLUCOTROL/BI OR GLUPITEL/BI OR GLYDIAZINAMIDE/BI OR GLYPIDIZINE
 /BI OR "K 4024"/BI OR K-4024/BI OR K4024/BI OR "KENFARMA BRAND
 OF GLIPIZIDE"/BI OR "LACER BRAND OF GLIPIZIDE"/BI OR "LILLY
 BRAND OF GLIPIZIDE"/BI OR MELIZIDE/BI OR MINDIAB/BI OR
 MINIDIAB/BI OR MINODIAB/BI OR OZIDIA/BI OR "PFIZER BRAND OF
 GLIPIZIDE"/BI OR "PHARMACIA BRAND OF GLIPIZIDE"/BI OR "PYRAZINE
 CARBOXAMIDE, N-(2-(4-(((CYCLOHEXYLAMINO) CARBONYL) AMINO) SULFONY
 L) PHENYL) ETHYL)-5-METHYL-"/BI)
 L120 723 SEA ABB=ON PLU=ON L98 OR L119
 L121 0 SEA ABB=ON PLU=ON (L94 OR L114 OR L116 OR L118 OR L120) AND
 (L99 OR L100 OR L101) AND (L102 OR L103) AND (L104 OR L105 OR
 L106) AND (L107 OR L108)
 L122 6 SEA ABB=ON PLU=ON (L94 OR L114 OR L116 OR L118 OR L120) AND
 (L91 OR L92)
 D TRIAL 1-6

FILE 'EMBASE' ENTERED AT 11:02:57 ON 07 MAR 2007

L123 46607 SEA ABB=ON PLU=ON (L71 OR (L95 OR L96 OR L97 OR L98))
 D TRIAL 1-5
 E NIFEDIPINE+ALL/CT

L124 3286 SEA ABB=ON PLU=ON (ADALAT/BI OR "ADALAT CRONO"/BI OR "ADALAT PA"/BI OR "ADALAT RETARD"/BI OR ADALATE/BI OR ALDIPIN/BI OR ANGBLOC/BI OR APONIFED/BI OR APRICAL/BI OR "APRICAL RETARD"/BI OR "BAY 1040"/BI OR "BAY A 1040"/BI OR "BAY A1040"/BI OR BAY1040/BI OR CALCIGARD/BI OR CHRONADALAT/BI OR CHRONADALATE/BI OR CORACTEN/BI OR CORDAFEN/BI OR CORDAFLEX/BI OR CORDICANT/BI OR CORDIPIN/BI OR CORINFAR/BI OR COROTREND/BI OR DEPIN/BI OR "DIMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2 NITROPHENYL) PYRIDINE 3,5 DICARBOXYLATE"/BI OR DURANIFIN/BI OR ECODIPIN/BI OR EMABERIN/BI OR FENIGIDIN/BI OR HERLAT/BI OR INFEDIPINE/BI OR MIFEDIPINE/BI OR MODERAT/BI OR MYOGARD/BI OR NIFANGIN/BI OR NIFEDICOR/BI OR "NIFEDICOR GOCCE"/BI OR NIFEDINE/BI OR NIFEDIPAT/BI OR NIFEHEXAL/BI OR NIFELAT/BI OR NIFENSAR/BI OR NIFEPIDINE/BI OR NIFICAL/BI OR NIFICARD/BI OR NOVONIFEDIN/BI OR PHENYGDINE/BI OR PIDILAT/BI OR "PIDILAT RETARD"/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI OR RONIAN/BI OR SEPAMIT/BI OR SLOFEDIPINE/BI OR "SLOFEDIPINE XL"/BI OR UNIDIPINE/BI OR ZENUSIN/BI)
E ISRADIPINE+ALL/CT

L125 1049 SEA ABB=ON PLU=ON (ISRODIPINE/BI OR LOMIR/BI OR "PK 200110"/BI OR "PN 200 110"/BI OR "PN 200-110"/BI OR "PN 200110"/BI OR "PN 200110 N"/BI OR "PN 205033"/BI OR "PN 205034"/BI OR "PN200 110"/BI OR PN200-110/BI OR PN200110/BI OR PRESCAL/BI OR "SDZ 200 110"/BI OR VASCAL/BI)
E LOVASTATIN+ALL/CT
E E2+ALL/CT

L126 2955 SEA ABB=ON PLU=ON (ALTOCOR/BI OR ALTOPREV/BI OR ARTEIN/BI OR "L 654969"/BI OR LIPIVAS/BI OR LOVACOL/BI OR LOVASTATIN/BI OR MEVACOR/BI OR MEVINACOR/BI OR "MK 0803"/BI OR "MK 803"/BI OR MK0803/BI OR MK803/BI OR "MONACOLIN K"/BI OR "MONAKOLIN K"/BI OR "MSD 803"/BI OR NEOLIPID/BI)
E GLIPIZIDE+ALL/CT

L127 524 SEA ABB=ON PLU=ON ("CP 28,720"/BI OR "CP 28720"/BI OR "CP28,720"/BI OR CP28720/BI OR GLIBENESE/BI OR GLIBINESE/BI OR GLIBIZIDE/BI OR GLIDIAZINAMIDE/BI OR GLUCATROL/BI OR GLUCOTROL/BI OR "GLUCOTROL XL"/BI OR GLYDIAZENAMIDE/BI OR GLYDIAZIAMIDE/BI OR GLYDIAZINAMIDE/BI OR GLYPIZIDE/BI OR "K 4024"/BI OR MINIDIAB/BI OR MINODIAB/BI)

L128 46760 SEA ABB=ON PLU=ON (L123 OR L124 OR L125 OR L126 OR L127)
E SODIUM ALGINATE+ALL/CT
E E2+ALL/CT

L129 13985 SEA ABB=ON PLU=ON (ALGIN/BI OR ALGINATE/BI OR "ALGINATE SODIUM"/BI OR ALGINATES/BI OR "ALGINIC GULURONIC ACID"/BI OR "BLUEPRINT RAPID"/BI OR COLOURGEL/BI OR "G-C FAST SET"/BI OR "G-C VERICOL AROMA"/BI OR KALGINATE/BI OR KELACID/BI OR "KELCOGEL LV"/BI OR KELGIN/BI OR KELTONE/BI OR "KERR ALGINATE"/BI OR "MANUGEL DJX"/BI OR "MANUGEL DMB"/BI OR MINUS/BI OR NORALGIN/BI OR NORGINE/BI OR POLYMANNUROATE/BI OR "POLYMANNURO NIC ACID"/BI OR "POLYMANNURONIC GULURONIC ACID"/BI OR PROTANAL/BI OR PSOTHANOL/BI OR "SODIUM ALGINATE"/BI OR "SODIUM POLYMANNURONATE"/BI OR SORBALGON/BI OR "ZELGAN GREEN"/BI OR "ZELGAN PINK"/BI)

L130 6223 SEA ABB=ON PLU=ON L74 OR (L100 OR L101)

L131 15293 SEA ABB=ON PLU=ON (L129 OR L130)

L132 649 SEA ABB=ON PLU=ON L77 OR XANTHAN GUM
E XANTHAN GUM+ALL/CT
E E2+ALL/CT

L133 699 SEA ABB=ON PLU=ON XANTHAN OR KELTROL OR RHODIGEL 23

L134 699 SEA ABB=ON PLU=ON (L132 OR L133)

L135 6010 SEA ABB=ON PLU=ON L80 OR (L105 OR L106)

E HYDROXYPROPYLMETHYLCELLULOSE/CT

E E3+ALL/CT

L136 1239 SEA ABB=ON PLU=ON (ADATOCEL/BI OR CONTACTOL/BI OR GONIOSOL/BI OR "HYDROXYPROPYL METHYL CELLULOSE"/BI OR "HYDROXYPROPYL METHYLCELLULOSE"/BI OR "HYDROXYPROPYLMETHYL CELLULOSE"/BI OR HYPROMELLOSE/BI OR "ISOPTO TEARS"/BI OR ISOPTONATURAL/BI OR ISOPTOPLAIN/BI OR ISOPTOTEARS/BI OR "K 8515"/BI OR LUBAFAX/BI OR "METHOCEL E 15"/BI OR "METHOCEL EFK"/BI OR "METHOCEL K100M"/BI OR "METHOCEL K15M"/BI OR "METHOCEL K4M"/BI OR "METHOLOSE TC 5"/BI OR "METHYLHYDROXYPROPYL CELLULOSE"/BI OR METHYLHYDROXYPROPYLCELLULOSE/BI OR METOLOSE/BI OR OCCUCOAT/BI OR OCUCOAT/BI OR "PHARMACOAT 603"/BI OR "PHARMACOAT 606"/BI OR ULTRATEARS/BI)

L137 6060 SEA ABB=ON PLU=ON (L135 OR L136)
D COST

L138 0 SEA ABB=ON PLU=ON L83
E PROPYLENE GLYCOL ALGINATE+ALL/CT
E E2+ALL

L139 23 SEA ABB=ON PLU=ON "ALGINIC ACID PROPYLENE GLYCOL ESTER"+UF/CT

L140 26 SEA ABB=ON PLU=ON ("PROPYLENE GLYCOL ALGINATE"/BI OR "PROPYLENEGLYCOL ALGINATE"/BI)

L141 34 SEA ABB=ON PLU=ON (L139 OR L140)

L142 0 SEA ABB=ON PLU=ON L128 AND L131 AND L134 AND L137 AND L141

L143 2 SEA ABB=ON PLU=ON L128 AND L131 AND L134 AND L137
D TRIAL 1-2

L144 0 SEA ABB=ON PLU=ON L131 AND L134 AND L137 AND L141

L145 1034 SEA ABB=ON PLU=ON WOO J?/AU

L146 165 SEA ABB=ON PLU=ON CHI M?/AU

L147 0 SEA ABB=ON PLU=ON L145 AND L146

L148 9 SEA ABB=ON PLU=ON (L145 OR L146) AND L128

L149 4 SEA ABB=ON PLU=ON (L145 OR L146) AND L131

L150 0 SEA ABB=ON PLU=ON (L145 OR L146) AND L134

L151 3 SEA ABB=ON PLU=ON (L145 OR L146) AND L137

L152 0 SEA ABB=ON PLU=ON (L145 OR L146) AND L141

L153 16 SEA ABB=ON PLU=ON (L147 OR L148 OR L149 OR L150 OR L151 OR L152)
D TRIAL 1-5

FILE 'STNGUIDE' ENTERED AT 11:22:20 ON 07 MAR 2007

D COST

FILE 'BIOSIS' ENTERED AT 17:16:06 ON 07 MAR 2007

L154 1198 SEA ABB=ON PLU=ON WOO J?/AU

L155 244 SEA ABB=ON PLU=ON CHI M?/AU

L156 0 SEA ABB=ON PLU=ON L154 AND L155

L157 25683 SEA ABB=ON PLU=ON L72 OR (L95 OR L96 OR L97 OR L98)

L158 422 SEA ABB=ON PLU=ON (ADALAT/BI OR "ADALAT CRONO"/BI OR "ADALAT PA"/BI OR "ADALAT RETARD"/BI OR ADALATE/BI OR ALDIPIN/BI OR ANGIBLOC/BI OR APONIFED/BI OR APRICAL/BI OR "APRICAL RETARD"/BI OR "BAY 1040"/BI OR "BAY A 1040"/BI OR "BAY A1040"/BI OR BAY1040/BI OR CALCIGARD/BI OR CHRONADALAT/BI OR CHRONADALATE/BI OR CORACTEN/BI OR CORDAFEN/BI OR CORDAFLEX/BI OR CORDICANT/BI OR CORDIPIN/BI OR CORINFAR/BI OR COROTREND/BI OR DEPIN/BI OR "DIMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2 NITROPHENYL) PYRIDINE 3,5 DICARBOXYLATE"/BI OR DURANIFIN/BI OR ECODIPIN/BI OR EMABERIN/BI OR FENIGIDIN/BI OR HERLAT/BI OR INFEDIPINE/BI OR MIFEDIPINE/BI OR MODERAT/BI OR MYOGARD/BI OR NIFANGIN/BI OR NIFEDICOR/BI OR "NIFEDICOR GOCCE"/BI OR NIFEDINE/BI OR NIFEDIPAT/BI OR NIFEHEXAL/BI OR NIFELAT/BI OR NIFENSAR/BI OR

NIFEPIDINE/BI OR NIFICAL/BI OR NIFICARD/BI OR NOVONIFEDIN/BI
OR PHENYMGIDINE/BI OR PIDILAT/BI OR "PIDILAT RETARD"/BI OR
PROCARDIA/BI OR "PROCARDIA XL"/BI OR RONIAN/BI OR SEPAMIT/BI
OR SLOFEDIPINE/BI OR "SLOFEDIPINE XL"/BI OR UNIDIPINE/BI OR
ZENUSIN/BI)

L159 4086 SEA ABB=ON PLU=ON (L125 OR L126 OR L127)
L160 26142 SEA ABB=ON PLU=ON (L157 OR L158 OR L159)
L161 23308 SEA ABB=ON PLU=ON (L129 OR L130)
L162 1552 SEA ABB=ON PLU=ON (L132 OR L133)
L163 1071 SEA ABB=ON PLU=ON L78
L164 1552 SEA ABB=ON PLU=ON (L162 OR L163)

FILE 'STNGUIDE' ENTERED AT 17:32:24 ON 07 MAR 2007

FILE 'BIOSIS' ENTERED AT 17:38:56 ON 07 MAR 2007

L165 4435 SEA ABB=ON PLU=ON L137 OR L81
L166 96 SEA ABB=ON PLU=ON L84 OR L141
L167 0 SEA ABB=ON PLU=ON L160 AND L161 AND L164 AND L165 AND L166
L168 2 SEA ABB=ON PLU=ON L161 AND L164 AND L165 AND L166
D SCA
L169 8 SEA ABB=ON PLU=ON (L154 OR L155) AND (L157 OR L158 OR L159
OR L160 OR L161 OR L162 OR L163 OR L164)

FILE 'USPATFULL' ENTERED AT 17:45:19 ON 07 MAR 2007

L170 1 SEA ABB=ON PLU=ON L154 AND L155

FILE 'CAPLUS' ENTERED AT 17:46:44 ON 07 MAR 2007

L171 62 SEA ABB=ON PLU=ON (L49 OR L50 OR L51 OR L52 OR L53 OR L54)
SEL AN
L172 60 SEA ABB=ON PLU=ON L171 AND P/DT
SEL PN

FILE 'USPATFULL' ENTERED AT 17:49:03 ON 07 MAR 2007

L173 67 SEA ABB=ON PLU=ON (WO2004037226/PN OR EP331385/PN OR
EP616508/PN OR EP782846/PN OR AU2003274655/PN OR CA2054822/PN
OR CA2411153/PN OR CA2503380/PN OR EP1150722/PN OR EP1296656/PN
OR EP1299499/PN OR EP1558222/PN OR EP241178/PN OR EP484186/PN
OR EP740528/PN OR EP812545/PN OR EP983326/PN OR US2002012680/PN
OR US2002032171/PN OR US2006057204/PN OR US6267985/PN OR
US6294192/PN OR US6451339/PN OR US6703044/PN OR US6761903/PN
OR WO2002000201/PN OR WO2002005620/PN OR WO2002005660/PN OR
WO2002005661/PN OR WO2003080056/PN OR WO2003090693/PN OR
WO2004113042/PN OR WO2005046363/PN OR WO2005107713/PN OR
WO9517104/PN OR AT103492/PN OR AT180170/PN OR AT188118/PN OR
AT203148/PN OR AT228776/PN OR AT235228/PN OR AT254157/PN OR
AT305802/PN OR AT334662/PN OR AT338800/PN OR AU2000063445/PN
OR AU2001013246/PN OR AU2003213020/PN OR AU2003218058/PN OR
AU2003230719/PN OR AU2003234240/PN OR AU2003237944/PN OR
AU2003297561/PN OR AU2004249662/PN OR AU2004289248/PN OR
AU2005230362/PN OR AU590403/PN OR AU618932/PN OR AU657706/PN
OR AU667471/PN OR AU683713/PN OR AU688837/PN OR AU713127/PN OR
AU725810/PN OR AU731072/PN OR AU740326/PN OR AU753760/PN OR
AU754917/PN OR AU772345/PN OR AU782828/PN OR AU8172030/PN OR
AU8770616/PN OR AU8770617/PN OR AU9176742/PN OR AU9186961/PN
OR AU9220020/PN OR AU9513020/PN OR AU9514318/PN OR AU9673269/PN
OR AU9724856/PN OR AU9856271/PN OR AU9879126/PN OR AU9888405/PN
OR AU9892840/PN OR AU9910043/PN OR AU9929241/PN OR AU9956852/PN
OR BG64100/PN OR BR2001008145/PN OR BR2001012014/PN OR
BR2004015741/PN OR BR9809674/PN OR BR9913227/PN OR CA1164264/PN
OR CA1300515/PN OR CA2069759/PN OR CA2177713/PN OR CA2188331/PN)

N OR CA2200620/PN OR CA2269769/PN OR CA2291040/PN OR CA2309380/
PN OR CA2338688/PN OR CA2361847/PN OR CA2388610/PN OR CA2397832
/PN OR CA2414161/PN OR CA2414166/PN OR CA24141

L174 6797 SEA ABB=ON PLU=ON NIFEDIPINE
L175 1469 SEA ABB=ON PLU=ON ISRADIPINE
L176 5820 SEA ABB=ON PLU=ON LOVASTATIN
L177 2595 SEA ABB=ON PLU=ON GLIPIZIDE
L178 15 SEA ABB=ON PLU=ON L173 AND (L174 OR L175 OR L176 OR L177)
L179 0 SEA ABB=ON PLU=ON (L154 OR L155) AND L178
D KWIC L178 1-5
D IND L178 1
D KWIC L178 2-15
SEL RN L178
DELETE SELECT
D COST
D COST FULL
SEL RN L178

FILE 'REGISTRY' ENTERED AT 17:55:09 ON 07 MAR 2007

L180 5 SEA ABB=ON PLU=ON (12619-70-4/RN OR 25322-68-3/RN OR
57-55-6/RN OR 57-88-5/RN OR 105-60-2/RN)
D COST FULL

L181 751 SEA ABB=ON PLU=ON (56-81-5/RN OR 616-45-5/RN OR 9003-39-8/RN
OR 9005-63-4/RN OR 50-70-4/RN OR 9004-65-3/RN OR 9005-37-2/RN
OR 106392-12-5/RN OR 57-83-0/RN OR 9002-89-5/RN OR 102-76-1/RN
OR 103628-46-2/RN OR 107-21-1/RN OR 112-80-1/RN OR 115-77-5/RN
OR 128-13-2/RN OR 1397-89-3/RN OR 1406-18-4/RN OR 162011-90-7/R
N OR 21829-25-4/RN OR 25322-69-4/RN OR 25618-55-7/RN OR
49562-28-9/RN OR 50-28-2/RN OR 57-10-3/RN OR 57-11-4/RN OR
675-20-7/RN OR 69-65-8/RN OR 73963-72-1/RN OR 82626-48-0/RN OR
9002-96-4/RN OR 9005-32-7/RN OR 100-51-6/RN OR 105-37-3/RN OR
105-54-4/RN OR 106-32-1/RN OR 107753-78-6/RN OR 110-27-0/RN OR
111-62-6/RN OR 111-90-0/RN OR 11103-57-4/RN OR 11140-04-8/RN
OR 113-15-5/RN OR 113665-84-2/RN OR 115-83-3/RN OR 124-07-2/RN
OR 127-19-5/RN OR 13081-97-5/RN OR 1331-12-0/RN OR 1338-39-2/RN
OR 1338-43-8/RN OR 141-22-0/RN OR 142-62-1/RN OR 142-91-6/RN
OR 143-07-7/RN OR 144034-80-0/RN OR 14440-80-3/RN OR 14605-22-2
/RN OR 150372-93-3/RN OR 151-41-7/RN OR 156259-68-6/RN OR
159989-64-7/RN OR 169590-42-5/RN OR 18559-94-9/RN OR 1951-25-3/
RN OR 22882-95-7/RN OR 23288-49-5/RN OR 25168-73-4/RN OR
25339-99-5/RN OR 25637-97-2/RN OR 25812-30-0/RN OR 26266-57-9/R
N OR 26266-58-0/RN OR 26446-38-8/RN OR 2687-91-4/RN OR
2687-94-7/RN OR 2687-96-9/RN OR 27195-16-0/RN OR 3068-88-0/RN
OR 31692-85-0/RN OR 334-48-5/RN OR 3445-11-2/RN OR 360-65-6/RN
OR 437-38-7/RN OR 4419-39-0/RN OR 463-40-1/RN OR 474-25-9/RN
OR 475-31-0/RN OR 4759-48-2/RN OR 511-12-6/RN OR 516-35-8/RN
OR 516-50-7/RN OR 51938-44-4/RN OR 5306-85-4/RN OR 53168-42-6/R
N OR 54392-26-6/RN OR 544-35-4/RN OR 544-63-8/RN OR 55142-85-3/
RN OR 577-11-7/RN OR 59467-70-8/RN OR 595-33-5/RN OR 60-33-3/RN
OR 623-84-7/RN OR 64-17-5/RN OR 640-79-9/RN OR 67-63-0/RN OR
68958-64-5/RN OR 74504-64-6/RN OR 76547-98-3/RN OR 7664-93-9/RN
OR 77-89-4/RN OR 77
D COST FULL

FILE 'CAPLUS' ENTERED AT 17:57:50 ON 07 MAR 2007

SEL HIT RN L49

FILE 'REGISTRY' ENTERED AT 17:58:09 ON 07 MAR 2007

L182 8 SEA ABB=ON PLU=ON (9005-38-3/BI OR 11138-66-2/BI OR 9004-65-3
/BI OR 9005-37-2/BI OR 9050-31-1/BI OR 71138-97-1/BI OR

70535-77-2/BI OR 497236-18-7/BI)

FILE 'USPATFULL' ENTERED AT 17:58:40 ON 07 MAR 2007
L183 9847 SEA ABB=ON PLU=ON L182
L184 9 SEA ABB=ON PLU=ON L183 AND L178
D KWIC 1-9

FILE 'REGISTRY' ENTERED AT 18:00:51 ON 07 MAR 2007

FILE 'CAPLUS' ENTERED AT 18:00:59 ON 07 MAR 2007
D STAT QUE L65
D STAT QUE L122

FILE 'MEDLINE' ENTERED AT 18:01:17 ON 07 MAR 2007
D STAT QUE L122

FILE 'EMBASE' ENTERED AT 18:01:22 ON 07 MAR 2007
D STAT QUE L153

FILE 'BIOSIS' ENTERED AT 18:01:31 ON 07 MAR 2007
D STAT QUE L169

FILE 'USPATFULL' ENTERED AT 18:01:42 ON 07 MAR 2007
D STAT QUE L170

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, USPATFULL' ENTERED AT 18:02:04 ON
07 MAR 2007
L185 23 DUP REM L65 L122 L153 L169 L170 (12 DUPLICATES REMOVED)
ANSWERS '1-4' FROM FILE CAPLUS
ANSWERS '5-10' FROM FILE MEDLINE
ANSWERS '11-22' FROM FILE EMBASE
ANSWER '23' FROM FILE USPATFULL
D IBIB ABS HITIND HITSTR L185 1-4
D IALL L185 5-22
D IBIB ABS L185 23

FILE 'REGISTRY' ENTERED AT 18:03:14 ON 07 MAR 2007

FILE 'CAPLUS' ENTERED AT 18:03:17 ON 07 MAR 2007
D STAT QUE L55
D STAT QUE L60

FILE 'MEDLINE' ENTERED AT 18:03:32 ON 07 MAR 2007
D STAT QUE L109
D STAT QUE L110
D STAT QUE L111
D STAT QUE L121

FILE 'EMBASE' ENTERED AT 18:03:59 ON 07 MAR 2007
D STAT QUE L143
L186 2 SEA ABB=ON PLU=ON L143 NOT L153

FILE 'BIOSIS' ENTERED AT 18:04:37 ON 07 MAR 2007
D STAT QUE L167

FILE 'USPATFULL' ENTERED AT 18:04:52 ON 07 MAR 2007
D STAT QUE L184
L187 9 SEA ABB=ON PLU=ON L184 NOT L170

FILE 'CAPLUS' ENTERED AT 18:05:23 ON 07 MAR 2007

FILE 'CAPLUS' ENTERED AT 18:05:40 ON 07 MAR 2007

D STAT QUE L55

D STAT QUE L60

L188 4 SEA ABB=ON PLU=ON L55 OR L60

FILE 'CAPLUS, EMBASE, USPATFULL' ENTERED AT 18:06:15 ON 07 MAR 2007

L189 14 DUP REM L188 L186 L187 (1 DUPLICATE REMOVED)

ANSWERS '1-4' FROM FILE CAPLUS

ANSWERS '5-6' FROM FILE EMBASE

ANSWERS '7-14' FROM FILE USPATFULL

D IBIB ABS HITIND HITSTR L189 1-4

D IALL L189 5-6

D IBIB ABS KWIC HITSTR L189 7-14

FILE 'USPATFULL' ENTERED AT 18:10:01 ON 07 MAR 2007

FILE 'EMBASE, USPATFULL, CAPLUS' ENTERED AT 18:10:37 ON 07 MAR 2007

D IBIB ABS KWIC HITSTR L189 7-14

FILE 'USPATFULL' ENTERED AT 18:10:42 ON 07 MAR 2007

FILE HOME

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Mar 2, 2007 (20070302/UP).

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Mar 2007 VOL 146 ISS 11

FILE LAST UPDATED: 6 Mar 2007 (20070306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAR 2007 HIGHEST RN 924962-30-1

DICTIONARY FILE UPDATES: 5 MAR 2007 HIGHEST RN 924962-30-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE MEDLINE

FILE LAST UPDATED: 6 Mar 2007 (20070306/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE

FILE COVERS 1974 TO 7 Mar 2007 (20070307/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNS) PRESENT FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 28 February 2007 (20070228/ED)

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Mar 2007 (20070306/PD)

FILE LAST UPDATED: 6 Mar 2007 (20070306/ED)

HIGHEST GRANTED PATENT NUMBER: US7188369

HIGHEST APPLICATION PUBLICATION NUMBER: US2007050874

CA INDEXING IS CURRENT THROUGH 6 Mar 2007 (20070306/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Mar 2007 (20070306/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006

=>